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SUMMARY 
Our studies on the synthesis and biological evaluation of novel anticancer drugs consist 
of three research areas; namely, synthesis of Mitogen Activated Protein (MAP) kinase inhibitors, 
Checkpoint (Chk 1) inhibitors and nordihydroguaiaretic acid (NDGA) analogues. 
The first research area involved synthesis of MAP kinase inhibitors. MAP kinases are a 
family of serine I and threonine II kinases which can act together to generate a process of 
phosphorylation events within the cell signalling pathway leading eventually to cell division. The 
compounds made in this project were specifically designed to target the stress related kinases, a 
MAP kinase pathway which controls the expression of genes involved in cell proliferation. 
The stress related kinases are known to have serine or threonine joined to a proline III 
residue. In an attempt to prepare selective inhibitors of stress related kinases, compounds of 
types IV and V were designed in which a conformationally restricted serine analogue is joined to 
L-proline via an amide link in one of two possible ways. Examples of these two sets of 
compounds were synthesised and those that were tested by Professor David Gillespie at the 
Beatson Institute for Cancer Research, Glasgow were shown not to be inhibitors of these 
kinases. 
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The second research area concentrated on the checkpoint signalling pathway. 
Components in the DNA damage checkpoint signalling pathway such as ChK 1 could be 
potential targets for chemical intervention. Caffeine VI and pentoxifylline VII have been shown 
to sensitise p53-deficient tumour cells to killing by DNA damage. We envisaged that the 
xanthine derivatives, caffeine VI and pentoxifylline VII might also disrupt the G2 checkpoint by 
preventing activation of Chk 1. To test this hypothesis, a range of xanthine derivatives shown 
below were prepared by alkylation of theophylline VIII or theobromine IX. 
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The biological evaluation of these xanthine derivatives by Professor Gillespie revealed 
that three of these compounds, X, XI and XII, suppressed G2/M arrest very effectively. All three 
active compounds possess a long aliphatic chain that provides a large degree of flexibility to the 
structures. The long aliphatic chains could bind to a hydrophobic pocket in the enzyme's active 
site that might confer selectivity on the compounds. 
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The third area, synthesis of NDGA analogues, was the major part of the synthetic work. 
NDGA XM is known to be a selective inhibitor of lipoxygenase and blocks small cell lung 
cancer growth in vitro and in vivo. In addition to its lipoxygenase activity, NDGA was 
demonstrated to inhibit c-kit, a tyrosine kinase that has been observed preferentially in SCLC. 
The main drawbacks to the use of NDGA in cancer treatment are its poor solubility and 
moderate potency. Therefore chemical modifications are required to provide better compounds 
for clinical use. Preliminary work in our group was performed by McDonald and Macleod. 
They synthesised a range of analogues of NDGA which were tested for their activity in vitro by 
Professor Michael Seckl at the Medical Oncology Department of Hammersmith Hospital, 
London. Improved potency over NDGA for new analogues with 4-6 atoms between the two 
aromatic rings was observed. Furthermore introduction of an amide linkage between the two 
aromatic residues resulted in NDGA analogues which are more active than NDGA. 
Based on these preliminary results, the structural modifications proposed for this project 
focused on three areas. The main programme of research was drug solubilisation of new 
analogues which have higher potency than NDGA for in vivo work. The second area of study 
sought to introduce position variations of the amide linkage between the two aromatic residues. 
The third area of work involved modification of the substituents on the two aromatic rings. 
A range of NDGA analogues was successfully synthesised and evaluated for anticancer 
activity in vitro. Compounds XIV and XV were confirmed as lead compounds which are ten 
times more active than NDGA. Compound XIV was successfully transformed into a water 
soluble form XVI which is now available for in vivo work. In addition NDGA was converted 
into a water soluble form which was more potent than NDGA in vitro. Moreover a NDGA 
analogue XVII with no free hydroxy groups was found to be as active as NDGA, which was an 
unexpected discovery. 
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CHAPTER 1 
General Overview of Cancer and its 
Treatment 
1.1 Basic Facts About Cancer 
The World Health Organisation (WHO) reported that an estimated 10 million cases of 
cancer occurred worldwide in 1998. Furthermore WHO predicted that the situation would get 
worse with numbers rising to 14.7 million over the next 20 years. I 
Cancer has afflicted our ancestors throughout the history of mankind, but it has become 
a major cause of mortality only in the last century. 2 Although cancer can occur at all ages, it 
becomes more prevalent as people grow older. Epidemiological analysis shows dramatic 
increases in cancer incidence with age, which accounts for the prevalence of cancer in our time. 
The average life expectancy has increased substantially as a result of the elimination of 
infectious diseases this century. 2 This has resulted in a larger fraction of older individuals in 
our population and consequently an increased incidence of cancer. 
The goal of an ultimate conquest of cancer remains a distant hope. Cancer cells closely 
resemble normal cells, as cancer results from uncontrolled growth of otherwise normal cells .2 
Most of the drugs currently available for use in cancer treatment act against all rapidly 
proliferating cells. Thus, they kill not only cancer cells but also some normal cells, particularly 
those that are rapidly dividing. The effectiveness of treatment is often severely limited by the 
toxic side effects of the drugs. The fundamental problem in cancer treatment is to kill cancer 
cells selectively without adverse side effects to the patient. 2 
1.2 Cell Proliferation and Cancer 
1.2.1 Stages of the Cell Cycle 
DNA replication had been thought to be a continual process between the period of cell 
division, but early in the 1950s it was found this was not the case as it then became possible to 
carry out some radioisotopic labelling experiments using the nitrogenous base thymidine. 3 
These experiments revealed a distinct gap during and after DNA formation even in rapidly 
proliferating cells and led to the discovery of the cell cycle. The process of mitosis is now a 
well-defined sequence of events that can be conveniently represented as shown in Figure 1.3 
i 
G2/S DNA Damage G1/S DNA Damage 
Checkpoint Checkpoint 
Figure 1 The cell cycle 
RNA and proteins are synthesised in the G1 (gap 1) phase and preparations are made to 
begin DNA synthesis. The S (synthesis) phase then follows where DNA is replicated and the 
DNA packing proteins, namely histones, are synthesised. The DNA is complexed with the 
proteins and preparations are made for cell division in the G2 (Gap 2) phase and finally the cell 
nucleus and cytoplasm divide in the process of mitosis, which is the M Phase. The two daughter 
cells then undergo the cycle again or enter a resting phase, Gp. All cells undergo this cell cycle. 
Cell replication is normally controlled in response to the needs of the whole organism. However 
in some cases, these control mechanisms are lost resulting in excessive cell division to form a 
mass of cancer cells .4 
1.2.2 Differences between Cancer Cells and Normal Cells5 
Comparative studies of cell growth and behaviour have identified the characteristic 
differences between cancer cells and their normal counterparts. 
Most tumour cells divide indefinitely regardless of the density-dependent inhibition of 
proliferation that is characteristic of normal cells in culture. In other words, tumour cells remain 
in the M-phase of the cell cycle until they die as a result of exhaustion of nutrients in the culture 
media. However, cancer cells stop proliferation at random points during the cell cycle rather than 
at the DNA checkpoints. 
One type of cell normally responds to growth factors secreted by a different type of cell. 
By contrast, some tumour cells secrete growth factors that drive their own proliferation. In such 
cases, abnormal production of growth factor results in continual autostimulation of cell 
proliferation (autocrine growth stimulation). In other cases, tumour cells are continually 
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stimulated to proliferate independent of extracellular growth factors as a result of alteration of 
their growth factor receptors. 
In addition to their reduced dependence on extracellular growth factors, cancer cells 
proliferate and migrate in an unregulated manner regardless of the contact with neighbouring 
cells or the extracellular matrix. 
Cancer cells produce enzymes, called proteases, that digest other proteins. Proteases 
break down extracellular materials enabling the cancer cells to penetrate through surrounding 
normal tissues. The further expansion of a tumour requires new blood vessels to provide 
nutrients for tumour cell proliferation. The formation of new blood vessels is termed 
angiogenesis. Secretion of proteases and angiogenesis play crucial roles in cancer metastases. 
Cancer cells are characterised by loss of capacity to differentiate at early stages of 
maturation. On the other hand, cancer cells fail to undergo programmed cell death, apoptosis, 
which is relevant to the invasiveness and spread (metastases) of cancers. Finally, cancer cells are 
the products of genetic mutations, which can lead to resistance to chemotherapeutic agents. 
Taken together, these properties of cancer cells are found to contribute to the progressive 
growth, invasiveness, and metastasis of malignant neoplasms. 
1.3 Causes of Cancer 
Tobacco smoking is undoubtedly the major cause of human cancer, accounting for about 
30% of all cancer deaths. Smoking is responsible for the majority of lung cancers and has been 
associated with the development of many other cancers; for instance, cancer of the oral cavity, 
pharynx, bladder, kidney, pancreas and so on. Other common causes of human cancer include 
alcohol abuse, radiation, carcinogenic medicines, and occupational carcinogens, each of which 
accounts for only a few percent of total cancer deaths. 6 Taken together, it is estimated that up to 
80% of human cancers may be attributable to environmental risk factors. 
Most cancers are a result of a mutation in the sequence of DNA. 7 The generation of 
cancer (carcinogenesis) is closely correlated to the induction of DNA changes (mutagenesis) 
brought about by the following three classes of agents. 
1.3.1 Chemical Carcinogenesis 
The common feature of most chemical carcinogens is their ability to generate active 
electrophilic forms that can attack the nucleophilic sites on DNA. These chemical carcinogens 
can either undergo enzyme metabolism prior to action or can react directly like dimethyl sulfate 
1 and uracil mustard 2 that are intrinsically electrophilic. 8 
3 
I 
12 
The activation of the procarcinogen to the active form may proceed directly or go 
through a number of less reactive intermediates called proximate forms. 9 A variety of enzymes 
are involved in these processes often catalysing conversion of the foreign lipophilic agent into a 
more hydrophilic form, and this enzymatic manipulation results in the production of a 
carcinogenic electrophile. 
An example of such a process is shown in Figure 29 involving the polycyclic aromatic 
hydrocarbon (PAH) benzo[a]pyrene 3 which is one of the carcinogens present in tobacco 
smoke. A series of enzymatic oxidations of the procarcinogen PAH leads to the 7,8- 
dihydrodiol-9,10-epoxide. The most reactive electrophilic epoxides are formed near the bay 
region of the PAH. This epoxide can in turn react with the 2-amino group of guanine residues 
in DNA. 
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Figure 2 Metabolic activation of benzo[a]pyrene 
1.3.2 Radiation 
Ionising Radiation 
Ionising radiation has a higher energy than ultraviolet (UV) light and includes X-rays 
and radiation produced by the decay of radioactive particles. The harmful nature of X-rays was 
evident shortly after their discovery in 1895 by Roentgen. Radiologists who used X-rays 
extensively in the early 1900s experienced a relatively high incidence of leukaemia, skin cancers 
and brain tumours. Subsequent animal experiments revealed the induction of sarcomas in 
laboratory animals after radiation exposure. 10 
The high energy associated with ionising radiation causes genetic mutations within the 
DNA. Absorption of dissipated energy by water is critically important in mutagenesis; 
ionisation ultimately leads to the generation of hydroxyl radicals, hydrogen radicals and solvated 
free electrons. 11 On interaction with DNA, these can lead to base deletions and alterations and 
attack on the sugar phosphate backbone, which can cause single, or double DNA strand breaks 
(Figure 3). 10 
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Figure 3 Base damage and ionizing radiation 
Ultraviolet Radiation 
Ultraviolet light is the major cause of human skin cancer. Skin cancer is very common 
but seldom lethal since the non-melanoma skin cancers metastasise slowly and are consequently 
highly curable. On the other hand melanoma is a much more serious form of skin cancer which 
rapidly spreads to other parts of the body .6 
In contrast to high-energy ionising radiation, UV radiation is not thought to cause 
genetic mutation through widespread nucleic acid bond-breaking processes. Its activity appears 
to be associated with the generation of excited states in DNA bases, which lead to mutagenic 
photochemical reactions. For example, excitation of pyrimidine bases (thymine or cytosine) 
allows them to dimerise to give a chemically stable cyclobutane linkage (Figure 4). 12 
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Figure 4 Photodimerisation of pyrimidines 
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1.3.3 Viruses 
Several kinds of viruses are found to induce human cancers. Hepatitis B virus-induced 
liver cancer and papilloma virus-induced cervical cancers are thought to account for 10-20% of 
overall cancer incidence. 13 The study of animal tumour viruses is extremely important to 
understanding the mechanisms of cancer in general. 
Oncogenic viruses do not kill their host cell but alter their critical genes resulting in the 
onset of cancer. 14 Structurally a virus consists of genetic material (DNA or RNA) encased in a 
protein capsid. On entry into the host cell the protein coat disappears and the viral DNA is 
integrated into the host's genome. After viral DNA integration, some of the viral genes are 
copied into mRNA molecules that in turn are translated into viral protein. Some of these can 
affect the activities of the host cell so that it becomes cancerous. Furthermore, these viral 
proteins can become incorporated into new viral particles able to leave and infect surrounding 
cells. 14 
1.4 Treatment of Cancer 
A variety of methods have been developed in cancer treatment, and the choice of 
treatment is largely dependent on the nature of the cancer and its extent of progression. 15 
1.4.1 Surgery 
Surgery is the first treatment option for many cancers. Early stage cancers that have not 
yet metastasised can be completely removed and are therefore highly curable. Unfortunately, 
over half of cancers by the time of diagnosis have already spread and cannot be cured solely by 
surgery. To improve the efficiency of treatment, the combination of surgery with other therapies 
described below is the most common strategy adopted today. 16 
1.4.2 Radiation Therapy 16 
Radiation therapy is similar to surgery being primarily a treatment for localised cancers 
although it can be used to attack cancer cells that have already spread beyond the surgical 
scope. 16 Radiation is frequently used in conjugation with surgery to eliminate cancer cells that 
have infected surrounding tissues outwith the primary tumour site. In addition, some cancers are 
particularly vulnerable to radiation, making it preferential in treatment of these diseases. 
A variety of types of irradiation sources are used in radiation therapy, including X-rays, 
and radioactive nuclei, such as cobalt-60 and radium. The basis for radiation therapy is to 
damage DNA, either directly or by the production of free radicals within cells. 16 This damage is 
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most pronounced in actively proliferating cells, which unfortunately includes some normal cells 
as well as cancer cells. 15 
1.4.3 Chemotherapy 
Chemotherapy is now the most widely used form of cancer treatment. The major 
advantage of chemotherapy is that, unlike surgery and radiation that are localised treatments, it 
can target cancer cells throughout the body. 15 However chemotherapy also has its drawbacks. 
Most of the currently used anticancer drugs target all rapidly proliferating cells including 
normal cells as well as cancer cells. They can consequently produce undesired side effects in the 
patient. Another major problem in cancer treatment is the development of resistance, particularly 
multidrug resistance to anticancer drugs. In this case, exposure to one particular drug results in 
resistance to a variety of other agents in addition to the initial drug. 15 
In spite of these limitations, cancer chemotherapy has achieved some remarkable 
successes. The chemotherapeutic agents briefly surveyed below are categorised according to 
their mechanism of action. 
1.4.3.1 DNA Interactive Compounds 
A large number of anticancer drugs exert their effect by damaging DNA or by 
interfering with DNA synthesis. Some drugs cause covalent interactions with DNA or between 
the base pairs of DNA that can result in crosslinks in either the minor or major grooves in an 
intramolecular or intermolecular fashion. 15 
1.4.3.1.1 Crosslinking Agents 
Nitrogen mustards 
Studies on sulfur mustard gas [S(CH2CH2C1)21 led to the nitrogen mustards; the first 
class of compounds to be investigated as anticancer agents. Mechlorethamine 4, the first 
nitrogen mustard to be synthesised, was found to depress the white blood cell count effectively 
and was used in the treatment of certain leukaemias. 15 
Aliphatic nitrogen mustards 
Nitrogen mustards are highly reactive and react readily with a wide range of 
nucleophiles, which results in the observed toxicities. The mechanism of action for aliphatic 
nitrogen mustards is illustrated in Figure 5.15 Under physiological conditions, the nitrogen 
mustards first undergo an intramolecular cyclisation with anchimeric assistance of the nitrogen 
8 
lone pair of electrons to form cyclic aziridinium ions. This cation is highly strained and hence 
highly reactive towards attack by the nucleophilic N-7-atom of a guanine residue in the major 
groove of DNA. The second chloroethyl group then reacts in a similar manner with a second 
guanine base on the complementary DNA strand. Thus the two strands of DNA are crosslinked 
and as a result DNA replication is terminated. 15 
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Figure 5 Mode of action of the aliphatic nitrogen mustards 
Due to its severe toxicity and short time of action mechloroethamine has only very 
limited application and is now confined for treatment of Hodgkin's disease and other 
lymphomas. In order to solve these problems, aromatic nitrogen mustards were developed as 
milder alkylating agents. 
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Melphalan 5 and chlorambucil 6 are typical examples of aromatic mustards. The 
electron-withdrawing effects of the aromatic ring of these agents decreases the rate of alkylation 
considerably. This decreased activity allows time for absorption and distribution before 
extensive alkylation occurs and these drugs can be taken orally which is a significant advantage. 
Melphalan 5 was developed in the hope that attachment of the amino acid phenylalanine 
to the nitrogen mustard might facilitate selective uptake by tumour cells. Although there is no 
evidence suggesting this to be the case, it has found clinical utility in multiple myeloma, breast 
and ovarian carcinoma and in the rare condition of macroglobulinaemia. 
Chlorambucil6 is probably the slowest acting and least toxic nitrogen mustard, often 
used in chronic lymphocytic leukaemia and carcinoma of the breast and ovary. 15 
Cyclophosphamide 
Cyclophosphamide 7 was synthesised with a view to producing more selective mustards 
as it was found that some tumours possess high concentrations of phosphoramidases. 15 The 
introduction of the P=O group into the lead compound should partially delocalise the nitrogen 
electron pair in a similar fashion to the phenyl ring of the aromatic mustards, thus decreasing the 
rate of alkylation. The cyclophosphamide was designed as a prodrug that would release the 
active drug at the required site of action. In practice, the drug was found to undergo initial 
metabolism in the liver prior to acting on tumour cells. 
Figure 6 illustrates the metabolism of cyclophosphamide. 17 Cyclophosphamide 7 
remains inert until metabolised in the liver by hepatic cytochrome P450 oxidases. The oxidised 
product 4-hydroxycyclophosphamide 8 exists in equilibrium with aldophosphamide 9. 
Aldophosphamide 9 is then conveyed to other tissues where it is transformed into 
phosphoramide mustard 13 and acrolein 12. The metabolite phosphoramide mustard 13 is the 
actual cytotoxic species and the side product acrolein 12 is responsible for haemorrhagic cystitis 
of the bladder. 17 
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Figure 6 The metabolism of cyclophosphamide 
Cyclophosphamide 7 proved to be the most successful mustard and has now been in use 
for over 20 years. Cyclophosphamide exhibits a broad spectrum of activity in treating malignant 
lymphomas and lymphoblastic leukaemia as well as carcinomas of the bronchus, breast, ovary 
and various sarcomas. 15 
Aziridines15 
The aziridines closely resemble the aziridium ions formed from the nitrogen mustards. 
Examples of this group of agents are thiotepa 14 and mitomycin 15 (mitomycin Q. Their mode 
of action is similar to the mustards. Aziridines have an aziridine ring already in their structure 
and the uncharged aziridine ring in 14 is less reactive than the fully charged aziridinium ions of 
the mustards. However, at physiological pH the aziridine ring in 15 is likely to be protonated 
due to the pKa of the aziridine nitrogen. Thus, in practice, the aziridinium ion may be the 
reactive species. 15 
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Mitomycin C is a natural antitumour antibiotic isolated from Streptomyces species, and 
is considered to be the prototype bioreductive alkylating agent. 15 The three components, 
quinone, aziridine and carbamate moieties of the mitomycin molecule are believed to be essential 
for its mode of action (shown in Figure 7)18. It is thought that the action starts with an enzyme- 
catalysed one electron reduction of the quinone ring system to a semiquinone radical. This 
radical can rapidly disproportionate to mitomycin C and a hydroquinone, which acts as a 
bifunctional alkylating agent. A molecule of methanol is lost from the hydroquinone and then 
the aziridine ring opens to generate the alkylating agent. Research has now revealed that the 
main mode of DNA interaction for mitomycin involves alkylation of two guanine-N-2 residues 
on different DNA strands that give rise to an interstrand crosslink within the minor groove. 
However the most prominent feature of mitomycin is its capability for bioreductive activation 
prior to DNA interaction. 15 It has been revealed that the centres of some tumours are hypoxic 
due to a poor blood supply. Therefore the bioreductive ability of mitomycin is thought to 
produce selective toxicity to hypoxic tumour cells. Mitomycin has now been successfully used 
in the treatment of solid tumours such as those of the colon, lung and breast. 15 
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Nitrosoureas 
Random screens performed by the USA National Cancer Institute in 1959 prompted the 
first work into nitrosoureas as potential chemotherapeutic agents. 19 
Two examples of clinically useful nitrosoureas are carmustine 16 [N, N'-bis(2- 
chloroethyl)-N-nitrosourea, BCNU] and lomustine 17 [N-(2-chloroethyl)-N-cyclohexyl-N 
nitrosourea, CCNU]. 
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The mechanism of action of this group of agents has not been firmly established. The 
mode of action shown here (Figure 8)20 was proposed by Reed et al. 21 The nitrosoureas are 
unstable at physiological pH and they decompose to an isocyanate and 2-chloroethyldiazene 
13 
hydroxide. It has been suggested that the latter compound spontaneously decomposes to 2- 
chloroethylcarbonium ion that is the major alkylating moiety. The carbonium ion is then 
attacked by the 0-6 position of a guanine (X) in one DNA strand followed by the slow loss of 
chloride ion resulting in a second alkylation of base (Y) in the complementary strand. This 
explains the important fact that all of the nitrosoureas, even those with only one chloroethyl 
moiety such as lomustine can form interstrand crosslinks in DNA. 
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Figure 8 Mode of action of nitrosoureas 
The most important feature of the nitrosoureas is their ability to cross the blood-brain 
barrier, which has allowed their successful application to cerebral cancers. 15 This feature is due 
to the high lipophilicity of these agents. BCNU and CCNU have also been used to treat 
malignant lymphomas and carcinomas of the breast, bronchus and colon. Unfortunately, the 
nitrosoureas suffer from dose-limiting adverse effects such as severe bone marrow toxicity. 15 
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Platinum Compounds22 
Cisplatin was discovered by chance as has happened with many other clinically used 
drugs. In 1965, Rosenberg and co-workers observed inhibition of bacterial division in an 
electric cell containing platinum electrodes. They discovered that it was the electrolysis products 
from the platinum electrode that caused the inhibition. Four years later, the same research group 
demonstrated the anticancer activity of several platinum complexes and cis- 
diamminedichloroplatinum (18, cisplatin) was identified as the most active one. Interestingly, the 
configurational isomer, trans-platin does not show any activity towards cancer cells. 
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Unlike most other alkylating agents, cisplatin forms intrastrand crosslinks 
predominately in the major groove of DNA with preferential interaction between the N-7 atoms 
of adjacent guanines, which results in the local denaturation of the DNA chain. 
Cisplatin was introduced into clinical use in the UK in 1979 and it is claimed to be the 
most effective drug for the chemotherapy of testicular and ovarian cancers. 59% of patients with 
testicular cancer and 30% with ovarian cancer were cured in clinical trials using cisplatin in 
combination with vinblastine. 15 Cisplatin has also shown activity towards many other tumours 
including cancers of the lung, bladder, head and neck. Major side effects of cisplatin are 
leukopaenia, extreme nausea and renal dysfunction that are usually dose limiting. Many 
analogues have been prepared in the hope of reducing the side effects of cisplatin. Of these, 
carboplatin 19 is now in clinical use and offers lower side effects towards the kidneys and 
nervous system. 
1.4.3.1.2 Intercalating agents 
These agents have a flat shaped structure usually containing three or four fused aromatic 
rings. The molecular structure allows them to insert between the hydrophobic faces of the base 
pairs of DNA perpendicular to the axis of the helix. The insertion is held by interactions with 
DNA base pairs via hydrogen bonding and van der Waals forces. 15 
Most examples of this class of anticancer drug were originally discovered from natural 
sources in screening programmes that tested antibiotics for cytotoxic activity. 23 The 
15 
intercalating agents normally used in the clinic are the anthracycline antibiotics (20,21 and 22), 
mitoxantrone 23, and dactinomycin 24. 
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Anthracyclines15 
The anthracycline antibiotics were first isolated from a variety of strains of Streptomyces 
fungi. They are the best known family of intercalating agents, consisting of a characteristic four- 
ring structure that is linked to an amino sugar. 
The exact mechanism for the activity of the anthracyclines has still not been fully 
elucidated but they are known to have several cytotoxic actions. Firstly, intercalation of the 
complementary strands of DNA is thought to interfere with DNA processing and transcription. 
The planar polycyclic moiety is inserted perpendicular to the axis of the helix and the amino 
sugar moiety is believed to interact with the sugar phosphate backbones of DNA to stabilise the 
adduct through hydrogen bonding. 
In addition, the anthracyclines are known to form complexes with topoisomerase II 
leading to the inhibition of this group of enzymes which normally direct strand breakage, 
uncoiling and annealing during DNA replication (see Section 1.4.3.1.3). 
Moreover, it has been observed that anthracyclines can bind to cell membranes, which 
could cause alteration of membrane fluidity and ion transport, and consequently change the 
biochemical equilibria in the cell. 
Finally, the quinone moiety of the anthracyclines can be reduced by a variety of quinone 
reductases. 23 Generation of semiquinone and dihydroquinone can produce free radicals that 
cause damage to DNA and cells. As shown in Figure 9,23 the one electron reduction of 
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anthracyclines provides the semiquinone, which then reacts with oxygen to generate superoxide 
anion 02', while the two-electron reduction affords the dihydroquinone derivative, which reacts 
with oxygen to generate 202°' or H202.23 Superoxide anion can dismutate to peroxide which 
in combination with an iron chelated drug complex can produce hydroxyl radicals which are 
believed to be responsible for the cardiotoxicity observed with the anthracyclines. 
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Figure 9 One-electron and two-electron reduction of anthracydines 
Doxorubicin 21 is an important anticancer drug exhibiting a wide range of activity 
against a variety of solid tumours including carcinoma of the breast, lung, thyroid and ovary. 
Daunorubicin 20 has an important role to play in the treatment of acute lymphocytic and 
myelocytic leukaemias. As doxorubicin and daunorubicin are valuable in clinical use, efforts 
have been made to develop semi-synthetic analogues including epirubicin 22. The 
anthracyclines produce unique cardiotoxic reactions in both adults and children, and also cause 
severe bone marrow suppression, nausea and vomiting. 15 
Anthracenes15 
These compounds were synthesised as anthracycline analogues and have three rather 
than four fused rings. Mitoxantrone 23 is an example of an anthracene that is used clinically to 
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2. Two-Electron Reduction 
treat childhood and adult myelogenous leukaemia, non-Hodgkin's lymphoma and breast cancer. 
These drugs have very low cardiotoxicity compared with the anthracyclines, as they are unable 
to generate free radicals. 
Phenoxazines23 
Dactinomycin 24 was isolated from Streptomyces parvulus in the 1940s. The compound 
has two identical pentapeptide lactones that are linked to a phenoxazone ring system. Much 
work has been done on the synthesis, biological action, and use of this drug. 
At low concentrations, dactinomycin inhibits DNA-directed RNA synthesis preventing 
chain elongation whereas at higher concentrations DNA synthesis is also inhibited. The 
phenoxazone ring can interact with the N-2-amino groups when inserted preferentially between 
guanine-cytosine base pairs of DNA. The cyclic pentapeptide moieties interact with functional 
groups in the narrow groove of DNA via hydrogen bonding and hydrophobic interactions, 
which stabilise the DNA adduct with dactinomycin and block RNA polymerase. It is notable 
that dactinomycin also causes single-strand DNA breaks either through radical formation or by 
interaction with topoisomerase. 
Dactinomycin is employed in the treatment of paediatric solid tumours, including Wilms' 
tumour and Ewing's sarcoma. It has been proved effective for gestational choriocarcinoma, and 
is also useful in the chemotherapy of some testicular sarcomas and Kaposi's sarcoma; a tumour 
associated with AIDS patients. 
1.4.3.1.3 Topoisomerase inhibitors24 
Etoposide 25 and teniposide 26 are semisynthetic analogues of podophyllotoxin 27, a 
microtubule inhibitor found in extracts of the American mandrake plant. It was initially expected 
that etoposide, too, would inhibit microtubule function. Further investigation indicated that its 
major activity arises from topoisomerase II inhibition. 
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The normal function of topoisomerase II involves initial interaction with DNA forming a 
noncovalent complex that is noncleavable, as removal of the enzyme at this stage would leave no 
strand breaks. The enzyme then cuts both DNA strands, and one of the newly formed 5'- 
phosphate ends of the DNA attaches to a protein subunit via covalent bonding. This enzyme- 
DNA complex is considered cleavable, since dissociation of the complex at this point would 
result in a permanent double strand break. However the cleavable complex is a transient form. In 
the absence of enzyme inhibitors, the complex either goes back to the noncleavable complex or, 
after a topological change has been affected, the breaks are resealed with subsequent release of 
the free enzyme from the DNA. Etoposide is known to stabilise the cleavable complex, thus 
preventing it from converting back into the noncleavable complex or from completing 
topological changes. As a result of this, the drug-complex may then undergo spontaneous 
denaturation leading to the generation of unrepairable double-strand breaks at critical sites. 
It has been observed that etoposide treatment prevents activation of the protein kinase 
p34. This kinase is usually activated at the end of the G2 phase of the cell cycle and has a 
pivotal role in the initiation of mitosis. It is thought that the observed arrest of cells in the G2 
phase, after treatment with etoposide, may be due to interference with p34 function. 25 
Etoposide is claimed to be one of the most effective drugs for the chemotherapy of lung 
cancer and testicular cancer; combination therapy with cisplatin and bleomycin is now the 
standard treatment for the latter condition. Etoposide has found clinical use in the treatment of 
lymphocytic leukaemia and brain tumours in adults. 
1.4.3.1.4 DNA Cleaving Agents 
The bleomycins 28 are a group of metal-chelating glycopeptide antibiotics isolated from 
cultures of Streptomyces verticillus. The general structure of the bleomycins is shown below. 
These compounds have very complex structures and have attracted much interest among organic 
chemists. The first total synthesis of bleomycin was reported in 1982.15 
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28 General structure of the bleomycins 
The most prominent feature of bleomycins is their ability to degrade DNA. 26 
Bleomycin has been found to break single strands of DNA predominantly and thus causes 
DNA fragmentation, but some double-strand breakage has also been observed. 26 These agents 
exhibit their anticancer activity by inhibition of DNA synthesis and have much less effect on 
RNA and protein synthesis. 25 
Three distinct regions of bleomycin are believed to be essential to its mechanism of 
action. 15 First, the planar shaped bithiazole moiety (top right as drawn) is thought to act as an 
intercalator which is inserted perpendicular to the axis of the DNA helix. The second part (top 
left) consists of primary amine, pyrimidine, and imidazole nitrogens which function as ligands 
to chelate with ferrous iron forming a metal coordination site. The Fe(II) bleomycin complex 
interacts with oxygen in a redox cycle to generate superoxide and/or hydroxyl radicals leading 
to single- and double-strand breaks. The third region of bleomycin (bottom left) has a 
glycopeptide structure which has no direct antitumour activity of its own, but may contribute to 
the water solubility of these drugs. Bleomycin has been found to affect the G2 phase of the cell 
cycle and mitosis profoundly and is also effective in Gp phase. 15 
Bleomycin produces very little bone-marrow depression which is a big advantage 
compared with most anticancer drugs. It has been widely used, in particular for the treatment of 
testicular carcinoma, squamous cell carcinomas, and lymphomas23 
1.4.3.2 Antimetaboltes 
An accumulation of nucleic acids and proteins is required in preparation for cell division. 
The antimetabolites interfere with this process by either of the following pathways. 27 Some of 
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the agents prevent the synthesis of DNA by poisoning the enzymes required in the formation of 
the deoxyribonucleoside triphosphates that are the immediate precursors for DNA synthesis, 
and this occurs in the S phase of the cell cycle. Alternatively, some antimetabolites are designed 
as structurally closed mimics of normal purines or pyrimidines that are able to compete for 
places in the nucleotide pathways. 27 The main antimetabolites include pyrimidine analogues, 
folate antagonists and purine analogues. 
1.4.3.2.1 Pyrimidine analogues 
A well known antimetabolite is 5-fluorouracil 30 which was designed as a close 
analogue of uracil 29 and thymidine 31, the corresponding bases in RNA and DNA 
respectively. It is known to inhibit cell division in several ways. 
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The structural similarity with a nucleotide allows 5-fluorouracil to be incorporated into 
DNA and RNA in place of thymidine and uracil, respectively, causing mutations in DNA and 
RNA. 
On the other hand, 5-fluorouracil exhibits its cytotoxic effect through inhibition of 
thymidylate synthetase, the key enzyme in the conversion of deoxyuridine monophosphate 
(dUMP) 32 into deoxythymidine monophosphate (dTMP) 33 (Figures 10 and 11)28 with the 
assistance of a cofactor called tetrahydrofolate 34. Inhibition of thymidylate synthetase 
interferes with the production of thymidine and consequently DNA synthesis and hence cell 
division is inhibited. 
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In the absence of inhibitor, thymidylate synthetase catalyses the conversion of dUMP 
into dTMP transferring a single carbon unit from tetrahydrofolate to the 5-position on the uracil 
skeleton, and the thymidine formed is subsequently used in DNA synthesis. 
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The mode of action of 5-fluorouracil is illustrated in Figure 11.28 5-Fluorouracil first 
combines with thymidylate synthetase and the cofactor to form a transition state complex. In 
this intermediate a methylene unit of the tetrahydrofolate bonds to the 5-position on the uracil 
skeleton. The next step, which usually involves the loss of a proton from the 5-position of uracil 
to release the enzyme, cannot occur as 5-fluorouracil has a fluorine atom at the 5-position 
instead of a hydrogen. Therefore further reaction is impossible since it would require fluorine to 
leave as a positive ion. Consequently 5-fluorouracil remains bound to the active site of the 
enzyme irreversibly. The synthesis of thymidine and hence DNA synthesis is thus terminated at 
this stage. 28 
5-Fluorouracil is successfully used in the treatment of skin cancer as a 5% cream, and 
has proved clinically useful in treating certain solid tumours such as those of the gastro- 
intestinal tract, breast and pancreas. 
v 
H" 
tF4 
22 
1.4.3.2.2 Folate antagonists 
Methotrexate (MTX) 36 is a folate antagonist and has been widely used in cancer 
chemotherapy. 
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The one-carbon groups (R) to be transferred by tetrahydrofolate 
can be attached to the folate structure at the N-5 or N-10 position 
(or both, forming an extra ring). 
The vitamin folic acid 37, the core structure for all folates, is essential for the synthesis 
of purine and pyrimidine nucleotides needed for the biosynthesis of DNA. In order to act as a 
coenzyme, folic acid must be reduced in two successive steps by dihydrofolate reductase 
(DHFR) to afford 7,8-dihydrofolate 35 (FH2) and then 5,6,7,8-tetrahydrofolate 34 (FH4) 
(Figure 12). 17 It is this final reduced form that delivers single carbon units in the methylation of 
dUMP to form dTMP (Figures 10 and 11), and also in the de novo synthesis of purines. 27 
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The primary biochemical function of methotrexate is to inhibit DHFR activity. 
Methotrexate binds more strongly to the active site on DHFR than 37 and FH2 due to the 
presence of an extra amino group that increases the basicity of the pyrimidine ring. Once this 
inhibition occurs, and the tetrahydrofolate is used up in dTMP synthesis, de novo production of 
uridine and thymidine nucleotide cease. 27 
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Methotrexate is highly effective in the treatment of choriocarcinoma. It is also employed 
in the treatment of acute leukaemia and many solid tumours. 
1.4.3.2.3 Purine analogues27 
The main purine analogues are 6-mercaptopurine and 6-thioguanine. They are first 
subject to enzymatic conversion into their active forms that in turn inhibit several enzymatic 
pathways in the biosynthesis of purines. Eventually DNA synthesis ceases due to a lack of the 
purine bases adenine and guanine. The major problem of these drugs is their lack of selectivity, 
since purines are involved in many cellular processes apart from nucleic acid synthesis. They 
are used primarily to treat acute childhood leukaemias. 
1.4.3.3 Antitubulin Agents29 
Microtubules are involved in various cellular functions including mitosis, cell movement 
and cell shape. The major component of microtubules is protein tubulin. Polymerisation of 
tubulin dimers to form microtubules is an integral part of mitosis. Microtubules exist in a very 
sensitive equilibrium between free tubulin dimers and assembled polymers. Antitubulin agents 
act by disrupting this equilibrium. 
Vinca alkaloids 
Two Vinca alkaloids, vinblastine 38 and vincristine 39, which were isolated from the 
Madagascar periwinkle plant (Vinca rosea), play an important role in cancer chemotherapy. 
Their cytotoxic effects arise from binding to the tubulin dimers, which disrupts the equilibrium 
between microtubule polymerisation and depolymerisation. As a result the mitosis is blocked by 
metaphase cell arrest. 
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Vinblastine is included in several drug regimens for treating Hodgkin's disease, breast 
cancer and testicular carcinoma. Vincristine is commonly used in drug combinations for the 
treatment of acute lymphoblastic, childhood leukaemias and many other solid tumours. 
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Paclitaxel (Taxol)30 
The important microtubule antagonist paclitaxel (Taxol) 40 was originally isolated from 
the bark of the yew Taxus brevifolia. In contrast to the Vinca alkaloids, Taxol disturbs the 
delicate tubulin-microtubule equilibrium in favour of microtubule formation. This causes 
stabilisation of the microtubules and hence the construction of an abnormal bundle of 
microtubules, and as a consequence the mitotic phase of the cell cycle is disrupted. 
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The clinical application of Taxol has been hampered by a lack of a synthetic source of 
this very scarce natural product. The yew tree Taxus brevifolia has remained as the major source 
of this compound until recently. Taxol is now generally obtained by semi-synthesis from 10- 
deacetylbaccatin III, isolated from the needles of a related plant. Taxol has attracted much 
interest among cancer biologists and organic synthetic chemists for its potential clinical value. 
Its total synthesis has been reported by the groups of Holton31, Nicolaou32, Danishefsky33 
and Mukaiyama. 34 
Taxol exhibits significant activity in the treatment of a variety of cancers including 
ovarian, breast, lung and head cancers. This promising agent is particularly useful in the 
treatment of the advanced metastatic forms of many cancers. 
1.4.3.4 Anti-hormonal agents35 
Tumours derived from sexually differentiated tissues such as the endometrium, prostate 
and breast can be strongly influenced by the levels of related hormones ' in the body. This 
hormone-dependent response can be exploited chemotherapeutically to control the growth of 
cancer. 35 Tamoxifen 41 and leuprolide are two successful anticancer drugs that have resulted 
from this work. 
Tamoxifen, an anti-oestrogenic agent, has pronounced activity in some cases of 
hormone-dependent breast cancer, and may be useful in preventing these cancers. Tamoxifen is 
known to exert its activity by binding to the oestrogen receptors of the tumour cells preventing 
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them from binding to endogenous oestrogens35 and it therefore inhibits the growth of 
oestrogen-dependent tumour. 
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Prostate cancers are hormone responsive and are known to be stimulated by androgens 
like testosterone. Testosterone is secreted by the Leydig cells of the testes in a process 
controlled by gonadotrophin releasing hormone (GnRH) and leuteinising hormone (LH). 
Leuprolide, a clinically used decapeptide drug, works by competitive inhibition of the GnRH 
receptors thereby reducing androgen production. 
1.5 The Search for New Anticancer Drugs 
The preceding sections have outlined the causes and treatments of cancer, with particular 
emphasis on the anticancer drugs and their mechanism of action. The discovery of clinically 
useful anticancer drugs has arisen from a variety of areas such as screening of natural products, 
analogue studies of active compounds and serendipity. The recent use of combinatorial methods 
has allowed the generation of libraries of compounds for screening purposes. Also, more 
emphasis has been placed on rational drug design based on key biological targets since 
substantial knowledge has been acquired of the fundamental biochemical differences between 
normal and tumour cells. In addition X-ray crystal structures are now available for a number of 
important enzymes and computer modelling is being used to design new compounds which 
should be prepared for evaluation as anticancer compounds. 
There have been prodigious advances in the understanding of the basis of malignancy, in 
particular the role of oncogenes and tumour suppressor genes. A large number of oncogenes 
have now been identified and sequenced, and the technology to design and produce gene- 
targeted agents is rapidly advancing. Exciting developments have been made in gene therapy in 
which tumour suppressor genes are inserted into the DNA of cancer cells. 
Recent advances in molecular biology have led to the development of new approaches 
towards selectivity enhancement of anticancer drugs. For example, The ADEPT15 (Antibody- 
Directed Enzyme Prodrug Therapy) and GDEPT15 (Gene-Directed Enzyme Prodrug Therapy) 
approaches have been investigated to enhance the selectivity of cytotoxic agents. In ADEPT, 
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firstly an antibody-enzyme conjugate is administered to the patient and this is delivered to the 
tumour site. A prodrug is then administered and this prodrug can be converted into the active 
cytotoxic agent only when contacted with the enzyme at the tumour site. 
As these and other novel therapies emerge, it is likely that dramatic advances in the 
treatment of cancer will occur in this century. 
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CHAPTER 2 
Cell Signalling and MAP Kinase Inhibitors 
2.1 Intracellular signal transduction 
Intracellular signal transduction is a process by which a signal is transmitted from the 
cell surface to the nucleus. 36 The signalling cascade, initiated by the binding of many diverse 
extracellular stimuli to specific receptor molecules on the target cell surface, serves to transmit a 
signal through the cytoplasm to the cell nucleus, ultimately resulting in cell division or other 
appropriate biological response. 
2.1.1 Protein kinases 
Protein kinases play a vital regulatory role within the cell signalling pathways in that 
they catalyse the phosphorylation of target proteins at specific sites in the pathways. Protein 
phosphorylation is a common process for signal transduction within cells. 37 The protein 
kinases are activated by phosphorylation catalysed by upstream kinases and, in turn, 
phosphorylate several different downstream kinases and other functional substrates. Thus a 
series of protein kinases can act as "molecular relay runners" to transmit signals from the cell 
surface to the nucleus, leading to changes in gene expression, DNA synthesis, and cell 
proliferation. 
The protein kinases comprise two main subdivisions: the protein tyrosine kinases and 
the protein serine/threonine kinases. 38 The two groups of kinases are distinguished by the 
specific amino acid residues which they modify by phosphorylation. In the phosphorylation 
process the y-phosphate of ATP is transferred to the phenolic group of tyrosine residues when 
catalysed by tyrosine kinases, and to the alcohol groups of serine or threonine residues when 
catalysed by serine/threonine kinases. As a result the phosphate monoester and ADP are 
formed (Figure 13). 39 
Phosphorylation of these phenolic and hydroxyl groups disrupts their hydrogen 
bonding and changes their polarity causing the enzyme to change its tertiary structure, and as a 
consequence the activity of the phosphorylated protein is frequently altered. 
Multiple signalling pathways integrate into a network within individual cells to elicit 
various physiological responses including cell proliferation. One of the most important of these 
pathways is the mitogen-activated protein (MAP) kinase pathway. 
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Figure 13 Phosphorylation Catalysed by Protein Kinase 
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2.1.2 Mitogen-Activated Protein (MAP) Kinase Cascade40 
MAP kinases are a family of serine/threonine kinases which can act together to generate 
a process of phosphorylation events within the signalling pathway. It has been revealed that the 
MAP kinases are divided into three main subfamilies. The extracellular signal regulated kinases 
(ERK1/2) comprise the first subdivision, which contains a mitogen-activated MAP kinase 
subfamily. The other two principal subfamilies are composed of the JNK/SAPK (stress- 
activated protein) and p38 kinases. 
Four distinct MAP kinase pathways have been so far identified in yeast and three in 
mammals. As an example, the best known ras/ERK MAPK pathway represents signalling 
transduction in the phosphorylation cascade (Figure 14)' 
2.1.2.1 Ras/ERK MAPK pathway41 
The ERKs are activated by MEKs (MAP/ERK kinases) via phosphorylation of 
threonine and tyrosine residues. These MAPK-activating enzymes are unusual in their ability to 
catalyse phosphorylation of both threonine and tyrosine residues. MEKs are in turn activated 
by phosphorylation of two adjacent serine/threonine residues by upstream kinases known as 
raf. Raf is a serine/threonine kinase oncogene which appears to require activation by association 
with ras in an undefined event. Ras, a G-protein (guanine nucleotide binding protein), which is 
only active in a GTP-bound state, links receptor tyrosine kinase activation to the intracellular 
MAP linse pathway. 
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Figure 14 rasIERK MAPK pathway 
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2.1.2.2 JNK/SAPK MAPK pathway42 
The JNK/SAPK pathway, which is activated in response to stress stimuli, represents a 
distinct MAPK pathway, targeting transcription factor c-jun which controls the expression of 
genes involved in cell proliferation. 
JNK/SAPKs are observed to be strongly activated by cellular stress stimuli and hence 
the name stress-activated protein kinase (SAPK) is derived. The SAPKs have been shown to 
stimulate phosohorylation and activation of the transcription factor c-jun and they are believed 
to be the main c-jun kinases (JNK). 
Molecular biological studies have revealed that the amino acid sequences (Serfrhr-Pro- 
Glu or Ser/Thr-Pro-Asp) represent a preferred consensus sequence for phosphorylation by 
JNK/SAPKs, and that JNK/SAPKs often bind directly to their substrates via a distinct docking 
domain as exemplified by the delta domain of c -Jun. 
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SAPKs are activated by chemicals, irritants or chemotherapeutic drugs and they are 
important for growth arrest, repair, apoptosis, etc. 30 
2.2 Model for MAP Kinase Inhibitors 
MAP kinases are involved in the regulation of a variety of transcription factors 
necessary for the transcription of DNA. Mutations or enhanced activity by overexpression in 
receptor tyrosine kinase or oncogenic forms of ras, raf or transcription factors, jun in the MAP 
kinase pathway can lead to cancer. Consequently, targeting the MAP kinase family of enzymes 
may lead to new drugs for the treatment of cancer. 
Previous work in the area of synthesis of MAP kinase inhibitors in our research group 
was carried out by Pearson 43 A series of aromatic compounds with oxygen substituents 
modelled on serine 42 were synthesised and several of them showed inhibitory activities in the 
MAP kinase biological assay. 
The compounds in this project were designed to target the stress related kinases 
specifically. As mentioned above, the stress related kinases are known to have a serine/threonine 
joined to a proline 44 residue. In an attempt to prepare selective inhibitors of stress related 
kinases, compounds 45 and 46 were designed in which a conformationally restricted serine 
analogue is joined to L-proline via an amide link in two possible ways. 
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Rl = F, OMe, OH 
R2 = H, OMe 
R3 = H, OMe 
These two set of compounds were synthesised and tested for biological assay. The 
synthsis and biological test results are discussed in Chapter 5. 
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CHAPTER 3 
Checkpoint Control 
Cell cycle checkpoints are parts of signalling pathways which control key transitions in 
the life of a cell to ensure the fidelity of DNA replication and chromosome segregation" In 
the event of DNA damage checkpoint regulatory pathways are activated resulting in cell cycle 
arrests at both the G1 /S and G2/M transitions to provide time for the repair of damaged DNA, 
or in the case of severe damage, for activation of programmed cell death. 
45 
In response to DNA damage, mammalian cells activate the p53 tumour suppressor gene, 
which induces transcription of p21C1I, a cyclin-dependent kinase inhibitor, resulting in cell 
cycle arrest at the G1/S checkpoint. 
46 On the other hand, G2/M arrest is caused by inhibitory 
phosphorylation of p342 protein kinase in both fission yeast and mammalian cells47. In the 
following section we will discuss the major features of the G2/M checkpoint that regulate the 
onset of M-phase during the cell cycle. 
3.1 Checkpoint pathways 
The pioneering work in the checkpoint control field was carried out by Hartwell and 
Weinert48 who identified checkpoint mutants which were able to undergo mitosis even if DNA 
damage was not repaired. In 1997 three groups of scientists` 
4,45,49 reported their 
breakthrough work in the understanding of the functions of checkpoint proteins. Combining 
their work, an elegant mode147 (shown in Figure 15) for a checkpoint pathway emerged. 
3.1.1 Rad3 Protein Kinase 
After DNA damage, the protein kinase Rad3 is activated. Rad3 is a rad mutant in the 
fission yeast Schizosaccharomyces pombe as it is sensitive to DNA damage caused by 
radiation. 50 Sequence analysis revealed that rad3 is related to ATM, a gene mutated in ataxia 
telangiectasia patients. 51 It is believed that Rad3 is required in activation of the DNA damage 
checkpoint in which phosphorylation of Chkl is increased by a Rad3-dependent process. 
45 
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3.1.2 Chkl Protein Kinase 
In 1993 Walworth et al. 50 reported the identification of Chkl protein kinase in fission 
yeast which links the rad checkpoint pathway to cdc2, a crucial regulator for the onset of 
mitosis. 52 The sequence of Chkl was found to be 30-40% identical to the family of 
serine/threonine protein kinases 44 Researchers suggested that in response to DNA damage 
Chk 1 is activated by phosphorylation in a Rad3-dependent manner. 50 Activated Chk 1 then 
functions upstream of Cdc25 in fission yeast and in mammalian cells 45 
3.1.3 Cdc25 Protein Kinases and 14-3-3 Protein Kinases44 
Cdc25 are dual-specificity protein phosphatases which can form complexes with 
Chk1.44 There are three Cdc25 homologues including Cdc25A, Cdc25B and Cdc25C, and it is 
Cdc25C which regulates Cdc2 at the onset of mitosis. Research identified Cdc25 as a direct 
substrate of activated Chkl which phosphorylates Cdc25C on a physiologically significant 
residue, Ser216. It appeared that phosphorylation of Cdc25 itself does not directly inhibit 
Cdc25.69 Peng et al. 49 found phosphorylation of Cdc25C on Ser216 facilitates the binding of 
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14-3-3 protein as the Ser216 residue is embedded in a potential recognition motif for the 
binding of 14-3-3 proteins. 14-3-3 proteins are a family of small acidic proteins that bind to 
signalling molecules including phosphatases. Binding of 14-3-3 proteins does not inactivate 
Cdc25C53 but may act by preventing entry of Cdc25C into the nucleus, therefore preventing the 
activation of Cdc2. In this way, onset of mitosis is blocked when inhibitory phosphorylation of 
Cdc2 remains intact. 
3.1.4 Cdc2 Proteins 
Cdc2 is believed to be the ultimate target of the checkpoint signalling pathway. 52 Cdc2 
is a cyclin-dependent kinase that regulates the entry into M-phase. In response to blockade of 
DNA replication, the inhibitory phosphorylation of Cdc2 causes arrest in the G2 phase of the 
cell cycle. Genetic studies revealed that phosphorylation of Cdc2 occurs on the Tyr15 residue in 
both fission yeast Schizosaccharomyces pombe and mammalian cells, and this phosphorylation 
is maintained in part by the activity of protein kinases Wee 1 and the inactivity of phosphatase 
Cdc25.53 Activation of Cdc2 is essential for the induction of mitosis and this can be facilitated 
by activation of Cdc25 and inhibition of Weel activity that cause dephosphorylation of the 
Tyr15 residue in Cdc2. The phosphotyrosine 15 in Cdc2 is located in the ATP binding site, 
which suggests that part of the activation mechanism involves the removal of this phosphate 
group allowing the kinase to use ATP and hence the kinase activity appears. 52 
3.2 Implications in Cancer Treatment 
The tremendous advance in understanding of the DNA damage checkpoint signalling 
pathway provides a new approach to cancer treatment. The cancer cells undergo mitosis with 
damaged genomes when the DNA damage checkpoint control is abrogated, and this eventually 
leads to tumour death. Components in the checkpoint signalling pathway such as Chkl, 14-3-3 
or Cdc25 could be potential targets for chemical intervention. It is of interest that the 
chromosomal location of Chkl was mapped to l 1g24 which is adjacent to the gene encoding 
ATM at 11g23, and this region has been associated with a number of cancers including lung, 
ovary and breast cancers 44 
3.3 Caffeine-mediated Activation of Cdc246 
The tumour suppressor gene p53 plays a crucial role in the induction of cell cycle arrest 
at the G1 checkpoint in response to DNA damage. Its inactivation is believed to be responsible 
for the resistance of many cancers to genotoxic anticancer agents. Inactivation of the tumour 
suppressor gene p53 is observed in many cancer cells. DNA damage results in preferential 
accumulation of p53-deficient cancer cells at the GJM transitions as these cells fail to arrest at 
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G 1. Thus abrogation of G2 arrest via chemical intervention may render those cancer cells more 
sensitive to DNA damaging agents. 
Caffeine 47 and pentoxifylline 48 have been demonstrated to suppress the G2/M 
checkpoint and prevent activation of Chkl, 46'54 presumably by inhibiting one or more 
upstream steps in the DNA damage signal transduction process. Although the mechanism of 
action of caffeine has not yet been fully elucidated, the upstream checkpoint kinases Rad3 in 
yeast and ATM/ATR in vertebrate cells are likely targets for inhibition. Caffeine has been 
shown to sensitise p53-deficient tumour cells to killing by DNA damage. This may provide a 
promising therapeutic strategy for circumventing the resistance of p53-deficient cancers to 
DNA damaging agents. 
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3.4 Proposed Work 
We envisage that xanthine analogues of caffeine 47 and pentoxifylline 48 may also 
disrupt the G2 checkpoint by preventing activation of Chkl. To test this hypothesis, we sought 
to prepare a range of xanthine derivatives (as shown in Figure 17) by alkylation of theophylline 
49. 
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CHAPTER 4 
NDGA and Its Mode of Action 
4.1 Introduction 
Nordihydroguaiaretic acid 50, more commonly abbreviated to NDGA, is a phenolic 
lignan isolated from the resinous extracts of many plants, especially Larrea divaricata. 55 
The species Larrea divaricata, also known as the creosote bush, is indigenous to the 
south western USA. The creosote bush grows in the desert and is one of the most drought 
tolerant plants of the region. It can survive a period of drought of up to two years and individual 
plants are known to live for 100-200 years. 
56 It has been used in treatment of a variety of 
diseases by native Americans for thousands of years 57 
The first isolation of NDGA 50 from the creosote bush was reported by Waller and 
Gisbold in 194555. NDGA has been used as an antioxidant in food and pharmaceutical 
preparations. NDGA has a non-toxic nature58 and found potential applications in cancer 
treatment in the 1980s. It has provoked much interest amongst cancer biologists in the past 
twenty years. 
4.2 Structure Determination 
The structure of NDGA was established by synthesis. NDGA was prepared by 
Schroeter and his co-workers in 1918 from the dimethyl ether of guaiaretic acid by 
hydrogenation and subsequent demethylation. 59 The authors suggested the meso configuration 
for the tetramethyl ether of NDGA. This compound has since been synthesised by Haworth et 
al., 60 who assigned the compound as the racemate (the two enantiomers of NDGA are shown 
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below). Later the work of Schrecker61 demonstrated that the naturally occurring optically 
inactive NDGA was the meso rather than the racemic form. 
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51 52 
Perry et al. 62 designed a number of experiments in order to provide unambiguous 
evidence for the configuration of NDGA. The commercial NDGA was methylated to give the 
tetramethyl ether 53 whose melting point was identical with that previously reported. 59,60,61 
Bromination yielded the dibromo derivative 54 in high yield (Figure 18). A single crystal X-ray 
analysis of 54 confirmed that NDGA has the meso configuration. 
62 
Figure 18 Structure Determination of NDGA 
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4.3 Synthesis of NDGA62 
Several syntheses of the natural product meso nordihydroguaiaretic acid have been 
reported in the literature. Among these synthetic pathways the approach62 (Figure 19) reported 
by Perry et al. in 1972 is the most efficient one and of practical interest. 62 The creosote bush 
had remained the only commercial source of NDGA before Perry's synthesis was published. 
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Figure 19 Synthesis of NDGA 
58 
50 
Perry's synthesis started with a Friedel-Crafts acylation of 1,2-dimethoxybenzene with 
propionyl chloride which afforded the ketone 55 in quantitative yield. The ketone was 
transformed into the a-bromoketone 56 in a high yield of 95%. The highly stereoselective 
condensation of ketone 55 with bromoketone 56 in liquid ammonia at -33 
°C gave the racemic 
diketone almost exclusively. The proposed mechanism leading to this stereoselectivity is 
depicted in Figure 20. The cyclodehydration was achieved by refluxing the CH2C12 solution of 
diketone 57 in the presence of methanolic HC1 to give the furan 58 in high yield. A remarkable 
solvent effect was observed in the hydrogenation of furan 58. The use of THE as a solvent and 
palladium oxide as a catalyst, together with high pressure and elevated temperature, gave rise to 
a good yield of 78% in the conversion of furan 58 into NDGA tetramethyl ether 53. Finally, 
demethylation of 53 with refluxing concentrated hydrobromic acid afforded NDGA 50 as white 
crystals in 66% yield after three recrystallisations from 20% aqueous AcOH. The final product 
was reported to be identical with a purified sample of the natural product. 
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The mechanism proposed for the stereoselectivity is as follows. Enolisation of ketone 55 
should give predominantly the (Z)-enolate 59 which can react with either enantiomer 56a or 56b 
from either above or below 59. However it would be less hindered when the aroyl group of 56 is 
furthest from the aroyl group of 59, and the methyl group of 56 is towards the oxygen of 59 
rather than the aryl group. Thus in the sample shown in Figure 20, the trans-enolate 59 would 
more likely react with 56b than 56a, and substitution of bromide with Walden inversion would 
lead to one enantiomer of the racemic diketone 57. Likewise, with equal possibility, attack of 56 
from the top face of 59 would give the other enantiomer of 57, with the net result that the racemic 
diketone 57 is formed. 
4.4 Mode of Action of NDGA 
All known lipoxygenase (LO) inhibitors have a catechol group which is believed to 
contribute towards their mechanism of action. Baicalein 61 and esculetin 62, both containing the 
catechol group, are found to be LO inhibitors. 63 
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It was observed that replacement of the two hydroxyl groups with methoxy groups 
reduced the activity of both baicalein and esculetin, which confirmed that the catechol group is 
essential for their activities. This observation prompted work into NDGA as a potential 
anticancer agent since it has two catechol groups. 
NDGA, known as a 5-lipoxygenase inhibitor, was found to suppress the in vitro growth 
of several different human cancers such as those arising in the breast, lung, stomach, pancreas, 
brain and cervix. 64 Moreover, NDGA also blocks the in vivo growth of several of these cancers 
including both small cell (SCLC) and non-small cell lung cancer (NSCLC). Lung cancer is the 
commonest cancer killer in the developed world and identification of novel therapeutic strategies 
are urgently required. Thus, NDGA has become a potentially important lead compound for the 
treatment of this cancer. 
Patients with SCLC usually die sooner than those with NSCLC. Consequently, the 
identification of new treatments prolonging survival are likely to be most rapidly discovered in 
patients with SCLC. In order to arrive at the rational design of novel anticancer agents, it is 
important to understand the biology of the cancer cell and of SCLC in particular. 
4.4.1 Small CeU Lung Cancer 
Small cell lung cancer (SCLC) constitutes about 20% of all lung cancers and causes 
significant morbidity and mortality around the world. 65 SCLC follows a highly aggressive 
clinical course and is a distinct clinicopathological entity among lung cancers. SCLC has nearly 
always metastasised at the time of diagnosis, 
65 and although it is initially sensitive to 
chemo/radiotherapy, most patients rapidly relapse with treatment-resistant disease. Therefore, 
the five year survival rate for these patients is < 5%. 65 consequently, the development of novel 
therapeutic strategies for SCLC is urgently required. The risk of developing SCLC is directly 
linked to the number of cigarettes smoked and it is very rare for a non-smoker to suffer from 
this cancer type. 
The search for novel therapeutic strategies has been directed by growth factors which are 
implicated in the proliferation of tumour cells in autocrine/paracrine loops. The factors and 
signalling pathways that stimulate the proliferation of the tumour cell have been extensively 
studied in SCLC. 
66 Multiple neuropeptide and certain polypeptide growth factors are now 
recognised to drive the proliferation of SCLC cells in both an autocrine and paracrine 
fashion. 66" 67 These growth factors bind to specific cell surface receptors and elicit intracellular 
signalling pathways communicating with various cellular compartments including the nucleus to 
orchestrate the synthesis of new proteins necessary for DNA synthesis and cell division as well 
as survival and migration. It has become clear that the signals used by distinct growth factors 
can overlap and so inhibition of such common signalling molecules may be an attractive 
therapeutic strategy to inhibit the actions of these different growth factors 68 One such common 
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signalling pathway involves the metabolism of arachidonic acid (AA) which is involved in 
tumour growth and metastasis 58,69,70 Therefore the development of small molecule inhibitors 
which target lipoxygenases provides a novel therapeutic approach. However, targeting a single 
molecule may be insufficient as cancers rapidly mutate their phenotype and so a better strategy 
might be to identify small molecule inhibitors which inhibit several targets in cancer cells. 
The elements of growth factors and their receptors and arachidonic acid metabolism 
pathways are considered in the succeeding section. 
4.4.1.1 Growth Factors and Their Receptors 
Growth factors are secreted proteins which serve as stimulators/inhibitors to regulate the 
proliferation of specific cell types in response to the needs of the whole organism. There are at 
least two types of growth factors, the neuropeptides and the larger polypeptide growth factors. 
Both of these are involved in SCLC biology. 66'71 
Extracellular growth factors act by binding to specific receptor on the surface of their 
target cells which then trigger a cascade of intracellular signal transduction. The intracellular 
signals are ultimately transmitted to the nucleus whereby they alter the programmes of gene 
expression which control cell behaviour. 72 
Growth factor receptors act as external sensors by transducing signals from outside the 
cell to its interior, and broadly can be divided into at least two types 66' 71 Neuropeptide growth 
factors receptors are members of the seven transmembrane domain receptor family and lack 
intrinsic kinase activity. Instead, they couple to intracellular signals via the heterotrimeric G 
protein family. In contrast, the polypeptide receptors span the membrane once consisting of 
three parts which are extracellular, transmembrane and intracellular domains. The extracellular 
domain is exposed outside the cell surface to bind growth factors. The transmembrane domain 
passes through the plasma membrane to connect the extracellular domain with the intracellular 
domain which interacts with signal transducting molecules inside the cell. The binding of a 
growth factor to the extracellular domain results in dimerisation of two receptor molecules, 73 
and the activation of the intracellular tyrosine kinase which phosphorylates the receptor 
(auto/transphosphorylation) and a number of second messenger signalling molecules attracted 
to the activated receptor, thus conveying signals from the outside to the inside of the cell. 
Many growth factor receptors function as protein-tyrosine kinases, that is the 
intracellular domains of these receptors are enzymes that activate their target protein molecules 
by phosphorylation of the tyrosine residue. These receptors are therefore called protein tyrosine 
kinases (see Chapter 3). 72 Intracellular signal transduction is a process of phosphorylation 
events which ultimately induce alterations in gene expression in the nucleus and hence, cell 
proliferation. The SCF receptor c-kit, highly expressed in the SCLC cell line, belongs to the 
protein tyrosine kinase family. 
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In 1983 two groups of scientists, 74 who were studying oncogene and growth factors, 
serendipitously discovered, for the first time, that normal cell growth factors can act as 
oncogenes. 74 Growth factors secreted by one kind of cell normally stimulate proliferation of a 
different kind of cell. The basic principle is that the type of cell does not respond to the growth 
factor that it also produces. When a growth factor acts as an oncogene, this requirement is no 
longer met, and a cell begins to produce a growth factor that stimulates its own proliferation. 
This situation is called autocrine growth stimulation. 72 
Normal receptor protein-tyrosine kinases can be activated as oncogenes by either of two 
kinds of alterations in their normal function. 74 First, overexpression of the normal receptor 
proto-oncogene is sufficient to induce an exaggerated cellular response to growth factor 
binding, resulting in excess cell proliferation. Secondly, structure changes of the normal proto- 
oncogene encoded receptor proteins can result in cell transformation. For instance, deletions of 
the extracellular domains can convert these receptors into biologically active oncogenes as the 
binding domains regulate the catalytic activity of the tyrosine kinase domain. Thus, the 
oncogene protein functions constitutively, independent of growth factor binding, leading to 
neoplastic transformation. In other cases, point mutations at critical positions in normal receptor 
proteins are also responsible for activating oncogenes. 
4.4.1.2. Coexpression of the Stem Cell Factor and C-kit genes in Small Cell Lung 
Cancer 
Growth deregulation in human SCLC results from multiple genetic defects acting in 
concert, rather than as independent events, to induce complete loss of growth control. 
Autocrine/paracrine stimulation has been a popular hypothesis used to explain the growth 
deregulation of SCLC. 70,75 Three autocrine growth loops involving gastrin-releasing peptide 
(GRP) growth factor, insulin-like growth factor-1 (IGF-1) and stem cell factor (SCF) and their 
three receptors have been implicated in deregulated SCLC growth. 70,75 
SCF, alternatively named mast cell growth factor (MGF), 75 kit ligand (KL), or steel 
factor, is a haemopoietic growth factor which, cooperating with other haemopoietic growth 
factors, regulates the proliferation and differentiation in various types of foetal and adult tissues 
as the ligand of the c-kit proto-oncogene product. 70,76 The proto-oncogene c-kit encodes a 
transmembrane tyrosine kinase growth factor receptor which is involved in cell differentiation 
and proliferation in various murine tissues including the lung 77 
SCF gene expression has been observed in a broad spectrum of human cancers 
including SCLC. In contrast, c-kit transcripts are expressed in very restricted types of 
cancers. 78 Co-expression of both the ligand SCF and the receptor c-kit has been observed 
preferentially in SCLC when compared with NSCLC and various other cancers, suggesting an 
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autocrine/paracrine mode of action via this autocrine growth loop in the pathogenesis of this 
aggressive cancer. 
Furthermore, evidence exists that no c-kit protein has been detected in foetal and adult 
normal bronchial epithelial cells, indicating that c-kit expression in SCLC is ectopic. 78 It is 
notable that SCLC metastasise to the haemopoietic environment of bone marrow much more 
frequently than non-small cell lung cancer. 78 Strong evidence has been provided that ectopic 
expression of c-kit in SCLC would enhance the migration of SCLC cells in vivo. It has been 
demonstrated78 that the c-kit protein in SCLC was autophosphorylated by the addition of 
exogenous SCF, resulting in the induction of positive chemotactic response of SCLC cells in 
vitro. This study has indicated that SCF can stimulate chemotaxis of the porcine aortic 
endothelial cells transfected with the c-kit expression construct, resulting in the acquisition of a 
higher invasive (metastatic) phenotype. 
It is also of considerable interest that molecular biological analysis revealed an amino 
acid substitution [CTG (leucine) instead of ATG (methionine)] within the transmembrane 
domain of c-kit in an SCLC cell line. This result suggests the possibility of either a germ line 
mutation or polymorphism. 78 
The remarkable advance achieved in the understanding of the pathogenesis of lung 
cancer on the molecular and biochemical basis is of great interest for the management of this 
highly aggressive cancer. The important autocrine growth factors, SCF and its receptor c-kit 
provide attractive targets for therapeutic intervention in SCLC. 
In addition, the molecular biological study on the pathogenesis of SCLC has revealed 
that autocrine growth factors activate the lipoxygenase pathway of arachidonic acid (AA) 
metabolism in SCLC cells. 
79 The eicosanoids, products of the AA metabolism, have been 
found to be implicated in tumour promotion, cell proliferation, metastases, and immune 
surveillance. 58 
4.4.1.3 Arachidonic Acid Pathway58,70 
Arachidonic acid (5,8,11,14eicosatetraenoic acid) 63 is a polyunsaturated fatty acid 
which is provided from the diet. Arachidonic acid metabolism consists of two major pathways: 
the cyclooxygenase and the lipoxygenase pathways (Figure 21) 58,70 
43 
Figure 21 The Metabolism of Arachidonic Acid 
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Lipoxygenase catalyses the hydroperoxy substitution of AA to give allylic 
hydroperoxides which are designated monohydroperoxyeicosatetraenoic acids (HPETEs). 
There is a family of lipoxygenases (LO), namely 5-, 12- and 15-LO, that differ in the position 
(C-5,12 and 15) at which they oxygenate the arachidonic acid (AA) backbone. The three 
hydroperoxides (5,12 and 15-HPETE) are unstable, and they can be either reduced to the 
corresponding hydroxyeicosateraenoic acids (HETEs) or converted into leukotrienes (LTs). 
Lipoxygenases are iron containing enzymes in which the iron exists in either the 2+ or 
3+ oxidation state. To exert their oxidative activities, the Fe2+ state must first be oxidised to the 
Fe3+ state. In the mode of action of 5-LO (Figure 22), 8 Fe3+ specifically oxidises the 5,8 
diene system of AA to generate a pentadienyl radical with the iron being reduced to the Fe2 + 
state. This radical then stereospecifically reacts with molecular oxygen at C-5 to generate the 5- 
S-hydroperoxy radical which undergoes electron transfer and protonolysis regenerating the 
active Fe3 + and 5-HPETE. 
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Figure 22 Mode of Action of 5-Lipoxygenase 
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The cyclooxygenase pathway leads to the formation of prostaglandin which contribute 
solely to the growth of tumours. On the other hand, the metabolites of the LO pathway have 
been found to play an important role in tumour initiation, promotion and metastases 58,7° Thus 
lipoxygenase enzymes present attractive targets for developing treatment and chemopreventive 
strategies. 
4.4.2 Nordihydroguaiaretic acid (NDGA) 
Research has suggested that NDGA exerts its antiproliferative effects in the treatment of 
SCLC mainly by the following two mechanisms. 
Lipoxygenase inhibitor 
NDGA is known to be a selective inhibitor of lipoxygenases and blocks SCLC growth 
in vitro and in vivo. A Studies of the molecular events involved in growth factor signalling 
suggest stimulation of or re-establishment of apoptotic growth regulation resulting from the 
interruption of the lipoxygenase pathway, as a possible mechanism for the antiproliferative 
effect of the lipoxygenase inhibitors. 80,81 Thus, lipoxygenase inhibitors represent a new 
pharmacological tool to renew growth regulation in transformed cell populations. 
Inhibition of c-kit receptor 
The preliminary data obtained by Seckl et al. 64 are consistent with the above findings, 
but they noticed that NDGA is a better inhibitor of SCLC growth than other more potent 
lipoxygenase inhibitors. Their results also suggest that NDGA has an alternative mechanism of 
action in SCLC cells. It was demonstrated that NDGA inhibits c-kit directly and also inhibits 
the platelet-derived growth factor (PDGF) receptor, 64' 82 which like c-kit has tyrosine kinase 
activity. This dual mechanism of lipoxygenase and c-kit inhibition may explain its superior 
effectiveness as an antitumour agent. 
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Nevertheless, NDGA itself has poor solubility and chemical modifications are required 
to provide a compound for optimal clinical use. In addition, the structure of NDGA is distinct 
from other lipoxygenase inhibitors and has not yet been exploited. Preliminary investigative 
work was performed by McDonald8 and Macleod83, who synthesised a range of analogues of 
NDGA which have been tested for their activity in vitro by Dr Michael Seckl at the Medical 
Oncology Department of Hammersmith Hospital, London. Their results demonstrated 
improved potency for new analogues with 4-6 atoms between the two aromatic rings over 
NDGA8, and furthermore the structural modification work revealed that introduction of an 
amide linkage between the two aromatic residues results in NDGA analogues which are more 
active than NDGA itself. 8' 83 
Based on these preliminary results, the programmed structural modifications proposed 
for this project focused on three areas. The main programme of research was drug 
solubilisation of the candidate analogues which have better potency over NDGA. The second 
area of study introduced position variations of the amide linkage between the two aromatic 
residues. The third area of work involved modification of substitutions on the two aromatic 
rings. 
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CHAPTER 5 
Synthesis of L-Proline Derivatives 
5.1 Introduction 
CRR, 
R 
H O 
COI 
45 46 
R=F" OCHS. OH Ri=F, OMe, OH 
R2 = H. Me 
R3 = H. OMe 
The general biological background of the inhibition of stress related kinases was 
discussed in Chapter 2 together with the general structures 45 and 46 for the proposed stress 
related kinase inhibitors. These were modelled on serine 42 and L-proline 44. It is a common 
tactic to design drugs to mimic the natural substrates in order to make a good fit at the active 
sites of the enzymes. As long as the drugs are in the active sites, they should block access to the 
natural substrates and the enzymatic reactions should slow or stop. In the designed structures 
the serine portion is in a conformationally restricted form and the amide link also adds rigidity 
to the molecules. These rigid functional groups were introduced based on the concept that rigid 
compounds often have enhanced biological activities and selectivities. In addition a number of 
fluorine compounds were synthesised with a view to introducing a fluorine atom as a 
bioisostere for a hydroxyl group in the hope of improving the potency and duration of action of 
the new compounds. 
5.2 Synthesis of L-Proline Derivatives containing Fluorine 
and Methoxy groups 
The proposed structures for the L-proline derivatives have an amide link between the 
conformationally restricted serine portion and the L-proline. The amide bridge can be 
positioned in two possible ways, therefore two sets of L-proline derivatives were synthesised. 
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5.2.1 Synthesis of N-Terminal L-Prolineamide Derivatives 
This set of compounds was prepared in a three step procedure as shown in Figure 23. 
The carboxyl group of the L-proline reacts with the amino group of the aniline derivative to 
form the amide bond in this set of compounds. This is the key step in the synthetic route and 
was achieved using DCC as coupling reagent and DMAP as a base and acyl transfer reagent. 
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Figure 23 
Our first approach to make the amide link by condensing the aniline derivatives directly 
with unprotected L-proline was unsuccessful. No signals expected for the products were found 
in the NMR spectra for the complex reaction mixtures. Therefore we decided to protect the 
amine group of the L-proline prior to carrying out the coupling reactions. 
L-Proline was protected as BOC-proline 64 in a 75% yield by a modified procedure 
used by Ookawa and co-workers. 84 The product was obtained as long white crystals giving a 
melting point consistent with that reported in the literature. 84 The 1H NMR spectrum revealed 
two singlets at 6 1.38 for the three methyl groups indicating the presence of rotamers, while a 
4H and 2H multiplet in the aliphatic region along with two deshielded methine multiplets at 8 
4.17 and 4.28 gave evidence for the proline ring. The N-protected L-proline was then subjected 
to a coupling reaction with aniline in the presence of DCC and DMAP according to the 
procedure of Hassner and Alexania. 85 The side product DCU of the reaction caused problems 
during purification. The majority of the byproduct DCU precipitated out of the reaction mixture 
and was filtered off, and the filtrate was stored in a freezer to encourage precipitation of the 
remaining DCU. After filtration of the DCU precipitate and concentration of the reaction 
mixture, the crude product was crystallised from alcoholic solvents. After all these attempts to 
remove DCU, the 1H NMR spectra for the white crystalline products still had small peaks for 
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DCU, indicating contamination with a trace of DCU. This problem might be overcome by using 
a water soluble version of DCC. 
Finally the deprotection of the amine group was achieved in good yields under acidic 
conditions. 86 In the 1H NMR spectra compounds 65 and 66 each gave peaks from 8 6.9 to 8.2 
for the aromatic ring and also gave a sharp peak for the tert-butyl group at about 8 1.4, but for 
compounds 67 and 68 there was no peak at 8 1.4. This indicates that the BOC group was 
removed. The IR spectrum of the two final products 67 and 68 revealed characteristic 
absorption frequencies in the 1684-1692 cm-1 region for the carbonyl bond and the NH 
stretching vibrations at about 3327-3494 cm-1. The 13C NMR spectra supported these findings 
with the carbonyl carbon signals at 8 169 and 177. The parent ions at m/z 208 and 220 in the 
mass spectrum gave further evidence for the proposed structure for compounds 67 and 68, 
respectively. 
5.2.2 Synthesis of C-Terminal L-Prolineamide Derivatives 
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Figure 24 
In order to prepare proline derivatives with the alternative amide linkage, the three step 
route shown in Figure 24 was used. L-Proline was protected as benzylproline 69 in high yield 
following the procedure of Neuman and Smith. 87 The structure of this known compound 69 
was confirmed by the spectroscopic data collected and the melting point recorded was found to 
be in agreement with that in the literature. 87 Our initial synthetic attempts towards amide 
formation using DCC and DMAP proved unsuccessful. It was found that the pH value of the 
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sample withdrawn from the reaction mixture was about 2. This indicated that the amine group of 
the benzylproline would be protonated in this acidic condition, which could make the reaction 
difficult. In order to change the pH value of the reaction, CDI was chosen as an alternative 
coupling reagent and a modified version of the method by Paul and Anderson88 was employed. 
The pH value of the sample taken from the reaction mixture was about 8 and the reaction was 
monitored by TLC (2: 1 EtOAc-hexane + 5% AcOH or 5% NH3-H20). After stirring under 
N2 at rt for 24 hours, completion of the reaction was confirmed by TLC which showed no sign 
of starting material and a product spot which was stained bright orange by dragendorff reagent. 
Following the procedure of Challis and coworkers, 89 catalytic hydrogenation of 73-75 over 
palladium removed the benzyl group with ease affording the final products 76-78 as crystals 
with sharp melting points and analytical purity. 
In the 1H NMR spectra, compounds 73,74 and 75 each gave an AB system at about 6 
5.1 for the benzyl methylene protons and also gave peaks at 6 4.6 and 4.3 for the methine 
proton on the proline ring while compounds 76,77 and 78 had no AB system signals at 8 5.1, 
which provided evidence for the removal of the benzyl groups. It is worthy of note that both the 
1H and 13C NMR spectra gave two sets of signals for compounds 73 to 78, due to the 
presence of rotamers. Integration of peak heights on the 1H NMR spectra enabled the rotameric 
ratio for each compound to be established. The ratio for the minormajor rotamer signals were 
calculated as about 1: 2 for the six compounds. The 1H and 13C NMR spectra of compound 77 
were chosen to exemplify this NMR phenomenon exhibited by the amide series (see 
Appendixes 1 and 2). From the 1H NMR spectrum of compound 77 (Appendix 1) a ratio of 
1: 2 for the minor: major rotamers was established. The signals on the 1H NMR spectrum for 
the five-membered proline ring were evident in the region 6 1.78 to 4.67. The three methylene 
groups produced three pairs of multiplets at 8 1.78 and 1.90,8 2.10 and 2.37,8 3.31 and 3.69 
respectively while the methine proton on the ring gave a pair of multiplets at 6 4.14 and 4.67. 
The 13C NMR spectrum of 77 (Appendix 2) also provided a very clear demonstration of paired 
signals, a feature preserved throughout the six compound series. 
Rotameric forms of amides are constantly interconverting and, in most cases, the rate of 
interconversion is faster than the gap between the NMR pulses. Consequently, only one set of 
signals in the spectrum is usually observed. In the case of amides 73 to 78, the nitrogen atom is 
on the proline ring and the carbonyl group is also conjugated to the aromatic ring. The two 
bulky substituents decrease the rate of interconversion of the two rotamers due to the increased 
energy requirement for the process. As a result a set of signals for each rotamer was observed 
in each NMR spectrum. 
The 1H NMR spectrum of compounds 73 to 78 showed multiplets in the aromatic 
region for the benzene ring while compounds 74,77 and 75,78 gave a 3H singlet and a 6H 
singlet, respectively, at 6 3.8 for the methoxy groups. Three characteristic stretches at 1743- 
1757 cm-1 region were recorded in the IR spectrum for the carbonyl groups in compounds 73 
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to 78. The 13C NMR spectrum of 73 to 78 provided evidence for the carbonyl groups through 
the signals at ca 6168-176. 
5.3 Synthesis of L-Proline Derivatives Containing a 
Phenolic Moiety 
In the foregoing section a fluorine atom was chosen as a bioisostere to replace the 
hydroxyl group on the rigid serine mimic in the L-proline derivatives. Alternatively, the hydroxy 
group was converted into a methyl ether in the conformationally restricted form of serine. This 
section will discuss the synthesis of L-proline derivatives containing rigid serine portions with a 
free hydroxyl group. 
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Figure 25 
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In the initial approach towards the target compound 83,2-aminophenol was coupled 
with BOC-proline in the presence of DCC and DMAP without protection of the hydroxy 
group. TLC analysis of the reaction mixture showed a streak indicating an intractable mixture of 
materials while the 1H NMR spectrum of the reaction mixture gave no signals for the desired 
product. 
This failure suggested that the free hydroxy group on 2-anunophenol should be 
protected as the benzyl ether 81. Conversion of the 2-aminophenol into the corresponding 
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benzyl ether 81 was accomplished by a three-step procedure described by Humm and 
Schneiderte (Figure 25). 2-Aminophenol was first protected as a phthalimide by heating at 
reflux with phthalic anhydride in acetic acid for one hour. The mixture was then diluted with 
water and heated to boiling. On cooling in ice, compound 79 crystallised in nearly quantitative 
yield. This procedure demonstrated a great simplicity in the work up and purification processes. 
The presence of the phthalimide moiety in compound 79 was confirmed by two characteristic 
multiplets at 6 7.68 and 7.85 observed in the 1H NMR spectrum. Subsequent benzylation of 
the N-protected 2-aminophenol 79 using benzyl bromide and sodium in dry EtOH proceeded 
smoothly affording compound 80, after crystallisation from hexane, in 75% yield. The 1H 
NMR spectrum and the melting point of the known compound 80 were in agreement with those 
reported in the literature. 90 Deprotection of the amino group in compound 80 was achieved by 
treatment with hydrazine hydrate. After the mixture was heated at reflux for one hour, TLC 
analysis indicated that no starting material was left and there was a spot on the origin. On 
completion of the reaction the side product phthaloyl hydrazide was removed by filtration from 
the reaction mixture and the solution was made alkaline to yield the crude o-benzyloxyaniline 
81 as the free base. All attempts to purify the crude aniline derivative by crystallisation were 
unsuccessful due to the low melting point (30-40 0C) of the compound. However trituration of 
the crude aniline derivative with water afforded compound 81 pure enough for synthetic work 
according to the 1H NMR spectrum. 
o-Benzyloxyaniline was in turn coupled with BOC-proline in the presence of DCC and 
DMAP to form the amide bond in compound 82. TLC analysis showed, after the reaction 
mixture was stirred at it for 24 hours, a homogeneous slower running spot for the product that 
was stained bright orange by Dragendorff reagent. 1H NMR spectroscopy identified 
compound 82 from the multiplets at 8 6.90 for the aromatic ring, S 5.04 for the benzyl 
methylene group and a singlet at S 1.29 for the ten-butyl group, a 1H multiplet at S 8.38 for the 
secondary amide together with the two multiplets at S 4.21 and 4.39 for the methine proton on 
the proline ring. There only remained the need to unmask the NH2 and OH from the carbamate 
and the benzyl ether as the free amine and the hydroxy group, respectively. As described in the 
above section the BOC protecting group was successfully removed under acidic conditions and 
the deprotection of the hydroxy group by hydrogenation was straightforward. The completion 
of deprotection of the BOC group was evident from TLC analysis showing no starting material 
and a homogeneous slower running spot stained orange by Dragendorff reagent. The crude 
product was used directly in the subsequent hydrogenation without further purification. The 
debenzylation via catalytic hydrogenation over palladium proceeded smoothly and afforded the 
crude product as a brown oil. Difficulties were experienced in the purification of the final 
compound 83 and we were unable to crystallise it. The target compound 83 was also unstable to 
chromatography on both silica and alumina columns, and this was evident from the 1H NMR 
spectrum of the column fractions. In an attempt to purify the compound 83 the crude product 
was triturated sequentially with petroleum ether and dichloromethane and dried in vacuo 
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affording compound 83 as a brown solid in 67% yield. We also suspected that the final 
compound 83 tended to be oxidised by 02 based on the observation that the brown solid 
compound 83 became a dark oil readily after exposure to the air. The 1H and 13C NMR 
spectra provided another demonstration of clearly paired signals. The successful deprotection of 
the amino group and the hydroxy group was evident from the IH NMR spectrum with the 
absence of the benzyl methylene signal at 8 5.04 and of the ten-butyl signal at 8 1.29. A broad 
phenolic stretch and NH stretching vibrations at ca 3500 cm-1 in the IR spectrum along with a 
parent ion at m/z 206 in the mass spectrum were also consistent with the proposed structure. 
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Attempted coupling of proline benzyl ester 69 with salicylic acid failed as had the 
attempt to couple BOC-proline with unprotected 2-aminophenol. Both failures indicated the 
coupling reaction conditions were not tolerant of free hydroxyl groups. Protection of the 
hydroxyl group was therefore necessary. The conversion of salicylic acid into the 
corresponding benzyloxybenzoic acid proceeded in two steps (Figure 26) according to the 
procedure of Farkas et al. 91 Benzylations of the o-hydroxybenzoic acids with benzyl chloride 
in the presence of ignited potassium carbonate afforded compounds 84 and 85, after 
crystallisation as yellow crystals in high yield. The melting point for the known compound 84 
was identical with that reported. 91 The 1H NMR spectrum revealed two 2H singlets at 8 5.08 
and 5.26 for the two benzyl methylene groups along with a 14H multiplet in the aromatic region 
providing further evidence for the proposed structure. In the 1H NMR spectrum of the novel 
compound 85, the two benzyl methylene groups and the methoxy group produced two 2H 
singlets at 6 5.01 and 5.27 and a 3H singlet at 6 3.69 respectively. The corresponding signals in 
the 13C NMR spectrum resonated at 8 67.2,72.2 and 56.2, respectively. 
The benzyl esters were then hydrolysed in concentrated NaOH solutions followed by 
acidification of the carboxylate salts with 2M HCl producing the o-benzyloxybenzoic acids in 
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quantitative yields. The successful deprotections of carboxyl groups in compounds 84 and 85 
were apparent through the absence of the benzyl methylene signals at 6 5.08 and 5.01 in the 1H 
NMR spectrum while the carboxylic acid proton produced a broad singlet at ca 6 11.0. The 
melting point for the known compound 86 was in agreement with that reported in the 
literature, 91 while the novel compound 87 was fully characterised. Following the modified 
version of the procedure of Paul and Anderson as before, the o-benzyloxybenzoic acids 86 and 
87 were coupled with benzylproline 69 using CDI in DMF at ambient temperature to form the 
amide bonds. TLC (1: 1 EtOAc-hexane, 3% acetic acid) of the reaction mixture after stirring for 
24 hours revealed no starting material and a homogeneous faster running product spot stained 
orange by Dragendorff reagent. The crude products were purified by column chromatography 
affording compounds 88 and 89 in 66-70% yields. The benzyl ester methylene groups of 88 
and 89 produced 1H NMR signals characteristic of two AB systems at 6 5.15 and 5.13 with J 
values of 9.6 and 12.4 Hz, respectively. Two singlets at 6 5.03 and 4.96 for the benzyl ether 
methylene groups in 88 and 89, respectively, were observed in the 1H NMR spectrum. The two 
methine protons on the proline ring of 88 and 89 gave two multiplets at 6 4.25,4.63 and 6 4.31, 
4.63, respectively, in the 1H NMR spectrum. Hydrogenation over palladium carbon at rt in 
ethanol simultaneously removed the two benzyl groups with ease. TLC of the reaction mixture 
after 6 hours showed no starting material indicating the efficiency of the debenzylation. 
Purification of the two desired compounds proved problematic. Attempted crystallisation of the 
crude products were unsuccessful while chromatography on both silica and alumina resulted 
only in extensive decomposition evident from the 1H NMR spectra for the column fractions. 
Trituration of the crude products with petroleum ether and concentration in vacuo afforded 
compounds 90 and 91 in 90% yield. Compounds 90 and 91 were found, like compound 83, to 
be unstable in air possibly due to the oxidation of the phenolic moiety. The 1H NMR spectrum 
showed no resonances for the benzyl methylene groups confirming the accomplishment of the 
debenzylation. Clearly paired signals were again observed in both the IH and 13C NMR 
spectra for all four compounds 88 to 91. Broad phenolic stretches at ca. 3500 cm71 and 
carbonyl absorptions at ca. 1740-1750 cm-1 in the IR spectrum along with parent ions found in 
the mass spectrum were also in agreement with the proposed structures. 
5.4 Biological Test Results 
The proline derivatives prepared were assessed for their SAP kinase inhibition by 
Professor David Gillespie at the Beatson Institute for Cancer Research, Glasgow. 
5.4.1 Method of Testing43 
The MAP kinase enzyme employed in the test was the c-jun N-terminal kinase, a 
component of the SAPK pathway. This assay involved the use of a recombinant GST-c-jun 
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protein (purified from E. cola) bound to Sepharose beads. This behaved as a combined affinity 
matrix and substrate for the SAPK kinases. Cell extracts were prepared from primary avian 
fibroblasts treated with anisomycin to provide the source of activated indigenous JNK to be 
incubated with the GST-c-jun beads. The assay followed standard experimental procedure and 
reactions were performed for each proline derivative at concentrations of 500,50 and 5 
micromolar. SDS gel electrophoresis was used to resolve the bead-bound reaction mixtures and 
following electroblotting, the labelling of the GST-c-jun from each reaction was visualised by 
autoradiography. 
5.4.2 Results 
At the 5,50 and 500 µM compound concentrations none of the proline derivatives 67, 
68,76 to 78 containing fluorine or methoxy groups were found to exhibit inhibitory activity in 
the assay, which is an indication that the these compounds may be poor substrates for stress 
related kinases. In the light of this failure we thought the free hydroxy group on the rigid serine 
mimic moiety might be essential for their inhibitory activities, and therefore we sought to 
prepare the proline derivatives 83,90 and 91 containing the rigid serine portion with the free 
hydroxyl group. Compounds 83,90 and 91 have improved structure similarity with the natural 
substrates, which could make them more competitive for the active site of the enzyme. 
Unfortunately, the compounds 83,90 and 91 prepared have not yet been tested for biological 
activity. 
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CHAPTER 6 
Synthesis of Theophylline Derivatives 
As outlined in Chapter 3, recent advances in the research area of DNA damage 
checkpoint control raised the possibility of manipulating the checkpoint pathways. In particular 
the Chkl pathway, which is implicated in a number of cancers, could be a potential target for 
therapeutic intervention in the development of anticancer agents. 
We intend to test caffeine and theophylline as reference compounds with a range of 
related derivatives prepared by alkylation of theophylline 49. The theophylline derivatives will 
be assessed to see if they override G2/M arrest by inhibiting Chk 1 kinase function. 
6.1 Synthesis of Alkylated Theophyllines 
A series of oxoalkyldimethylxanthines has been synthesised by Mohler et al. 92 as 
solubilisers for various therapeutically useful substances. Based on this preliminary work our 
proposed structural modifications involved variations of the oxoalkyl moiety. A range of 
theophylline derivatives was synthesised by alkylation at N-7 on the xanthine ring of 
theophylline with bromides probably via an SN2 mechanism. 
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The preparation of the target compound 95 was achieved by a four step synthesis which 
is depicted in Figure 27. The known compound 94 was prepared in three steps following the 
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patent procedure. 92 The patent gave the melting points (or boiling points) but no spectroscopic 
data for each compound prepared. Reaction of 1,3-dibromopropane with ethyl acetoacetate 
under basic condition in ethanol proceeded uneventfully according to the TLC analysis, and the 
standard work-up followed by fractional distillation under reduced pressure afforded 
dihydropyran 92 in 76% yield as a pure clear oil. The pertinent features in the 1H NMR 
spectrum were a 2H multiplet at 6 1.75, a 2H triplet at 6 2.23 with aJ value of 6.4 Hz and a 
deshielded 2H triplet at 6 3.94 with aJ value of 4.2 Hz for the three methylene groups on the 
pyran ring. The expected signals at 6 1.21 and 4.11 for the ethyl group and a 3H singlet at 6 
2.15 for the exomethylene protons provided further evidence for the proposed structure. The 
pyran ring was opened after stirring with 48% HBr at rt for two days followed by heating at 
reflux for a further two hours. Following work-up and low pressure fractional distillation, 
bromoketone 93 was isolated as a yellow oil in 62% yield. The four methylene groups were 
observed as two 2H triplets and two 2H multiplets while the methyl group was seen as a 3H 
singlet in the IH NMR spectrum of 93. The 13C NMR spectrum revealed the expected six 
resonances including the carbonyl functionality at 6 208.6. The nucleophilic substitution of 
bromoketone 93 with theophylline was performed in 1M NaOH and the reaction mixture was 
heated at reflux for 12 hours. TLC analysis showed a new spot for the product along with two 
spots for the starting materials indicating that the reaction was incomplete. In an attempt to force 
this reaction to completion, the reaction mixture was heated at reflux for two days; however no 
improvement in yield was observed. After workup the crude product was crystallised from 
isopropanol on cooling in a ice-NaCI bath to give the oxoalkyldimethylxanthine 94 in 19% 
yield. The pure product 94 gave a melting point in agreement with that reported92 and was 
further characterised by its 1H NMR spectrum. The most pertinent features of the 1H NMR 
spectrum were two 2H multiplets at 6 1.49 and 1.82 along with two 2H triplets at 6 2.34 and 
4.21 for the aliphatic chain between the 7-N and the carbonyl group. The 1H NMR spectrum 
also produced signals characteristic of the xanthine skeleton at 6 3.33,3.35 and 7.49. Finally 
NaBH4 reduction of the aliphatic ketone 94, according to the procedure of Maugras et -al. 
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proceeded smoothly at rt for one hour and the reaction was quenched by addition of a few 
drops of conc. HCI. The by-product NaCl was removed by chromatography (Florisil®) and 
crystallisation from isopropanol afforded the racemic alcohol 95 as a white solid in 50% yield. 
The characteristic appearance of the aliphatic proton resonances for the alkyl alcohol moiety 
was observed in the 8 1.04-4.30 region of the IH NMR spectrum giving evidence for the 
transformation of the ketone 94 into alcohol 95, while the OH stretching vibration at ca 3475 
cm-1 was also found in the IR spectrum. The presence of the xanthine skeleton was verified 
from the key features in the 1H NMR spectrum at 8 3.26,3.45 and 8.27. The characteristic 
bands at 1600 and 1649 cm-1 found in the IR spectrum for the imidazole ring and the carbonyl 
groups gave further support for these findings. The thirteen resonances anticipated in the 13C 
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NMR spectrum coupled with a parent ion at m/z 280 in the mass spectrum were also consistent 
with the proposed structure. 
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The synthetic route for theophyffine alkyl alcohol derivative 97 is illustrated in Figure 
28. The known compound 96 was prepared by a Michael addition according to a modified 
version of the literature method. 92 The Michael reaction carried out in dry pyridine afforded, 
after workup and crystallisation from isopropanol, the oxoalkyldimethylxanthine 96 as a pale 
yellow solid in 70% yield giving a melting point identical with that reported. 92 The identity of 
the compound 96 was further verified by the 1H NMR spectrum with two 2H triplets and a 3H 
singlet in the aliphatic region for the alkyl ketone moiety together with two 3H singlets and a 
1H singlet characteristic of the xanthine skeleton. Conversion of the ketone 96 into the 
corresponding alcohol 97 was accomplished by NaBH4 reduction as before giving the racemate 
of alcohol 97. The 1H NMR spectrum of the product 97 revealed a 3H doublet, a1H multiplet 
and two 2H multiplets in the aliphatic region for the alkyl alcohol moiety while the IR spectrum 
showed characteristic OH absorption frequenceis at ca 3450 cm-1 confirming the completion of 
the reduction of the ketone. The xanthine skeleton produced the expected resonances at 8 3.20, 
3.39 and 7.89 while the characteristic pattern for the imidazole ring and carbonyl groups were 
found at ca 1715 and 1596 cm' 1. The expected eleven resonances including the carbonyl 
resonances at 8 152.8 and 156.0 were observed in the 13C NMR spectrum and a parent ion at 
m/z 252 in the mass spectrum were in agreement with the proposed structure. 
In addition some more alkylated theophyllines (shown in Figure 29) were prepared via 
nuleophilic substitions. 
Compound 98 was prepared in a fashion similar to that described for compound 94. The 
alkylation of theophylline with hexyl bromide in 1M NaOH-EtOH afforded, after crystallisation 
from hexane, the theophylline derivative 98 as white crystals in 14% yield. The presence of the 
six carbon aliphatic chain was clearly evident from the IH NMR spectrum which contained two 
triplets, a multiplet and a singlet in the alkyl region and the 13C NMR spectrum showed the six 
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resonances anticipated. The xanthine skeleton was clearly observed as three singlets at 6 3.33, 
3.52 and 7.46 in the 1H NMR spectrum, and the 13C NMR and IR spectra of the product 98 
were also in agreement with these findings. A parent ion at m/z 264 recorded in the mass 
spectrum provided further support for the proposed structure. 
0H RBr0 0R 
IM NaOH, EtOH, refux, 18h 0N 
or NaH. DMF, m 18 h, 14-76 % 
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Figure 29 
It is worthy of note that, despite the claimed yield of 80% for compound 94 in the 
literature, 92 compounds 94 and 98 were prepared in very low yields (19 and 14%, respectively) 
following the patent method92 via SN2 reaction performed in protic solvents, e. g. water/EtOH. 
The low yields we obtained were expected since the protic solvent mixture waterlEtOH with 
NaOH is not appropriate for SN2 reactions. It is well known that the SN2 reaction is favoured 
by a high concentration of a strong (negatively charged) nucleophile in an aprotic polar solvent 
which dissolves ionic reagents chiefly through their bonding to the cation leaving the anion 
relatively free and highly reactive. In order to improve the conditions for the preparation of the 
other theophylline derivatives, the aprotic solvent DMF and stronger base NaH were employed 
in place of the NaOH and water/EtOH mixture. 
A mixture of theophylline 49 and 2-bromoacetophenone in DMF with NaH was stirred 
at rt overnight and TLC analysis showed no starting material was left. The solvent was removed 
and the crude product was crystallised from EtOH affording compound 99 as yellow crystals in 
76% yield. The melting point for the known compound 99 was in agreement with that 
reported94 and the proposed structure was confirmed from its 1H NMR spectrum showing a 
multiplet in the aromatic region for the benzene ring and a singlet at S 5.96 for the methylene 
group along with the characteristic patterns resembling those found in the 1H NMR spectra of 
compounds 94 and 95 to 98 for the xanthine skeleton. 
Compound 100 was prepared by the procedure used to prepare compound 99 except for 
the method of workup. Dichloromethane was added to the reaction mixture to precipitate the 
unreacted theophylline which was filtered off. The filtrate was concentrated and the crude 
product was crystallised from isopropanol to give compound 100 as a grey solid in 19% yield 
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despite the apparent efficiency of the reaction by TLC analysis. A 3H triplet at S 1.24, a 2H 
quartet at S 4.20 and a 2H singlet at S 5.01 in the IH NMR spectrum along with a characteristic 
ester resonance at 6 167 in the 13C NMR spectrum confirmed that the ethyl ester was present. 
The same characteristic patterns for the xanthine skeleton were observed in the NMR and the IR 
spectra as for those recorded for the other theophylline derivatives. A parent ion at m/z 266 in 
the mass spectrum provided further evidence for the proposed structure. 
Compound 101 was prepared in 55% yield following the procedure used to prepare 
compound 100. The acetal moiety produced a 4H multiplet at S 3.79, a 2H doublet at S 4.51 and 
a1H triplet at S 5.51 in the 1H NMR spectrum together with four characteristic resonances in 
the 13C NMR spectrum. The NMR and IR spectra revealed the characteristic patterns for the 
xanthine skeleton. The proposed structure was also confirmed by high resolution mass 
spectrometry. Initially we envisaged that compound 101 should be readily converted into the 
corresponding aldehyde which appeared to be a good point for subsequent functional group 
manipulations. Unfortunately, attempts to hydrolyse the acetal to the aldehyde in 10% HCl or 
by treatment with PPTS were not successful. In consequence this plan was abandoned. 
6.2 Synthesis of Theophylline Dimers 
A series of theophylline dimers was synthesised (Figure 30) in order to establish the 
optimum bridging distance between the two heterocycles. We postulated that the theophylline 
dimers might act as intercalating agents which could interact with both DNA strands. 
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Figure 30 
All eleven theophylline dimers 102 to 112 were prepared in the same manner following 
the procedure of Itahara and Imamura. 95 Alkylations of the dibromides with theophylline in a 
suspension of NaH in DMF were carried out at ambient temperature overnight. To encourage 
the completion of these reactions, the reaction mixtures were then heated at 70 °C for 3h. TLC 
analysis showed no starting material and a homogeneous spot for the product. Following 
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completion of the reaction, product precipitation was achieved by the addition of water to the 
cooled reaction mixture. The melting points for the seven known compounds 102 to 108 were 
identical to those reported in the literature. 95 No commonly used solvents were found to 
dissolve compounds 103 and 104, therefore there are no NMR spectral data for them. The 
parent ions at m/z 386 and 400 in the high resolution mass spectra gave evidence for the 
proposed structures of compounds 103 and 104, respectively. The IH NMR spectra of 
compounds 102 and 105 to 108 revealed characteristic resonances for the two xanthine 
skeletons with two 6H singlets at 8 3.34 and 3.49 along with a 2H singlet at 8 8.29, a feature 
preserved throughout the five compound series, which were consistent with literature findings95 
for these known compounds. Compounds 110 and 111 produced a 4H singlet at ca 8 5.5 and 
multiplets in the aromatic region in the 1H NMR spectrum for the xylylene moiety together 
with distinct resonances for the two xanthine skeletons. The proposed structures were also 
confirmed by 13C NMR, IR and accurate mass spectrometry. Compounds 109 and 112 were 
insoluble in commonly used solvents, and therefore NMR spectra could not be obtained. IR and 
accurate mass spectrometry provided evidence for the proposed structures of compounds 109 
and 112, and the purity of compound 109 was confirmed by combustion analysis. 
6.3 Biological Evaluation of Theophylline Derivatives 
6.3.1 Water Solubility of Theophylline Derivatives 
The water solubility of each of our theophylline derivatives was estimated by Miss 
Isabel Freer of the Tissue Culture Unit, University of Glasgow. The results are shown in Table 
1. For comparison the theobromine derivatives (shown below) were prepared by Ms J. Milne in 
her MSci project in 1999 and their water solubility data are provided in Table 2.96 
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Theo h lline Derivatives Compound Water Solubility 
Caffeine 20 g/L 
Theo h lline 49 10 g/L 
ThN(CH2)4COMe 94 10 mm 
ThN(CH2)4CHOHMe 95 10 mm 
ThN(CH2)2COMe 96 100 mm 
ThN(CH2)2CHOHMe 97 10 mm 
ThN(CH2)5Me 98 1- lo mm 
ThNCH2COPh 99 <0.1 mm 
ThNCH2CO2Et 100 <0.1 mM 
n] 101 <0.1 mm 
ThNCH2NTh 102 < 0.01 mM 
ThN(CH2)2NTh 103 < 0.01 mm 
ThN(CH2)3NTh 104 < 0.01 mm 
ThN(CH2)4NTh 105 < 0.01 mm 
ThN(CH2)5NTh 106 < 0.01 mm 
ThN(CH2)6NTh 107 < 0.01 mm 
ThN(CH2)10NTh 108 < 0.01 mm 
ThNCH2CH=CHCH2NTh 109 <0.01 mm 
o- ThNCH2C6H4CH2NTh 110 < 0.01 mm 
m- ThNCH2C6H4CH2NTh 111 <0.01 mm 
p- ThNCH2C6H4CH2NTh 112 <0.01 mm 
Theophylline = ThNH 
Table 1 
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Theobromine Derivative Compound Water Solubility 
Theobromine 0.5 g1L 
ThNCH2CH2COMe JM 13 100 mm 
TbN(CH2)4COMe im 55 1 mm 
TbN(CH2)5Me JM 66 <0.1 mm 
ThNCH2COPh iM 85 < 0.1 mm 
TbN(CH2)4NTh im 91 < 0.01 mm 
TbN(CH2)6NTb JM 105 < 0.01 ni. M 
o- TbNCH2C6H4CH2NTb JM 115 < 0.01 mm 
m- TbNCH2C6H4CH2NTh im 99 < 0.01 mm 
p- TbNCH2C6H4CH2NTh im 111 < 0.01 mm 
Theobromine = ThNH 
Table 2 
A range of theophylline and theobromine derivatives was assessed for water solubility. 
Much to our disappointment but not to our surprise, most of the compounds except for the 
theophylline and theobromine keto and alcohol derivatives were found to be almost insoluble in 
water (< 0.1 mM). 
6.3.2 Method of Biological Assay 
The theophylline and theobromine derivatives prepared were assessed for their inhibition 
of G2/M arrest by Professor David Gillespie at the Beatson Institute for Cancer Research, 
Glasgow. 
DT40 B-lymphoma cells in exponential growth phase (200 ml total culture volume) 
were divided into 33 individual replicate 5 ml cultures. One replicate 5 ml culture was not treated 
with irradiation or addition of test compound apart from addition of 5µl of vehicle (DMSO). 
The other 32 replicate culture were irradiated with 10 Gy y-irradiation followed by addition of 5 
µl of vehicle or test compound to 1 mM. 33 cultures were then incubated at 37 °C overnight. 
After fixation the harvested cells were stained with propidium iodide and analysed by flow 
cytometry. 
6.3.3 Results and Discussion 
The process of mitosis is a sequence of events called the cell cycle which was briefly 
described in Chapter 1. As shown in Figure 1, the cell cycle consists of a number of sequential 
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stages: G1 phase; S (synthesis) phase; G2 phase; and M (mitosis) phase. After mitosis, the two 
daughter cells undergo the cycle again or enter a resting phase, G. All cells undergo this cell 
cycle. The sequential events in the cycle for DT40 B-lymphoma cells before irradiation 
treatment were analysed by flow cytometry in our biological assay and they are shown in Figure 
31 at the top. 
The cell cycle also has two checkpoints: G1/S and G2/M. In the event of DNA damage 
checkpoint regulatory pathways are activated resulting in cell cycle arrests at both the G1 /S and 
G2IM transitions to provide time for the repair of damaged DNA, or in case of severe damage, 
for activation of programmed cell death. DT40 B-lymphoma cells, used in the biological assay, 
have inactivated tumour suppressor gene p53, a critical component for induction of G 1/S arrest. 
DNA damage (such as irradiation) results in preferential accumulation of p53-deficient cancer 
cells at the G2IM transition as these cells have an incompetent G 1/S checkpoint. The effect of 
the irradiation in inducing G2/M arrest in DT40 B-lymphoma cells is shown in Figure 31 at the 
bottom, where it is apparent that the number of events at the G2/M boundary has increased 
substantially after irradiation (DNA damage). 
The preferential accumulation of these cells on the G2/M checkpoint raised the 
possibility that pharmacological inhibition of G2/M may render these tumour cells more 
sensitive to DNA damaging agents. The biological evaluation of the xanthine derivatives is 
shown in Figure 32. Most of the compounds show no effect on the G2/M boundary events 
after irradiation except for three of them, 98, JM66 and 108. The effects of these compounds on 
irradiation of cells is shown in more detail in Figure 33. These three compounds suppressed 
GYM arrest very effectively. The cancer cells undergo mitosis with damaged genomes when the 
DNA damage checkpoint G2/M is inhibited, and this eventually leads to tumour death. 
All three active compounds have in common a long aliphatic chain which provides a 
large degree of flexibility to the structures. It is worthy of note that the ten-carbon chain of 
compound 108 is nearly twice as long as the side chain (six carbons long) of compounds 98 
and JM66. The long aliphatic chains could bind to a hydrophobic pocket in an enzyme's active 
site giving rise to the activities of compounds 98, JM66 and 108. On the other hand the large 
alkyl chains increase the bulk of the compounds as a whole and this might assist the uptake of 
the compounds into cells. If this is the case, it is not clear why these three compounds are 
effective whereas compounds with slightly different alkyl chains such as 107 are not. 
Caffeine 47 has been demonstrated to suppress the G2/M checkpoint and to prevent 
activation of Chk 1,46,54 presumably by inhibiting one or more upstream checkpoint kinases 
Rad3 in the DNA damage signal transduction process. Compounds 98,108 and JM66 may 
exhibit their inhibitory activity by a similar mechanism. It is not known why caffeine 47 failed 
to induce G2/M arrest in our experiments. It should be noted that the mode of action of caffeine 
and its derivatives has not yet been My elucidated. 
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Figure 31 Ionising radiation-induced G2/M arrest 
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Figure 33 3 Compounds (98,108, and JM66) inhibit 
G2/M arrest induced by Irradiation 
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CHAPTER 7 
Synthesis of NDGA Analogues 
The synthesis of NDGA analogues was the major area of our synthetic work. NDGA 
and its mode of action were briefly overviewed in Chapter 4 together with the proposed research 
work. This chapter describes our efforts on the synthesis of NDGA analogues along with the 
preliminary test data. 
7.1 Synthesis of a C3-Bridged Phenol Analogue 
A C3-bridged biscatechol analogue was prepared previously by McDonald. 8 In order to 
determine if the catechol moiety is essential for biological activity, the C3-bridged phenolic 
compound 115 was prepared following the modified procedure of McDonald8 except for the 
demethylation method. Compound 115 was prepared via a three step synthetic route depicted in 
Figure 34. 
EtOH, Conc. H2SO` 
p reflux, 24 h, 88 % 
0 
I\ oool*% 
Me0 M, O& NaH. PbCH, ieflux. 24h, 29 % 
113 
o OH 
1) H2(100 P60- 10 * PdIC, 
EtOH-EtOAc, 28 °C, 5 h, 
Me0 OMe 2)48% HHr, AcOH, reflux, 4h, HO OH 37% 
114 115 
Figure 34 
The esterification of 4-methoxybenzoic acid was carried out under acidic conditions 
affording the ethyl ester 113 as a colourless oil in 88% yield. The characteristic ethyl ester 
resonances at 81.30 and 4.27 together with multiplets for the aromatic ring in the IH NMR 
spectrum were in agreement with those reported. 97 The condensation of 4- 
methoxyacetophenone with the aromatic ester 113 is the key step in the synthetic approach. The 
reaction was undertaken with a suspension of NaH in refluxing toluene. 10% HC1 was used to 
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quench the reaction and, after workup in a standard manner, the crude product was crystallised 
from EtOH affording the ß-diketone 114 in 28% yield. Despite the low yield crystallisation was 
achieved in a straightforward manner to yield the pure compound 114. The melting point and 
IH NMR spectrum of the known compound 114 were identical with those reported 97 
Conversion of the ß-diketone 114 into the target compound 115 was achieved by a two step 
procedure. The ß-diketone 114 was hydrogenated over Pd/C for five hours and then, without 
purification, the crude product was deprotected in a refluxing mixture of 48% HBr and AcOH 
affording the crude product 115 as a yellow oil. Deprotection with 48% HBr was carried out 
following the procedure of Kawasaki et al. 98 Trituration of the crude product 115 in petroleum 
ether and the following recrystallisation afforded the final product 115 as a yellow solid giving a 
melting point in agreement with that reported 99 The 1H NMR spectrum revealed a 2H 
multiplet and a 4H triplet in the aliphatic region for the three carbon alkyl bridge together with 
two 4H multiplets in the aromatic region for the two benzene rings. The demethylation was 
confirmed by the characteristic appearance of an OH proton resonance at 6 4.76. 
7.2 Synthesis of C4-Bridged Analogues 
The trihydroxy substituted diarylbutane 127 is more polar than the dicatecholbutane 
126, hence is likely to be more soluble in water. Therefore we sought to examine the effect of 
adding one more hydroxy group to each aromatic ring on the biological activity. For this 
purpose the diarylbutanes 126 and 127 were synthesised via a six step approach shown in 
Figure 35 and 36. 
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116 R=H 
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Figure 35 
The substitutions of the benzyl alcohols with triphenylphosphine hydrobromide in 
refluxing acetonitrile proceeded smoothly and afforded, after crystallisation from EtOH, the 
phosphonium salts 116 and 117 in high yields (Figure 35). The melting points of the products 
116 and 117 were identical with those reported8"100 while the 1H NMR spectra revealed a 15H 
multiplet in the aromatic region for the three phenyl groups and a deshielded doublet at 8 5.2 
for the methylene protons coupled with the adjacent P atom. The propionic acids were 
elaborated to the corresponding aldehydes 120 and 121 in two steps (Figure 36). Reduction of 
the acids to the corresponding alcohols 118 and 119 proceeded well with LiAIH4 in THE at it 
70 
After quenching by 1M HCl-ether the products 118 and 119 were isolated in nearly quantitative 
yields as viscous oils satisfactory for synthetic work without further purification. The 1H NMR 
spectra of the two alcohols 118 and 119 were in agreement with those reported. 101,102 The 
subsequent oxidations proceeded in a straightforward manner following the standard Swern 
oxidation procedure 103 to furnish the aldehydes 120 and 121 in high yields as yellow oils pure 
enough to use without further purification. In their 1H NMR spectra each oil 120 and 121 
exhibited the characteristic peak at S 9.7 for the aldehyde proton and two 2H triplets at 8 2.7 
and 2.8 together with signals for the aromatic ring and the methoxy groups, which were 
consistent with literature findings. 104,105 
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Figure 36 
With the aldehydes (120 and 121) and the phosphonium salts (116 and 117) in hand, 
attention turned to the employment of the Wittig reaction to install the double bonds. Treatment 
of the phosphonium salts 116 and 117 with n-butyllithium in THE at 0 OC generated the 
phosphonium ylids which then reacted with the aldehydes 120 and 121 at the same temperature 
to form the double bonds. To facilitate the purification of compound 122, the reaction mixture, 
after workup, was stirred with MeOH to precipitate the majority of the product as a yellow solid 
while the filtrate was concentrated and then subjected to chromatography to yield the rest of the 
product. The alkene 122 was isolated as a mixture of geometrical isomers and the purification 
procedure was found to affect the isomeric ratio. Integration of the characteristic peaks in the 
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1H NMR spectrum showed Z: E ratios of ca. 1: 9 and 2: 1 for the alkene 122 purified from 
trituration in MeOH and by chromatography, respectively. The two isomers could be readily 
distinguished by the J value for the doublet of triplets for the homobenzylic methine proton with 
the cis-isomer giving J values of 11.6 and 6.8 Hz and the trans-isomer 15.8 and 6.8 Hz. 
Difficulties were experienced in the preparation of the trimethoxyphenylbutene 123 with a 
streak observed on a TLC plate and a low yield of 14-20% obtained after chromatography. The 
problem appeared to result from the inherent unstable nature of the anion generated from the 
trimethoxybenzylphosphonium salt 117 by treatment with n-butyllithium. The three methoxy 
substituents, as strong electron donors, increased the electron density of the conjugated system 
of the anion and hence destablised the ylid. As a consequence, this Wittig olefination gave a low 
yield. The melting point and the 1H NMR spectrum for the known compound 122 were found 
to be consistent with those reported. 8 The geometrical isomers of compound 123 were observed 
as a pair of doublets of triplets in the 1H NMR spectrum, one at 8 5.59 with J values of 11.6 
and 6.8 Hz, the other at 6 6.11 with J values of 15.8 and 6.8 Hz for the homobenzylic methine 
proton. The six methoxy groups of compound 123 were clearly seen as a 18H multiplet at ca 6 
3.7 in the III NMR spectrum and there was a C-H stretching band at ca 2930 in the IR 
spectrum. A parent ion at m/z 388 in the high resolution mass spectrum was in agreement with 
the proposed structure. The mixture of alkene geometrical isomers was not separated as the 
subsequent hydrogenation transformed the alkenes 122 and 123 into the corresponding alkanes 
124 and 125. Catalytic hydrogenations over Pd/C, were carried out with ease to produce the 
butanes 124 and 125 in good yields. The accomplishment of the hydrogenation was quite 
apparent through the absence of the characteristic signals for the double bond protons in the 
1H 
NMR spectrum. The known compound 124 provided a melting point identical with that 
reported 104 and produced signals in the 1H NMR spectrum in agreement with data cited in the 
literature. 8 The symmetrical structure of the novel compound 125 was clearly evident from the 
NMR spectra with the 1H spectrum showing a 4H multiplet and a 4H triplet in the aliphatic 
region together with a 4H singlet at 6 6.31, and the 13C NMR spectrum gave the expected 
eleven resonances. The mass spectrum revealed a parent ion at the expected m/z 390 and a 
combustion analysis provided further evidence for the proposed structure for compound 125. 
The demethylation of the methyl ethers 124 and 125 was carried out by treatment with refluxing 
48% HBr affording the corresponding phenolic diarylbutanes 126 and 127 in good yields. The 
absence of peaks for the methyl ether and the characteristic appearance of the phenolic proton 
resonances in the 1H NMR spectra confirmed that demethylation had been successful. The 
melting point and the 1H NMR spectrum of the known compound 126 were found to be 
consistent with those reported in the literature. 106'8 The presence of the six hydroxy groups in 
compound 127 was observed in the IH NMR spectrum as a 2H broad singlet at 6 7.7 and a 4H 
singlet at 6 8.6 along with the broad phenolic stretches at ca 3500 cm-1 in the IR spectrum. 
Two 4H multiplets in the aliphatic region and a 4H singlet at 8 6.06 were also observed in the 
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IH NMR spectrum and the 13C NMR spectrum showed the expected six resonances providing 
support for the structure assignment of compound 127. A parent ion at m/z 306 in the mass 
spectrum accompanied by a combustion analysis were also consistent with the proposed 
structure. 
In conclusion, the syntheses of target compounds 126 and 127 were accomplished in 
five steps with overall yields of 40 and 9% for compounds 126 and 127, respectively. The low 
yield (14-22%) obtained in the preparation of alkene 123 led to the low overall yield of 9% for 
target compound 127. Further efforts are needed in the development of an alternative route to 
circumvent the difficulties in the installation of the C4 bridge in compound 127. 
7.3 Synthesis of Conformationally Restricted Analogues 
As mentioned in Chapter 4 preliminary work in the Robins group revealed that NDGA 
analogues with an amide linkage between the two aromatic rings are more potent than NDGA 
itself. To extend this work, a series of amide (or thioamide) analogues of NDGA with both 4 
and 5 atoms between the rings were synthesised. 
7.3.1 Synthesis of Amide (or thioamide) Analogues with a4 Atom 
Bridge 
Given the improved potency of amide analogues of NDGA, we envisaged that 
replacement of the amide group by the thioamide group might result in the formation of an 
analogue with improved activity because of the increased lipophilicity. To test this hypothesis, 
the thioamide compound 132 was prepared. The thioamide 132 was prepared by thionation of 
the amide 130 and the synthesis is depicted in Figures 37 and 38. 
'Y"ký NI-16 
m 
Wý00`ý 
---ow 
160°C 
81-90% 
ORMe 
H 
Me0 
128 R: H 
129 R- OMe 
BBr3, CH2a3OH rH 
-78 °C - 0°C, 3h, HO 
87-92% 
130 R=H 
131 R=oH 
Figure 37 
73 
We investigated two methods to form the amide bond. The coupling reagent system 
EDCI-DMAP was employed in the procedure of McDonald8 to install the amide bond 
affording the amides 128 and 129 in good yields. However, considering the stability of the 
starting materials and the products, we sought to simplify the reaction conditions. It was later 
found that the amides 128 and 129 could be readily obtained in high yields by simply heating 
the acids and the amines together at 160 0C, and this method aided the procedure of workup and 
purification. After washing sequentially with dilute acid, base and water, the amides were 
obtained free of contaminants, and could be used directly in the next step. The melting point and 
1H NMR spectrum of the known compound 129 were found to be identical with those 
reported8 while the novel compound 128 was fully characterised. Demethylation of the methyl 
ether 129 was reported8 to proceed in a low yield (15-20%), therefore effort was focused on 
improving the efficiency of this reaction. Following the reported procedure8 lM BBr3-DCM 
solution was introduced to a DCM solution of the methyl ether 129 at -78 0C. The mixture was 
stirred at the same temperature for 20 min and then allowed to warm to 0 OC and stirred for a 
further 50 minutes. TLC analysis (EtOAc-hexane, 5% AcOH or NH3-H20) revealed only a 
single spot sticking at the origin indicating that the starting material was used up. However, after 
workup, the 1H NMR spectrum showed that two-thirds of the crude product was the desired 
compound and the rest was starting material. The carbonyl oxygen atom in the amide 129, as an 
electron donor, could chelate with BBr3 to form a boron complex which stuck at the origin. 
This might explain the absence of the starting material spot on the TLC plate. This indicated that 
the reaction did not proceed long enough to be complete. Furthermore, the reported procedure8 
of work-up involved washing the crude product 131 with saturated sodium bicarbonate and this 
was found to cause further loss of product. TLC analysis of both the NaHCO3 layer and the 
organic layer revealed that most of the crude product had been washed into the NaHCO3 
solution. This is not surprising given the considerably higher acidity of the dicatechol system of 
compound 131 compared with a phenolic system. In addition, it was also noticed that following 
an ice/water-mediated quench of the reaction, the mixture should be left stirring for 30 minutes 
to ensure the complete decomposition of the product-boron complex as only the free hydroxy 
product could be extracted into EtOAc and hence be isolated. The purification of compound 
131 also proved problematic as the compound is so polar that it produced a streak on both silica 
and alumina TLC plates eluting with solvent systems containing 3% AcOH or NH3-H20. Thus 
the product could be lost on the column when purified by chromatography. Attempted 
crystallisation was not successful as the compound was highly hygroscopic and susceptible to 
oxidation. It was also found that compound 131 was only soluble in water and alcoholic 
solvents and EtOAc. In the modified procedure of purification, the crude compound 131 was 
extracted from the EtOAc extracts into the NaHCO3 solution. The NaHCO3 extracts were then 
acidified and re-extracted with EtOAc to remove organic contaminants. Trituration with 
petroleum ether and DCM afforded the product 131 as a brown solid in 87% yield reasonably 
pure for synthetic work giving a melting point and IH NMR spectrum identical with those 
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reported. 8 BBr3 demethylation of 128 was carried out following the procedure of McOmie et 
al. 107 The purification of the diphenol amide 130 was easier than that of dicatechol amide 131 
as the diphenol amide 130 with two fewer hydroxy groups was less polar, less hygroscopic and 
less susceptible to oxidation. The EtOAc solution of crude product 130 could be washed with 
saturated NaHCO3 solution without loss of the product in the aqueous layer. Crystallisation 
from EtOAc afforded the novel compound 130 as yellow crystals in 92% yield. Two 2H 
singlets in the aliphatic region and two 4H multiplets in the aromatic region were recorded in the 
1H NMR spectrum of compound 130 for the two methylene groups and the two benzene rings, 
respectively while the absence of the characteristic methoxy resonance indicated the completion 
of the demethylation. The phenolic groups were characterised by the OH stretching band at ca 
3300 cm- 1 in the IR spectrum. The amide bond was shown to be intact with a NH stretching 
band near 3300 cm-1 and a carbonyl absorption frequency at 1650 cm-1 observed in the IR 
spectrum together with a carbonyl resonance at S 175 in the 13C NMR spectrum. A parent ion 
at m/z 257 in the mass spectrum and a combustion analysis provided further support for the 
structure assignment of compound 130. 
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Lawesson and his coworkers108 have demonstrated that the conversion of amides into 
thioamides could proceed smoothly in very mild conditions when Lawesson's reagent was 
employed. They also reported109 that the thionation using HMPA or DME as solvent was 
tolerant of free hydroxy groups as HMPA and DME are known to form complexes with 
hydroxyaromatic compounds. Lawesson suggested that HMPA and DME act as a protecting 
agent for hydroxy groups in these reactions. T'herefore we decided to carry out the thionation 
following Lawesson's procedure with some modifications. Amide 130 was treated with 
Lawesson's reagent in DME and the suspension was heated at reflux for 48 hours. DME was 
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chosen as the solvent in this reaction rather than HMPA for two reasons: DME was 
reported109 to protect the phenol group more satisfactorily than HMPA in thionation; and 
HMPA is much more toxic than DME. TLC analysis of the reaction mixture revealed several 
higher running spots and a starting material spot together with a lower running streak. In an 
attempt to force the reaction to completion, the reaction mixture was heated at reflux for a 
further 24 hours; however TLC analysis showed no improvement. One of the higher running 
spots, which was stained light blue and relatively easy to separate, was isolated and its NMR 
characteristics were those expected for the thioamide 132, but the yield was only 17%. The 
conversion from compound 130 into compound 132 was confirmed by a major spectroscopic 
difference between the thioamide and the parent amide in the 13C NMR spectra, namely the 
carbonyl carbon in amide 130 came into resonance at 6 175 while the thiocarbonyl carbon in 
thioamide 132 resonated at 8 204. This shift is due to poor orbital overlap, as the n-bonding 
electrons in thioamide groups are not as delocalised as those of amides. This causes deshielding 
of the thioamide sp2-hybridised carbon atom leading to a 13C NMR chemical shift of ca 8 200, 
some 30 ppm higher than that of the corresponding amide. Two 2H singlets at 8 3.76 and 8 
4.58 for the two methylene groups of compound 132 were recorded in the 1H NMR spectrum 
which were 0.4 ppm higher than those for the methylene groups in the corresponding amide 
130. The IR spectrum and a parent ion at m/z 273 in the high resolution mass spectrum were in 
agreement with the proposed structure. 
Thionation of compound 131 under the same conditions as those for compound 130 
was unsuccessful. Compound 131 was found to be insoluble in DME even at elevated 
temperatures and this might be the reason for the failure. The thionation of compound 131 was 
then performed in HMPA in place of DME as compound 131 was soluble in HMPA; 
unfortunately this attempt only gave a complex mixture without a trace of the desired product as 
revealed by 1H NMR spectroscopic analysis. Further effort to transform the dicatechol amide 
131 into the corresponding thioamide 133 was not attempted. 
Compound 135 was prepared in an attempt to ascertain the position of the amide group 
required for optimum activity of NDGA amide analogues (Figure 39). 
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Compound 135 was prepared by the same route under the same reaction conditions 
employed in the preparation of compounds 130 and 131 except for the workup and purification 
after demethylation. To quench the demethylation, the reaction mixture was poured into iced 
water and shaken for 30 minutes and the resulting grey suspension was filtered affording 
compound 135 as a grey solid in 91 % yield pure enough without further purification. Two 2H 
triplets in the aliphatic region for the two methylene groups and two singlets at 8 3.70 and 3.71 
for the methoxy groups in compound 134 were observed in the 1H NMR spectrum along with 
multiplets in the aromatic region characteristic of protons on benzene rings. The 13C NMR and 
IR spectra together with the accurate mass spectrum were found to be consistent with the 
proposed structure of compound 134. The successful deprotection of compound 134 was 
clearly evident from the 1H NMR spectrum with the absence of methoxy resonances at ca 8 
3.7. The 1H NMR spectrum of compound 135 revealed two triplets in the aliphatic region and 
multiplets in the aromatic region while the 13C NMR spectrum showed the expected 
resonances including the carbonyl functionality at 8 174. Characteristic phenolic and NH 
stretching frequencies at ca 3148 cm- 1 were found in the IR spectrum. A parent ion at m/z 258 
in the high resolution mass spectrum was consistent with the proposed structure. 
7.3.2 Synthesis of Amide Analogues with a Five Atom Bridge 
Compound 137 (Figure 40) was prepared by the same procedures used to prepare 
compound 131. 
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Difficulty was encountered in the purification of compound 137. Like compound 131, 
the dicatechol amide 137 was too polar to be purified by chromatography and it was also 
hygroscopic and susceptible to oxidation when exposed to air. Attempted crystallisation in a 
variety of solvents was unsuccessful and therefore the crude product was purified by trituration 
from DCM and petroleum ether affording compound 137 as a brown solid in 66% yield. The 
1H and 13C NMR spectra of compound 137 are shown in Appendixes 3 and 4. The three 
methylene groups of compound 137 came into resonance as a 2H triplet and a 4H multiplet in 
the aliphatic region and the characteristic appearance of aromatic proton resonances was also 
observed in the 1H NMR spectrum. The characteristic OH and NH absorption bands at ca 
3400 cm-1 along with the carbonyl and aromatic absorption frequencies at 1600-1657 cm-1 
were recorded in the IR spectrum. A parent ion at mlz 304 in the high resolution mass spectrum 
provided further support for these findings. 
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The intended amide coupling reaction of 3,4-dimethoxyaniline with 4-(3,4- 
dimethoxyphenyl)butyric acid following the procedure used in preparation of compounds 128 
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and 129 proved unsuccessful. In an attempt to improve the efficiency of the reaction, EDCI was 
employed as the coupling reagent which has the advantage of facilitating the purification of the 
product as the urea by-product resulting from EDCI could be readily removed by an aqueous 
wash. Characteristic NH and carbonyl stretching bands observed at ca 3300 cm-1 and 1657 
cm-1 respectively in the IR spectrum along with carbonyl resonance in the 13C NMR spectrum 
were consistent with the expected compound from the successful amide coupling reaction. The 
1H NMR spectrum of compound 138 revealed a 2H triple triplet and two 2H triplets in the 
aliphatic region and three singlets for methoxy groups together with aromatic proton 
resonances. The proposed structure was further confirmed by 13C NMR and accurate mass 
spectra. Deprotection of the methyl ether 138 was undertaken following the procedure 
employed in the preparation of compound 131 with the exception of the isolation. The 
demethylation was quenched in iced water and the reaction mixture was shaken for 30 minutes. 
A grey solid was observed to precipitate between the aqueous and the DCM layers. The grey 
solid was collected and crystallised from EtOAc-EtOH to furnish the dicatechol amide 139 as a 
brown solid in 50% yield. The accomplishment of demethylation in compound 138 was evident 
from the absence of methoxy proton resonances in the 1H NMR spectrum along with the 
presence of the phenolic stretching band at ca 3400 cm-1 in the IR spectrum. The amide bond 
was proved to remain intact with characteristic absorption frequencies near 1650 cm' 1 for the 
carbonyl bond and the NH stretching vibrations at ca 3400 cm-1 in the IR spectrum together 
with carbonyl resonance at ca 6 175 in the 13C NMR spectrum. The NMR and the accurate 
mass spectra were consistent with the proposed structure. 
79 
7.4 Synthesis of Analogues Containing Heterocycles 
Isosteric interchanges are a common strategy used to determine the structure-activity 
relationships of a lead compound and its analogues. Among the five-membered heteroaromatic 
compounds containing one heteroatom, thiophene, with the least electronegative heteroatom, has 
the greatest aromaticity and is usually introduced into a lead structure as an isostere of a 
benzene ring. The preparation of a number of NDGA analogues containing thiophenes is 
described in this section. 
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Koßmehl et al. 110 have reported the preparation of 1,4-di(2-thienyl)butane in 49% 
yield. We carried out the reaction following their procedure with a few modifications; prolonged 
reaction time and elevated temperature were employed to force the reaction to completion. The 
crude product was purified by chromatography affording compound 140 as a light yellow oil in 
47% yield. The four methylene groups produced two 4H multiplets in the aliphatic region and 
the six thiophene proton resonances were recorded as three 2H multiplets in the aromatic region 
in the IH NMR spectrum of compound 140. 
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The preparations of compounds 141 and 142 were accomplished in a similar fashion to 
that described for compound 128. Novel compounds 141 and 142 were fully characterised. The 
successful deprotection of the methyl ethers 141 and 142 were confirmed by the 
1H NMR 
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spectra with the absence of the methoxy proton resonance at ca 8 3.8 and the presence of the 
OH peaks at ca 8 8.9 together with the IR phenolic stretching band. The IR spectra of 
compounds 143 and 144 revealed characteristic absorption bands for NH and carbonyl 
functionalities indicating that the amide bonds remain intact while the carbonyl resonance at ca 
8 170 in the 13C NMR spectrum was also consistent with those findings. The accurate mass 
spectra of the novel compounds 143 and 144 were in agreement with the proposed structures. 
7.5 Attempted Synthesis of an Analogue Containing an 
Alkene with Z Geometry 
As mentioned in the foregoing section preliminary work demonstrated that more rigid 
NDGA analogues are superior in biological activity by incorporating a rigid functional group 
such as an amide. This result prompted us to investigate an alternative tactic to introduce rigidity 
into the lead structure, and therefore compound 151 (Figure 46) was designed in which the 
amide group was replaced by a double bond. We intend to prepare an NDGA alkene analogue 
as a single geometrical isomer given the likely different biological activities of the E- and Z- 
isomers. The control of double-bond geometry in the preparation of alkenes is well 
documented. Schlosser's modification of the Wittig reaction provides an easy entry to cis- 
alkenes. Therefore we sought to prepare a NDGA alkene analogue with Z-geometry following 
Schlosser's method. 111 
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The phosphonium salt 150 was prepared via a five-step procedure as depicted in Figures 
44 and 46. According to Schlosser's procedure the phosphine was prepared as follows. 
Conversion of phenol into the corresponding phenyl ether 145 was performed by treatment with 
sodium hydride and chloromethyl methyl ether in DMF affording 145 as a colourless oil in 
63% yield. Two deshielded 3H and 2H singlets in the aliphatic region along with the aromatic 
proton resonances in the 
1H NMR spectrum confirmed the proposed structure. It was known 
that the introduction of the acetal function in compound 145 could facilitate the metalation of 
neighbouring positions required for the preparation of the phosphine 146. Treatment of phenyl 
ether 145 with butyllithium at 0 OC in THE with TMEDA as cosolvent generated a 2- 
alkoxyphenyllithium intermediate which was then reacted with triphenyl phosphite to provide 
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the phosphine 146 in 76% yield. The melting point and the 1H NMR spectrum for the known 
compound 146 were found to be consistent with those reported. I 11 
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LiAIH4 reduction of (3,4-dimethoxyphenyl)acetic acid in THE at rt produced the 
corresponding alcohol 147 which was then elaborated to the bromide 149 and the aldehyde 148, 
respectively. Following the procedure of Kocienski et all 12 bromination of alcohol 147 with 
carbon tetrabromide and triphenylphosphine proceeded smoothly affording the bromide 149 in 
74% yield while the oxidation of the alcohol 147 was surprisingly difficult. Attempted Swern 
oxidation of 147 gave a reaction mixture whose NMR spectra showed no traces of the desired 
aldehyde. Oxidation of 147 with PCC was carried out following the general procedure of Corey 
and Suggs. 113 The crude residue was purified by flash chromatography affording the aldehyde 
148 as a colourless oil in 29% yield. The melting point for the known bromide 149 was 
identical with that reported 114 and the 1H NMR spectrum of the two known compounds 148 
and 149 were found to be in agreement with those reported. 115,114 
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The substitution of the bromide 149 with the phosphine 146 in refluxing EtOH 
proceeded smoothly and provided the phosphonium salt 150 in 68% yield. The phosphonium 
salt 150 produced two multiplets in its 1H NMR spectrum at 6 2.83 and 3.70 for the four 
methylene protons adjacent to the phosphorus atom which were different from those in the 
bromide 149 giving two triplets at 8 3.02 and 3.47. The characteristic acetal resonances 
appeared in the 1H NMR spectrum as two singlets at S 2.99 and 5.05. The proposed structure 
was confirmed by 13C NMR and IR spectra. A parent ion at m/z 607 in the high resolution 
mass spectrum provided further support for these findings. The attempted Wittig reaction 
employing Schlosser's procedure was unsuccessful because the ylid failed to be generated 
from the phosphonium salt. The reaction using NaNH2 was carried on a 1.17 mmol scale, i. e. 
0.04 g NaNH2 was needed. Practical difficulty was encountered when 0.04 g chemical was 
weighed in a drying box due to the pressure changing, and also the purity of the NaNH2 in a 
tiny amount was suspicious. Lack of time prevented further work in this area. 
7.6 Biological Test Results 
The compounds synthesised in this project were assessed for their inhibitory potential 
on small cell lung cancer (SCLC) cells in vitro by Prof. Michael Seckl at the Medical Oncology 
Department of Hammersmith Hospital, London. The preliminary test data are shown in Table 3. 
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7.6.1 Method of Biological Assay8 
Cell Culture: SCLC cell lines H-69 were maintained in RPMI 1640 supplemented with 
10% (v/v) foetal bovine serum (heat inactivated at 57 'C for 1 hour) in a humidified atmosphere 
of 10% C02/90% air at 37 OC. They were passaged every 7 days. For experimental purposes, 
the cells were grown in HITESA which consisted of RPMI 1640 supplemented with 10 nM 
hydrocortisone, 5 µg/ml insulin, 10 µg/m1 transferrin, lOnM oestradiol, 30nM selenium and 
0.25% bovine serum albumin. 
Liquid Culture Assay: SCLC cells, 3-5 days post passage, were washed and 
resuspended in HITESA. Cells were then aliquoted in 24 well Falcon plates at a density of 
50,000 cells in 1 ml HITESA in the presence or absence of increasing concentrations of NDGA 
analogues. One and two weeks later, cell number was determined from a minimum of 3 wells 
per condition using a Coulter counter, after cell clumps were disaggregated by passing the cell 
suspension 5 times through a 19 and subsequently 21 gauge needle. These times were chosen 
to coincide with log phase and plateau phase growth of the cells. 
7.6.2 Results and Discussion 
The C3-bridged bisphenol analogue 115 is surprisingly about as active as NDGA and 
much more potent than its counterpart C3-bridged biscatechol analogue which had shown no 
inhibitory activity against the H-69 SCLC cell line. 8 However the C4-bridged dicatechol 
analogue 126 is the most active compound and is ten times more active than NDGA. The C4- 
bridged tetramethoxy analogue 124 is also surprisingly active as it had been thought that the 
free hydroxy groups were obligatory. The tetramethoxy compound 124 may exhibit its 
inhibitory potential via a different mechanism, and this needs further investigation. The C4- 
bridged bis(trihydroxy) analogue 127 shows no increase in activity arising from the presence of 
the extra hydroxy groups. The biscatecholamide 131 is nearly equipotent to analogue 126, 
therefore compound 131 is a new lead compound. Thioamide 132 and its amide counterpart 
130 were both found to be inactive. The bisphenolic amide 135 is more active than 130 but it 
does appear that the presence of catechol groups is necessary to increase the activity. The 
dihydroxy analogue 144 containing thiophene is less active than NDGA whilst the 
monophenolic analogue 143 and the dithiophene compound 140 have no appreciable activity. 
This indicates that the presence of catechol groups is obligatory for good activity of amide 
analogues. 
In summary compounds 126 and 131 have been identified as two new lead compounds 
which are ten times more active than NDGA when tested against the H-69 small cell lung cancer 
cell line. Both new lead compounds possess two catechol groups joined by a C4 bridge or a 4- 
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atom amide link. Part of the above results have already been published, 116 although we still 
await the biological results of the amide analogues 137 and 139 with five atom bridges. 
NDGA and its analogues are believed to exert their inhibition of SCLC cell growth by 
targeting several signalling systems like SCF and its receptor c-kit, lipoxygenases and the 
PDGF receptor. The precise relationship between the inhibitory effect of NDGA on 
lipoxygenases and the other two signalling systems has not been elucidated. Inhibition of 
several targets in the SCLC cell line gives NDGA and its analogues superior efficacy, and this 
approach might provide a better strategy for developing effective anticancer agents than having a 
single target. 
NDGA Analogue Compound IC50 (µm01) 
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CHAPTER 8 
Solubilisation of NDGA and Analogues 
Preliminary work on the synthesis of NDGA analogues revealed several compounds 
that have improved potency over NDGA. We sought to transform those promising candidates 
into their water soluble forms as greater solubility is essential for in vivo work. 
8.1 Synthesis of a Tetraglycyl Ester 
1,4-Bis-(3,4-dihydroxyphenyl)butane 126 is the most active analogue identified from the 
structural modification work. A water soluble tetraglycyl salt of this compound was synthesised 
for in vivo work. 
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BOC protected glycine was esterified with the dicatecholbutane 126 utilising DCC and 
pyridine as coupling reagents to install the four ester bonds in compound 152 (Figure 47). The 
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presence of the four BOC-glycine moieties in compound 152 was evident from the NMR 
spectra with the 1H NMR spectrum showing a 36H multiplet at 8 1.38 for the four tert-butyl 
groups and a deshielded 8H multiplet at 8 4.04 for the four methylene groups adjacent to the 
amino groups. The 13C NMR spectrum contained carbonyl resonances at 8 157 and 169 for 
the carbamate and ester functionalities respectively which were further confirmed with 
characteristic absorptions at 1681 and 1783 cm-1, respectively, in the IR spectrum. The 
successful installation of all four ester functionalities was also confirmed by an observed peak 
in the mass spectrum at m/z 925 for (M+Na)+ run in the FAB+ mode. Deprotection of the 
amino groups with subsequent formation of the HCl salt was achieved by passing dry HC1 
through a cold solution of compound 152 in anhydrous EtOAc. After three minutes the amine 
salt 153 precipitated and the reaction mixture was allowed to warm to rt and stirred for a further 
two hours. The four ester functionalities proved inert to these reaction conditions. The 1H 
NMR spectrum of compound 153 showed the deshielded 8H multiplet at 8 4.22 for the four 
glycyl methylene groups while the removal of all four tert-butyl groups was evident from the 
absence of the large peaks at 61.38 in the 1H NMR spectrum. An ester absorption at 1774 cm- 
1 was observed in the IR spectrum and a (M+H)+ peak at m/z 503 in the mass spectrum was 
consistent with the proposed structure. 
8.2 Synthesis of Amine Salts 
A number of aromatic amines and analogues containing polyamines were prepared with 
a view to introducing solubilising ammonium groups into the structures of some of the active 
compounds. 
8.2.1 Synthesis of C4-Bridged Aromatic Amine Salts 
In addition to the glycyl HCl salt 153, a water soluble form of the most potent 
compound 126 was prepared with solubilising ammonium groups directly on the aromatic 
rings. 
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Nitration of compound 124 with 70% HNO3 in glacial AcOH provided the 
nitrobenzene 154 in 89% yield. 
IH NMR spectroscopy distinguished the nitrobenzene 154 
from compound 124 by the integral of the aromatic protons which was reduced from 6H to 4H. 
The regiochemistry of the addition was apparent from the 1H NMR spectrum with only two 
singlets observed in the aromatic region confirming the introduction of the nitro groups in the 
6-positions. This novel nitro compound 154 was further characterised by 13C NMR and IR 
spectroscopy. A parent ion at m1z 420 in the mass spectrum together with the combustion 
analysis were consistent with the proposed structure. Catalytic hydrogenation of the 
nitrobenzene 154 at 3.5 bar over palladium in a mixed solvent of DCM and EtOH afforded the 
aromatic amine 155 as a dark green solid. The completion of the reduction of the nitro groups 
was evident from the 1H NMR spectrum. A broad 4H singlet at 6 4.57 was observed for the 
two NH2 groups in compound 155 and the position of the aromatic singlet for the H-5 proton 
shifted from 6 7.52 to 8 6.32 as a result of being ortho to two electron donating groups. The 
subsequent demethylation of the crude amine 155 with 48% HBr proceeded smoothly affording 
the target compound 156 in good yield. The removal of the methyl groups was apparent from 
the absence of the methyl singlets at ca. 8 3.6 in the 1H NMR spectrum. The identity of the 
water soluble amine salt 156 was further confirmed by 
13C NMR spectrum with the expected 
eight resonances. The IR spectrum of the amine salt 156 and a peak recorded at m/z 305 in the 
accurate mass spectrum for [M(-2HBr)+H]+ run in the FAB+mode provided further support 
for those findings. 
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8.2.2 Synthesis of NDGA Amine Salts 
As mentioned above NDGA is poorly soluble in water and therefore it is one of our 
objectives to convert NDGA into a water soluble form. The synthesis of a water soluble NDGA 
amine salt 158 is depicted in Figure 49. 
H M 
70 %HNq, 
#j 
MezSO4 
Me0 ACOH, Ih, HO 
MeOH, H2O, 92% 
KOH, rt, 96 % 
OH OMe 
OH OMe 
50 53 
NOZ NH3 
1) H2 (6.6 aim. ), Pd/C, 
McOH - CH2P2, Mao 25QC 86 HO 
OMe , NO2 OH 
+ 
NH3 
2) 49 % HBr. 
mfluz, A. 63 % / 2 Br 
Me0 HO 
OMe OH 
157 158 
Figure 49 
The preparation of the NDGA amine salt 158 was achieved by a four step synthesis 
following the protocol of McDonald. 8 Methylation of commercially available NDGA with 
dimethyl sulfate produced the tetramethyl ether 53 in good yield. The product was obtained as a 
yellow solid giving a melting point identical with that reported. 
62 The presence of the four 
methoxy groups was evident from the 1H NMR spectrum with a 12H singlet at 6 3.78. The 
subsequent nitration of the tetramethyl ether 53 was undertaken following the procedure 
employed in the preparation of the nitro compound 154 in high yield. The melting point and the 
IH NMR spectrum of compound 157 were found to be consistent with those reported. 8 
Hydrogenation of the nitrobenzene 157 to the corresponding aromatic amine was carried out 
under 6.6 bar of hydrogen over palladium in a mixed solvent of DCM and MeOH and then, 
without purification, demethylation with refluxing 48% HBr provided the NDGA amine salt 
158 in good yield. The nitrobenzene 157 and the NDGA amine salt 158 were identified as 
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known compounds and the data recorded for these two compounds were found to be consistent 
with the findings reported in the literature. 8 
8.2.3 Synthesis of C(-Bridged Aromatic Amine Salts 
The C6-bridged analogue, 1,6-bis-(3,4-dihydroxyphenyl)hexane, was found to be 
equipotent with NDGA. Thus we set about the synthesis of an amine salt of this analogue 
which is shown in Figure 50. 
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Friedel-Crafts acylation of veratrol with adipoyl dichloride was undertaken according to 
the procedure of Fliedner et al. l 17 using anhydrous chloroform in place of tetrachloroethane. 
The product was obtained as pale yellow crystals in 66% yield giving a melting point identical 
with that reported. 
117 The regiochemistry of the addition was identified by the 1H NMR 
spectrum with two 1H doublets and a1H doublet of doublets in the aromatic region. Diketone 
159 was then subjected to hydrogenation over palladium in AcOH to furnish the diarylhexane 
160 in moderate yield. The melting point and the 1H NMR spectrum of this yellow crystalline 
product 160 were found to be consistent with the literature findings. 
117 The subsequent 
nitration of the diarylhexane 160 followed by hydrogenation and demethylation were carried out 
in an analogous fashion to that used in the synthesis of C4-bridged aromatic amine 156. The 
IH NMR spectrum of the novel nitro compound 161 revealed three 4H multiplets in the 
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aliphatic region for the six carbon bridge along with two 6H singlets for the four methoxy 
groups, and the aromatic protons were observed as two 2H singlets at 8 6.64 and 7.50. The 13C 
NMR spectrum showed the expected nine resonances and the proposed structure of the nitro 
compound was further confirmed by its IR spectrum and combustion analysis. A parent ion at 
ndz 448 in the mass spectrum was also in agreement with these findings. The identity of the 
water soluble amine salt 162 was confirmed by the 1H NMR spectrum with the characteristic 
appearance of the benzylic proton resonance at 6 2.41 and two 4H multiplets in the aliphatic 
region together with two singlets in the aromatic region. The expected nine peaks were recorded 
in the 13C NMR spectrum and the IR spectrum revealed characteristic phenolic stretching 
bands at ca 3600 cm-1. An (M+H)+ peak at m/z 333 in the high resolution mass spectrum 
provided further support for the proposed structure. 
8.2.4 Synthesis of an Analogue with an NH Group in the Chain 
As previously mentioned, the preliminary work produced a new lead compound, 1,4-bis- 
(3,4-dihydrophenyl)butane 126. We envisaged that isosteric replacement of one of the bridging 
methylene moieties with an ammonium group could afford a water soluble derivative as its HBr 
salt. The three step synthetic route developed by McDonald8 is illustrated in Figure 51. 
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Figure 51 
Condensation of 3,4-dimethoxybenzaldehyde with 2-(3,4-dimethoxyphenyl)ethylamine 
was performed in refluxing EtOH for 16 hours and then, without purification, the intermediate 
imine was subjected to a NaBH4 reduction to furnish the secondary amine 163 in high yield. 
The product 163 was obtained as a yellow solid that was identified as a known compound and 
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the data recorded for this compound were found to be consistent with the findings reported in 
the literature. 8 Demethylation of the amine 163 with 48% HBr proceeded smoothly to provide 
the dicatecholamine salt 164 as tan coloured crystals giving a melting point and a1H NMR 
spectrum identical with those reported. 8 The proposed structure was further confirmed by the 
13C NMR and IR spectrum together with the high resolution mass spectrum. 
8.3 Synthesis of NDGA Analogues Containing 
Polyaminen 
Polyamines are known to be implicated in the regulation of cell growth, proliferation and 
differentiation through interactions with a variety of cellular macromolecules, 118 and 
furthermore researchers have suggested that polyamines may also play a role in the cellular 
process as "second messagers". 118 Interference with polyamine biosynthesis may thus 
provide access to anticancer treatment. We intended to introduce a polyamine component into 
the structure of a lead compound to produce a number of water soluble analogues of NDGA as 
their HBr salts. 
8.3.1 Synthesis of an Analogue Containing Diaminobutane 
Samejima et all 19 have reported the synthesis of a range of polyamines using KF- 
Celite to promote the efficiency of alkylations under mild conditions. Therefore we decided to 
apply their reaction conditions to the alkylation of the secondary amine 163. A mixture of the 
amine 163 and one equivalent of N-(4-bromobutyl)phthalimide in acetonitrile was heated at 
reflux for 48 hours. The reaction proved sluggish with the TLC analysis showing only a trace 
of product. To drive the reaction to completion, three equivalents of 4-bromobutylphthalimide 
were employed and a catalytic amount of triethylamine was used. The reaction mixture was 
heated at reflux for four days and the starting material could hardly be seen on a TLC plate. The 
crude product was purified by chromatography affording the diamine as a yellow oil in only 
35% yield. To improve the efficiency of this reaction, attention was turned to an alternative 
literature method. Ozaki et all 20 have reported the synthesis of several diamines via alkylations 
of secondary amines with N-(2-bromoethyl)phthalimide or N-(4-bromobutyl)phthalimide in the 
presence of K2C03 with DMF as solvent. Therefore we chose to utilise this method in our 
synthesis of the 1,4-diaminobutane 167 which is shown in Figure 52. 
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167 
The method of Ozaki et a1120 was modified as follows. A mixture of the secondary 
amine 163, N-(4-bromobutyl)phthalimide and potassium carbonate was heated at 110 OC in 
DMF for 48 hours. TLC analysis showed a trace of starting material and a product spot that 
was stained bright orange by Dragendorff reagent. The crude residue was purified by 
chromatography to furnish the product 165 as a light yellow oil in 53% yield. The conversion 
of the secondary amine 163 into the tertiary amine 165 was verified by NMR spectroscopy. The 
phthalimide protons provided a prominent feature in the 1H NMR spectrum as two 2H 
multiplets at b 7.6 and 7.7. The benzylic protons adjacent to the nitrogen atom were observed as 
a 2H singlet at 6 3.48 and a 4H multiplet was recorded for the two methylene groups between 
the protected catechol moiety and the nitrogen atom. The four carbon chain between the two 
nitrogen atoms was identified by two 2H multiplets and two 2H triplets in the aliphatic region 
and the twelve methoxy protons came to resonance at ca. 8 3.7. The characteristic appearance of 
the imide stretching band was observed at 1720-1770 cm-1 in the IR spectrum and the 13C 
NMR spectrum supported these findings with the carbonyl carbon signals at ca. 6 167. The 
structural assignment of compound 165 was further confirmed by accurate mass spectrometry 
with a peak at m/z 555 for (M+Na)+ run in the FAB+ mode. 
The subsequent deprotection of the amino group in compound 165 with hydrazine 
hydrate was carried out in refluxing MeOH and, in turn, in refluxing 6M HCl according to the 
procedure described by Ozaki et al. 
120 to produce the diamine 166 in high yield. The 
completion of the deprotection was apparent from the absence of the two characteristic 
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multiplets in the 1H NMR spectrum at 8 7.63 and 7.75 for the phthalimide protons. On the 
other hand the diamine 166 produced a triplet at 8 2.42 for the methylene group adjacent to the 
primary amine group which was previously found to resonate at 8 3.58 when next to the imide 
group. Moreover, the primary amine protons of the diamine 166 were observed as a broad 2H 
singlet at 6 1.69. 
Finally the demethylation of compound 166 was performed in refluxing 48% HBr to 
yield the NDGA analogue as a diamine HBr salt 167 in good yield. The 1H and 13C NMR 
spectra of compound 167 are shown in Appendixes 5 and 6. The NMR spectrum of the 
diamine HBr salt 167 showed the absence of the signals for the methoxy groups confirming the 
removal of the four methyl groups. The diamine HBr salt 167 was further characterised by its 
IR spectrum with phenolic and primary ammonium bands at 3609 and 2402 cm-1 respectively, 
together with an aromatic band at 1609 cm-1. A (M+H)+ peak at m/z 347 in the high resolution 
mass spectrum was consistent with the proposed structure. 
8.3.2 Synthesis of an Analogue Containing Diaminopropane 
The synthetic route for the preparation of the NDGA analogue 170 containing 
diaminopropane is illustrated in Figure 53. 
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The synthesis started with a Michael addition of the amine 163 to acrylonitrile following 
a modified version of the method used by Slater. 
121 A mixture of the secondary amine 163 and 
acrylonitrile was heated at 60-70 
oC in a sealed tube for 48 hours and the starting material could 
hardly be seen on a TLC plate. The crude residue was then purified by column chromatography 
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to produce the nitrile 168 as a colourless oil in good yield. The identity of the nitrile 168 was 
verified by NMR, IR and accurate mass spectra. A 2H triplet at 8 2.30 was observed for the 
methylene group adjacent to the cyanide group and a 2H singlet at S 3.56 was recorded for the 
benzylic protons next to the tertiary amine group while the remaining methylene protons came 
into resonance as a 6H multiplet at S 2.72. The methoxy groups produced four singlets at ca. 6 
3.8 and the characteristic aromatic proton resonances were found as a 6H multiplet at 6 6.70. 
The expected twenty-two resonances were recorded in the 13C NMR spectrum including the 
cyanide resonance at S 119. The important spectroscopic features of compound 168 in the IR 
spectrum were the characteristic nitrile band at 2245 cm-1 and an aromatic band at 1606 cm-1. 
A parent ion at m/z 384 in the mass spectrum provided further support for the structural 
assignment. 
Reduction of the nitrite 168 with a mixture of LiA1H4 and A1C13 in THE according to 
the procedure of Slater121 afforded the primary amine 169 as a light yellow oil in good yield. 
The completion of the reduction was evident with the appearance of a 2H broad singlet in the 
1H NMR spectrum at 8 1.29 characteristic of the amino group along with a 2H triplet at S 2.46 
for the methylene group adjacent to the amino group. Furthermore, the diamine 169 exhibited a 
2H triple triplet at 6 1.54 for the central methylene group on the propyl moiety that was 
previously found to resonate at 8 2.30 when adjacent to the cyanide group. The IR spectrum 
provided further support for those findings with the presence of amino stretches at 3370 cm-1 
and the absence of the nitrite band at 2245 cm-1. The 
13C NMR spectrum revealed the 
expected twenty-two peaks and the proposed structure was further confirmed with a (M+H)+ 
peak at m/z 389 in the high resolution mass spectrum. 
The diamine 169 was finally demethylated with 48% HBr to yield the diamine salt 170 
in high yield. The demethylation was apparent from the NMR spectra of compound 170 with 
the absence of the signals for the four methoxy groups while the IR spectrum showed the 
presence of the characteristic phenol stretches at 3570 cm-1. The structure was confirmed by 
accurate mass spectrometry with an observed peak at m/z 333 in the FAB+ mode. 
8.3.3 Synthesis of a Diamine Bridged Analogue 
In designing NDGA diamine analogue, the diimine 171, which had been prepared by 
Kliegman and Barnes, 122 was viewed as an appropriate precursor, and indeed the diamine 
analogue 173 was obtained therefrom by several functional group manipulations. 
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The condensation of glyoxal with p-anisidine was performed in refluxing MeOH 
according to the procedure of Kliegman and Barnes122 to furnish the diimine 171 as bright 
yellow crystals giving a melting point and IH NMR spectrum in agreement with those 
previously cited in the literature. 122 Reduction of the diimine 171 with sodium borohydride in 
refluxing EtOH afforded the diamine 172 as a yellow solid in 91 % yield. The characteristic 
appearance of the aromatic proton resonances for the two para disubstituted benzene rings was 
found in the 1H NMR spectrum of the diamine 172 as an AA'BB' system at 8 6.55 and 6.72. 
Furthermore the diamine 172 provided a 6H singlet at 6 3.68 characteristic of the two methoxy 
groups along with another 4H singlet at 8 3.25 for the two methylene groups. The signals for 
the two NH groups collapsed to a 4H singlet after shaking the sample with D20. The expected 
six peaks were observed in the 13C NMR spectrum, and the IR spectrum revealed a NH 
stretching band at 3274 cm-1 along with a characteristic absorption for the benzene ring at 1593 
cm-1. A parent ion at m/z 272 that was observed in the mass spectrum was consistent with the 
structural assignment. 
The diamine 172 was then subjected to demethylation with 48% HBr to afford the 
analogue 173 as its HBr salt. The removal of the methyl groups was confirmed by the IH NMR 
spectrum with no sign of methyl ether functionality and the diamine salt 173 was further 
characterised by its 
13C NMR and IR spectra together with a combustion analysis. The 
structural assignment was also verified by accurate mass spectrometry with a peak at m/z 245 
run in the FAB+ mode. 
8.3.4 Attempted Synthesis of an Analogue containing Spermidine 
Since we had an analogue containing a diamine in hand, we sought to extend the diamine 
backbone to incorporate a spermidine moiety in the NDGA analogue. 
96 
OMe 
MeO 
OMe 
I\ 
M\ý 
pý N'0ý44%00011ýý Mc 
mI/ 
00 Me0 
70 QC, 48 h, 68 % 
x 
166 174 
N 
OMe OH 
Me0 HO%ý 
1)00'ý OMe OH 
wo HO 
LiAIH4. Ala, 
175 
\176 
NH NH 
Figure 55 
Michael addition of the diamine 166 to acrylonitrile according to the procedure of 
Slater121 afforded the nitrile 174 as a light yellow oil in 68% yield. The extension of the 
diamine backbone was confirmed by the 1H NMR spectrum with each integral of the two 
multiplets at 6 2.70 and 6 2.35 increased by 2H and the IR spectrum showed the characteristic 
nitrite stretching band. The subsequent reduction of the nitrite 174 with a mixture of LiAIH4 
and A1C13 led to the cleavage of the carbon-nitrogen bond of the tertiary amine moiety. 
Alternative ways to reduce the cyanide group to an amine group could be tried in future work. 
The cyanide group may be hydrogenated over Rh/A1203 or Rh/C under mild conditions to 
minimise cleavage of the benzylic C-N band, and reduction of the nitrile by borane hydride 
reagents could be considered. 
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8.4 Biological Results and Discussion 
The biological evaluation data for the NDGA analogues are shown in Table 4. All of the 
new compounds were shown to be much more soluble in water (> 1 mM) than NDGA as 
expected. The activity of the tetraglycyl tetrahydrochloride salt against SCLC cell line H-69 
encouragingly matched its parent compound, the new lead compound 1,4-bis-(3,4- 
dihydroxyphenyl)butane 126 in vitro. The diamine salt 156 of the new lead compound was 
found to be as active as NDGA at one week but less potent after two weeks in culture. The 
diamine salt analogue 158 of NDGA appeared to have slightly more activity than NDGA and 
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the diamine salt 162 of the 1,6-bis-(3,4-dihydroxyphenyl)hexane was found to be slightly less 
potent than its parent compound. The C4-bridged analogue 164 containing an amine salt in the 
bridge was found to be significantly less active than NDGA and adding an aminopropyl group 
in 170 reduced the activity further. The diamine salt 173 was also inactive. We still await the 
results of the other analogues containing amine salts. 
In conclusion the tetraglycyl tetrahydrochloride salt of the new lead compound 126 was 
successfully synthesised and is now available for testing on animals. NDGA diamine salt 158 
displays potency in the same region as NDGA. However the introduction of two amino groups 
on the aromatic rings of the new lead compound 126 produces a compound 10 times less active 
than its parent. 
NDGA Analogue Number IC50 (µmol) 
ON NDGA 3.5 
0 
Ný 153 0.3 
OH 156 3.5 
NOH 
°" 158 2.0 
H4 ON 
Of 162 8.0 
Nr OH 
ON Dooo" 164 27 
CH 
170 >100 
It. H. 
N. __. N 173 >100 ý 2tr' 
Table 4 
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CHAPTER 9 
Experimental 
Reagents were purchased from Aldrich Chemical Company (Gillingham, UK) 
or Lancaster Synthesis (UK) and were used without further purification. Organic 
solvents were obtained from Rhone-Poulenc Rorer and were dried, as necessary, using 
the procedures described in Leonard, Lygo and Procter. 145 Melting points were 
determined in open capillaries using Gallenkamp apparatus and are uncorrected. III 
and 13C NMR spectra were obtained on a Bruker DPX/400 spectrometer operating at 
400 MHz and 100 MHz respectively. 13C NMR spectra were assigned with the aid of 
Distortionless Enhancement by Polarisation Transfer (DEPT)-edited spectra and 1H 
NMR coupling constants were calculated and reported in Hz. The numbering schemes 
shown are used for ease of assigning the NMR spectra and do not refer to the system 
of nomenclature. Thin layer chromatography was performed using Merck aluminium- 
backed silica plates of 0.25 mm thickness and chromatograms were visualised using 
UV conditions at 254nm or using a variety of common stains prepared using the 
procedures described in Leonard, Lygo and Procter. 124 Column chromatography was 
carried out on silica gel (particle size 70-230 mesh). Mass spectra (MS) were recorded 
on AEI MS12 or MS902 spectrometers using the electron-impact ionisation (EI) mode 
or, if stated, chemical ionisation (CI) or fast atom bombardment (FAB) modes. Infra- 
red (IR) spectra were recorded on a Perkin Elmer PU 9800 FT-IR spectrometer. 
Combustion analysis was carried out on a Carlo-Erba 1106 elemental analyser. 
Experimental to Chapter 5 
N-(t-Butoxycarbonyl)-L proline 6484 
s 2H 
BM,. ý x 
10 
1 
96 NO 2 
10 v 
43 
A modified version of the method by Ookawa and Soai84 was used. To a 
solution of L-proline (5 g, 43.5 mmol) in dioxane (25 ml) and water (28 ml) was added 
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potassium carbonate (13.1 g, 95 mmol) slowly with stirring. (BOC)20 (9.9 g, 47 
mmol) in dioxane/water was added dropwise, and the reaction mixture was stirred 
overnight. The reaction mixture was acidified with citric acid (saturated solution), and 
the product extracted with DCM (3 x 50 ml). The organic extracts were washed with 
brine (40 ml), dried over MgSO4, and concentrated in vacuo to give a white solid. 
Recrystallisation from ethyl acetate/hexane yielded compound 64 as white needles (7.1 
g, 33 mmol, 76%) mp 129-131 OC (lit., 84 136-137 OC). SH (400 MHz, CDC13) 1.35 
and 1.41 (9H, two s, H-8 to 10), 1.82 to 2.25 (4H, m, H-2 and 3), 3.26 to 3.52 (2H, m, 
H-4), 4.23 (1H, m, H-1), 9.6 (1 H, bs, C02H). 
N-(t-Butoxycarbonyl)-N'-(2 fluorophenyl)-L prolineamide 65 
3 16 
12 fý15 
s: 
ýrINN 
O 
$ý\1314 
6 11 
9 
10 
A modified version of the literature method85 was used. To a solution of N-(t- 
butoxycarbonyl)-L-proline (2 g, 9.3 mmol) in DCM (40 ml) was added DCC (2.42 g, 
11.2 mmol) then DMAP (181.8 mg, 1.5 mmol) with stirring. 1h later 2-fluoroaniline 
(1.2 ml, 1.41 g, 12.6 mmol) was added. The reaction mixture was stirred for 24 h under 
N2 at room temperature. The DCU precipitate was filtered off, and the filtrate stored in 
a freezer overnight to encourage precipitation of the remaining DCU. The DCU was 
filtered, acetic acid was added dropwise to the filtrate, and the filtrate washed with brine, 
dried (anhydrous MgSO4) and the solvent evaporated in vacuo to give a pale yellow 
solid. Recrystallisation from EtOH yielded compound 65 as white needles (2.4 g, 7.8 
mmol, 84%), mp 150-152 OC. vn (KBr disc)/cm-1 3265s (NH), 3062m (Ar-H), 
1699-1620s (CO), 1598s (Ar), 1367s (C-F); SH (400 MHz, CDC13) 1.42 (9H, s, H-14 
to 16), 1.89 (2H, m, H-10), 2.14 and 2.45 (2H, two bs, H-9), 3.38 (2H, m, H- 11), 4.42 
(IH, m, H-8), 6.97 to 8.25 (4H, m, H-3 to 6); SC (100 MHz, CDC13) 24.0 (C-10), 27.2 
(C-14 to 16), 26.0 (C-9), 46.1 (C-11), 59.8 (C-8), 80.0 (C-13), 113.7 (C-6), 113.8 (C- 
3, JCF 20 Hz), 120.6 and 123.3 (C-4 and 5), 126.0 (C-1, JCF 23 Hz), 151.5 (C-2, JCF 
243 Hz), 169.0 (CO); m/z (EI) 308.1537 (M+'). C16H21O3N2F requires 308.1538; 
m/z (%) 308 (10), 235 (12), 207 (5), 114 (95), 70 (100), 57 (55). 
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N-(t-Butoxycarbonyl)-N'-(2-methozyphenyl)-L prolineamide 66 
5 16 
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Compound 66 was prepared from 64 (1.92 g, 8.95 mmol) and o-anisidine (1.50 
g, 8.95 mmol) in the presence of DCC (2.33 g, 11.28 mmol) and DMAP (0.18 g, 1.41 
mmol) by the modified method used to prepare compound 65. Recrystallisation from 
isopropanol/hexane yielded the title compound 66 (1.11 g, 3.50 mmol, 40%). mp 213- 
220 OC. vmax (KBr disc)/cm-1 3327m (CONH), 1774s and 1691 s (CONH), 1601 s 
(Ar); 8H (400 MHz, d4-MeOH) 1.44 (9H, two m, H-14 to 16), 1.84 to 2.33 (4H, m, H- 
9 and 10), 3.50 (3H, m, NH and H-11), 3.89 (3H, s, OCH3), 4.40 (1H, bs, H-8), 6.94 
to 8.09 (4H, m, H-3 to 6); 6C (100 Mz, d4-MeOH) 26.5 and 27.2 (C-10), 28.9 (C-14 
to 16), 32.9 and 35.2 (C-9), 48.4 (C-11), 49.6 (OCH3), 56.4 and 56.6 (C-8), 82.1 (C- 
13), 111.9 and 112.2 (C-3 and 6), 121.9 and 126.6 (C-4 and 5), 124.0 (C-1), 140.0 (C- 
2), 176.3 (CO); m/z (EI) 320.1736 (M+'). C17H2404N2 requires 320.1736; m/z (%) 
320 (30), 247 (13), 224 (8). 170 (22), 114 (92), 70 (100), 57 (50). 
N-(2-Fluorophenyl)-L prolineamide 67 
3 
4ý 0H 
S$ 11 
6 
at 
H 
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A modified version of the method by Stahl and co-workers86 was used. 
Compound 65 (0.5 g, 1.62 mmol) was dissolved in 1M HC1-MeOH (9 ml). The 
reaction mixture was stirred at room temperature for 48 h. The solvent was removed in 
vacuo to yield a pale yellow solid which was recrystallised from absolute ethanol giving 
the compound 67 as white needles (280 mg, 1.35 mmol, 83%), mp 223-229 OC. vmax 
(KBr disc)/cm-1 3327s (NH), 1684s (CONH), 1608s (Ar), 1105 and 1384 (C-F); SH 
(400 MHz, d4-MeOH) 2.03 and 2.48 (4H, two m, H-9 and 10), 3.33 (2H, m, H-11), 
4.44 (IH, m, H-8), 7.08 (3H, m, H-3 to 5), 7.82 (IH, m, H-6); 8C (100 MHz, d4- 
MeOH) 25.5 and 26.5 (C-10), 31.7 and 35.1 (C-9), 47.9 (C-11), 62.0 (C-8), 117.1 (C- 
3, JCF 19.6 Hz), 125.9 (C-6, JCF 4 Hz), 126.0 (C-4, JCF 10 Hz) 126.7 (C-1, JCF 14 
Hz), 128.2 (C-5, JCF 7 Hz), 156.2 (C-2, JCF 240 Hz), 169.0 (CO); m/z (EI) 208.1015 
(M+'). C 11 H 13ON2F requires 208.1018; mlz (%) 208 (5), 111 (10), 83 (5), 70 (100), 
68 (5). 
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N-(2-Methoxyphenyl)-L-prolineamide 68 
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Compound 68 was prepared from 66 (0.4 g, 1.2 mmol) by the method used to 
prepare 67. Purification was by column chromatography eluting with hexane-ethyl 
acetate-conc. NH3 (2: 1: 0.3). The fractions Rf 0.2 were combined and the solvent 
evaporated in vacuo to yield 68 as a grey solid (0.2 g, 0.91 mmol, 79%), mp 218 OC 
(from acetonitrile). vmax (KBr disc)/cm-1 3494s (NH), 1692s (CO), 1600s (Ar); 6H 
(400 MHz, d4-MeOH) 2.05 and 2.42 (4H, two m, H-9 and 10), 3.26 (2H, m, H-11), 
4.29 (1H, m, H-8), 6.94 to 7.14 (3H, m, H-3 to 5), 8.05 (1H, dd, J 1.56 Hz, J8 Hz, H- 
6); 8C (100 MHz, d4-MeOH) 26.4 (C-10), 32.0 (C-9), 48.1 (C-11), 56.7 (OCH3), 
62.3 (C-8), 112.2 (C-6), 121.9 (C-3), 123.1 (C-4), 126.8 (C-5), 128.0 (C-1), 151.7 (C- 
2), 176.8 (CO); m/z (EI) 220.1209 (M+') C 12H 1602N2 requires 220.1206; m/z (°10) 
220 (10), 123 (18), 108 (8), 70 (100), 68 (5). 
L-Proline Benzyl Ester Hydrochloride 6987 
67 C1 
xr0Ö 12 
10 11 
3 
The method of Neuman and Smith87 was used. L-Proline (6 g, 52.2 mmol) was 
suspended in benzyl alcohol (84 ml) and dry HCl was passed through for 1h at 0 0C. 
The mixture was then heated at 85 °C for 1h under reduced pressure to remove water 
and HCI. Ether (840 ml) was added to the cooled residue (0 0C) to give a white 
precipitate, which was stored at 0 °C overnight. The solvent was removed and the solid 
was dried in vacuo to give compound 69 as a white powder (9.7 g, 47 mmol, 90%) 
which was satisfactory for synthetic work, mp 147-148 OC (lit., 87 148-148.5 0C). 
New data: 6H (400 MHz, d4-MeOH) 2.00 and 2.32 (4H, two m, H-10 and 11), 
3.25 (2H, m, H-12), 4.39 (IH, dd, J 6.4 Hz, J 8.8 Hz, H-9), 5.18 (2H, AB system, J 6.8 
Hz, H-7), 7.26 (5H, m, H-2 to 6); 6C (100 MHz, d4-MeOH) 24.9 and 25.1 (C-11), 
29.7 and 30.2 (C-10), 47.5 (C-12), 61.1 (C-9), 69.7 (C-7), 130.1 to 130.2 (C-2 to 6), 
136.8 (C-1), 170.4 (C-8). 
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N-(2-Fluorobenzoyl)-L-proline Benzyl Ester 73 
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A modified version of the method by Paul and Anderson88 was used. 2- 
Fluorobenzoic acid (0.6 g, 4.28 mmol) and compound 69 (1.76 g, 8.56 mmol) were 
dissolved in DMF (21 ml). Carbonyldiimidazole (1.043 g, 6.42 mmol) was added and 
the solution was stirred for 24 h under N2 at room temperature. The reaction mixture 
was dissolved in water (210 ml), and extracted with ether (3 x 70 ml). The organic 
extracts were washed with saturated Na2CO3 solution (100 ml), dried (anhydrous 
Na2SO4) and concentrated in vacuo. The crude product was purified by coloumn 
chromatography, eluting with hexane-ethyl acetate (1: 1). The fractions Rf0.3 were 
combined and the solvent was evaporated in vacuo to yield compound 73 as a yellow 
oil (0.9 g, 2.7 mmol, 63%). vmax (neat)/cm-1 1745s (CO), 1610m (Ar), 1171s (C-F); 
8H (400 MHz, CDC13) 1.79 and 2.28 (4H, two m, H-9 and 10), 3.35 and 3.43 (2H, 
two m, H-8), 4.24 and 4.66 (1H, two m, H-11), 5.16 (2H, AB system, J 12 Hz, H-13), 
7.09 (9H, m, H-3 to 6 and H-15 to 19), 8C (100 MHz, CDC13) 21.0 and 23.1 (C-9), 
29.8 and 31.6 (C-10), 46.9 and 48.6 (C-8), 59.3 and 60.7 (C-11), 65.6 and 67.3 (C- 
13), 116.2 (C-3, JCF 21), 124.9 (C-5, JCF 3.6 Hz), 125.2 (C-1, JCF 18 Hz), 127.9, 
128.5,128.6,128.9 and 129.4 (C-15 to 19), 129.5 (C-6, JCF 6 Hz), 131.8 (C-4, JCF 10 
Hz), 135.4 and 136.1 (C-14), 158.9 (C-2, JCF 247 Hz), 165.9 (C-7), 172.1 (C-12); m/z 
(EI) 327.1271 (M+') C19H18O3NF requires 327.1271; m/z (%) 327 (4), 230 (20), 
192 (45), 160 (10), 123 (100), 98 (67), 91 (74), 70 (44). 
N-(2-Methoxybenzoyl)-L-proline Benzyl Ester 74 
Me OO 
2 11 
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1 
1Ö 
18 
37 
10 
1S 
16 
17 
568 9 
Compound 74 was prepared from 69 (0.5 g, 3.29 mmol) and 71 (1.69 g, 8.23 
mmol) in the presence of CDI (0.8 g, 4.94 mmol) by the method used to prepare 
compound 73. Purification was by column chromatography eluting with hexane-ethyl 
acetate (1: 2). The fractions Rf0.3 were combined and concentrated in vacuo to yield 
74 as a viscous oil (0.90 g, 80%); vmax (neat)/cm-1 1744s and 1636s (CO), 1601s 
(Ar); 6H (400 MHz, CDC13) 1.80 to 2.17 (4H, three m, H-9 and 10), 3.25 and 3.33 
(2H, two m, H-8), 3.71 (3H, s, OCHS), 4.18 and 4.65 (1H, two m, H-11), 5.14 (2H, AB 
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system, J 13.2 Hz, H-13), 6.86,7.07 and 7.26 (9H, three m, H-3 to 6 and H-15 to 19); 
6C (100 MHz, CDC13) 23.2 and 25.0 (C-10), 30.0 and 31.6 (C-9), 46.6 and 48.4 (C- 
11), 55.9 and 56.0 (OCH3), 59.0 and 60.7 (C-8), 67.11 and 67.18 (C-13), 111.4 and 
111.5 (C-3), 121.2 (C-5), 126.6 and 126.8 (C-1), 128.4 to 128.9 (C-6,15 to 19), 131.0 
(C-4), 135.6 and 136.2 (C-14), 155.3 and 155.8 (C-2), 168.4 and 168.6 (7-CO), 172.4 
(12-CO); m/z (EI) 339.1472 (M+'). C20H2104N requires 339.1474; m/z (%) 339 
(5), 279 (5), 204 (35), 149 (22), 135 (100), 91 (13), 86 (54), 77(18), 49(15). 
N-(2,4-Dimethoxybenzoyl)-L-proline Benzyl Ester 75 
OMe O0 13 19 
21 11 
lZ14 18 37 
LO 1 17 
MeO 456$9 16 
Compound 75 was prepared from 69 (0.6 g, 3.3 mmol) and 72 (1.36 g, 6.6 
mmol) in the presence of CDI (0.8 g, 4.94 mmol) by the method used to prepare 73. 
Purification was by column chromatography eluting with hexane-ethyl acetate (1: 2). 
The fractions Rf0.4 were combined and concentrated in vacuo to yield 75 as a viscous 
oil (0.79 g, 64%); vmax (neat)/cm-1 1751s (ester), 1687s and 1638s (CON and Ar); 
bH (400 MHz, CDC13) 1.80,1.91 and 2.18 (4H, three m, H-9 and 10), 3.28 and 3.36 
(2H, two m, H-11), 3.68 and 3.72 (6H, two s, OCHS), 4.21 and 4.62 (IH, two m, H-8), 
5.13 (2H, AB system J 13.6 Hz, H-13), 6.34 and 7.21 (8H, each m, ArH); bC (100 
MHz, CDC13), 23.2 and 25.1 (C-10), 29.9 and 31.6 (C-9), 46.6 and 48.5 (C-11), 55.7 
and 56.0 (OCH3), 59.1 and 60.6 (C-8), 67.0 (C-13), 98.9 and 99.0 (C-3), 105.1 (C-5), 
119.5 and 119.7 (C-1), 128.4 to 128.9 (C-15 to 19), 129.7 and 129.9 (C-6), 135.6 and 
136.3 (C-14), 157.3 (C-2), 162.2 (C-4), 168.3 (7-CO), 172.5 (12-CO); m/z (EI) 
369.1573 (M+'). C21H2305N requires 369.1570; m/z (%) 369 (9), 232 (4), 165 
(100), 122 (5), 91 (21), 77 (3). 
N-(2-Fluorobenzoyl)-L-proline 76 
F0 
211 10 
37 
89 46 
5 CO2H 
A modified version of the method by Challis and co-workers89 was used. A 
solution of compound 73 (0.9 g, 2.7 mmol) in absolute EtOH (20 ml) containing 5% 
Pd-C (45 mg) was stirred under a hydrogen balloon at rt for 6 h. The catalyst was 
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removed by filtration, and the filtrate concentrated under vacuum to give a yellow solid, 
which was recrystallised from ethyl acetate to give 76 (0.35 g, 1.48 mmol, 55%), mp 
165-166 0C; vmax (KBr disc)/cm-1 2485s (N+H ), 1757s and 1621s (CO and Ar), 
1033s and 1346s (C-F); 6H (400 MHz, d4-MeOH) 2.06 and 2.40 (4H, two m, H-9 
and 10), 3.47 and 3.77 (2H, two m, H-11), 4.28 and 4.61 (1H, two m, H-8), 7.32 and 
7.48 (4H, each m, Ar-H); bC (100 MHz, d4-MeOH) 24.1 and 26.0 (C-10), 31.1 and 
32.6 (C-9), 48.2 and 50.2 (C-11), 60.8 and 62.5 (C-8), 117.5 (C-3, JC F 21 Hz), 126.2 
(C-1, JCF 15 Hz), 126.3 (C-5, JCF 3.5 Hz), 130.3 (C-6, JCF 7 Hz), 133.6 (C-4, JCF 9 
Hz), 160.1 (C-2, JCF 246 Hz), 167.9 (CO), 175.5 (CO2H); m/z (EI) 237.0802 (M+'). 
C12H12O3NF requires 237.0803; m/z (%) 237 (5), 193 (80), 192 (75), 123(100), 95 
(65), 75 (22). 
N-(2-Methoxybenzoyl)-L-proline 77 
OMe 0 
21 
11 
10 
3I 7 
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Compound 77 was prepared from 74 (0.76 g, 2.2 mmol) in absolute ethanol 
(20 ml) containing 5% Pd-C (45 mg) by the method used to prepare 76. Purification 
by chromatography eluting with EtOAc-hexane (2: 1) containing acetic acid (5%), and 
recrystallisation from EtOAc provided 77 as light yellow crystals (0.34 g, 62%). mp 
135 OC. (Found: C, 62.71; H, 6.11; N, 5.51; C13H15NO4 requires C, 62.65; H, 6.02; 
N, 5.62%); vmax (KBr disc)/cm-1 2975s (C02-H), 2496s (N+ H), 1748s (CO), 1589s 
(Ar); 6H (400 MHz, CDC13) 1.80 and 1.93 (2H, two m, H-10), 2.12 and 2.33 (2H, two 
m, H-9), 3.29 (2H, m, H-11), 3.78 (3H, s, OCHS), 4.10 and 4.69 (IH, two m, H-8), 
6.79 to 7.34 (4H, m, ArH); 6C (100 MHz, CDC13) 23.0 and 24.9 (C-10), 28.6 and 
32.0 (C-9), 46.5 and 49.1 (C-11), 56.1 (OCH3), 60.1 and 61.0 (C-8), 111.2 and 111.6 
(C-3), 121.2 and 121.3 (C-5), 125.7 (C-1), 128.4 and 128.9 (C-6), 131.1 and 131.6 (C- 
4), 155.6 (C-2), 168.9 (7-CO), 170.5 (CO2H); m/z (CI) 250.1077 (M+'). 
C 13H 15O4N requires 250.1075; m/z (%) 249 (2), 205 (25), 135 (100), 92 (10), 77 
(18). 
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N-(2,4-Dimethoxybenzoyl)-L-proline 78 
9Me 0 
?, ý* 11 
10 
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Compound 78 was prepared from 75 (0.79 g, 2.1 mmol) in absolute ethanol 
(20 ml) containing 5% Pd-C (40 mg) by the method used to prepare 76. Purification 
by chromatography eluting with EtOAc-hexane (2: 1) containing acetic acid (5%), and 
recrystallisation from EtOAc provided 78 as light yellow crystals (0.34 g, 57%), mp 
134-135 OC. (Found: C, 59.89; H, 6.06; N, 4.94; C 14H 17NO5 requires C, 60.21; H, 
6.09; N, 5.02%); vmax (KBr disc)/cm-1 2959s (C02-H), 2511 s (N+ H), 1743s (CO), 
1591s (Ar); 8H (400 HMz, CDC13) 1.93 and 2.10 (2H, two m, H-10), 2.29 and 2.39 
(2H, two m, H-9), 3.40 and 3.69 (2H, two m, H-11), 3.80 (6H, s, OCHS), 4.24 and 4.55 
(IH, two m, H-8), 6.33 to 7.20 (3H, m, Ar-H), 8.06 (1H, bs, CO2H); 6C (100 Hz, 
CDC13) 24.9 (C-10), 28.4 (C-9), 49.3 (C-11), 55.9 and 56.1 (OCH3), 60.4 (C-8), 99.1 
(C-3), 105.3 (C-5), 118.1 (C-1), 129.8 (C-6), 157.2 (C-2), 162.8 (C-4), 171.1 and 
173.2 (CO or CO2H); m/z (EI) 279.1109 (M+'). C 14H 17O5N requires 279.1112; 
m/z (%) 279 (3), 235 (20), 193 (10), 165 (100), 123 (35), 95 (8), 63 (8), 63 (7). 
N-2-Hydroxyphenylphthalimide 79 90 
O 
10 8 
OH 
N13 
12 
l3 
14 64 
05 
2-Aminophenol (5.45 g, 50 mmol) and phthalic anhydride (14.8 g, 100 mmol) 
were added to acetic acid (125 ml), and the mixture was heated at reflux for 1 h, then 
diluted with water (125 ml) and heated to boiling. On cooling in ice, 79 (10.1655 g, 
42.5 mmol, 85%) crystallised, mp 218-219 OC 0it., 90 223-224 OC); 8H (400 HMz, d6- 
DMSO) 6.92 (IH, m, H-3), 7.01 (IH, m, H-5), 7.30 (2H, m, H-4 and 6), 7.91 (2H, m, 
H-11 and 12), 7.96 (2H, m, H-10 and 13), 9.87 (IH, s, OH). 
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N-(2-Benzyloxyphenyl)phthalimide 80 90 
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Compound 79 (5 g, 21 mmol) was added to a solution of Na (0.483 g, 21 
mmol) in 99% EtOH (54 ml). Under rapid cooling, benzyl bromide (5.39 g, 31.5 
mmol) was added dropwise and the mixture was heated for 22 h at 80 OC. Water (130 
ml) was added to the reaction mixture while it was cooled in ice. Compound 80 was 
extracted with DCM (100 ml x 3). The organic extracts were washed with 10% NaOH 
(150 ml) and water (150 ml), dried with Na2SO4 and concentrated in vacuo to give a 
yellow solid which was recrystallised from hexane to yield 80 (5.1148 g, 15.5 mmol, 
75%), mp 143-144 OC (lit., 147-148 OC); 8H (400 HMz, CDC13) 5.02 (2H, s, H- 
15), 7.00,7.18 and 7.29 (9H, three m, H-17 to 21 and H-10 to 13), 7.67 (2H, m, H-3 
and 4), 7.85 (2H, m, H-2 and 5). 
2-Benzyloxyaniline 8190 
cc0O 
Hydrazine hydrate (0.6 ml) was added to a solution of 80 (4.0 g, 12 mmol) 
suspended in EtOH (50 ml) and heated to reflux for 1 h. After cooling, ether (150 nil) 
was added and the precipitate was filtered off. The filtrate was concentrated and the 
residue was heated in 10% HC1(40 ml). After cooling an excess of conc. NaOH was 
added. The oily precipitate was dissolved in ether, washed with water, dried (anhydrous 
Na2SO4) and concentrated in vacuo to yield compound 81 as a brown solid (1.588 g, 
8 mmol, 67%), mp 30 OC (lit., 37-39 OC); SH (400 HMz, CDC13) 3.74 (2H, bs, 
NH2), 4.99 (2H, s, H-7), 6.64 and 6.75 (each 2H, each m, H-3 to 6), 7.27 (5H, m, H-9 
to 13). 
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N-(t-Butoxycarbonyl)-N'-(2-benzyloxyphenyl)-L-prolineamide 82 
15 
4 
4 
Compound 82 was prepared from 64 (0.75 g, 3.5 mmol) and 81 (0.5 g, 2.5 
mmol) in the presence of DCC (0.72 g, 3.5 mmol) and DMAP (0.05 g, 0.4 mmol) by 
the method used to prepare 65. Purification was by column chromatography eluting 
with hexane-ethyl acetate (1: 1). The fractions Rf0.4 were combined and concentrated 
in vacuo to yield 82 as a yellow solid (0.9 g, 2.3 mmol, 91 %), mp 111-113 OC. (Found: 
C, 69.70; H, 7.01; N, 7.31; C23H2804N2 requires C, 69.69; H, 7.07; N, 7.07%); 
vm (KBr disc)/cm-1 3316m (NH), 1698s (CO), 1597s (Ar); bH (400 MHz, CDC13) 
1.29 (9H, s, H-14 to 16), 1.45 to 2.14 (4H, m, H-9 and 10), 3.29 and 3.39 (2H, two m, 
H-11), 4.21 and 4.39 (1H, two m, H-8), 5.04 (2H, m, H-17), 6.90 to 8.38 (9H, m, ArH); 
8C (100 MHz, CDC13) 25.0 (C-10), 28.7 (C-14 to 16), 32.0 (C-9), 47.0 (C-11), 81.0 
(C-13), 111.8,120.5,121.8,124.1,127.6,128.6,129.1 and 147.0 (C-1 to 6 and C-18 
to 23); m/z (EI) 396.2050 (M+'). C23H2804N2 requires 396.2051; m/z (%) 396 
(35), 340 (13), 226 (28), 170 (30), 114 (100), 70 (98), 57 (53). 
N-(2-Hydroxyphenyl) L-prolinamide 83 
OH 
NH 
V N%. 
11 
56 
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Compound 82 (0.72 g, 1.8 mmol) was dissolved in 1M HCl-MeOH (10 ml). 
The reaction mixture was stirred at room temperature for 24 h. The solvent was 
evaporated in vacuo to yield a brown oil. The brown oil was then dissolved in absolute 
EtOH (20 ml) and Pd-C (0.5 g) was added. The reaction mixture was stirred under a 
hydrogen balloon for 24 h at A. The catalyst was removed by filtration, and the filtrate 
concentrated under vacuum to give a dark brown oil, which was washed with DCM. 
The DCM was separated and the remaining brown oil was concentrated in vacuo to 
give 83 as a dark brown gum (0.2454 g, 1.2 mmol, 67 %); vmax (neat)/cm71 3532s 
(NH or OH), 1742s (CO), 1610s (Ar); 8H (400 MHz, d4-MeOH) 2.01,2.34 and 2.48 
(4H, three m, H-9 and 10), 3.33 (2H, m, H-11), 4.37 and 4.50 (IH, two m, 8-H), 6.60 to 
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7.69 (4H, m, 3 to 6-H); SC (100 MHz, d4-MeOH) 25.0 and 25.5 (C-10), 31.8 and 
32.3 (C-9), 47.9 and 48.0 (C-11), 61.7 and 62.2 (C-8), 116.8 and 117.6 (C-6), 120.9 
and 121.4 (C-3), 124.6,125.3,127.6 and 131.7 (C-4 and 5), 126.5 (C-1), 150.3 (C-2), 
169 (CO); m/z (EI) 206.1056 (M+'). C 11 H 14O2N2 requires 206.1057; m/z (%) 206 
(10), 199 (5), 122 (4), 109 (28 ), 80 (14), 70 (100), 62 (13), 55 (8). 
Benzyl 2-benzyloxybenzoate 8491 
20 
21 19 
432O1 
18 
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Salicylic acid (6 g, 43.4 mmol), ignited K2C03 (27 g, 195.3 mmol), benzyl 
chloride (17.4 g, 137.5 mmol) and DMF (50 ml) were heated at reflux with stirring for 
2.5 h, then the mixture was diluted with water and stored at room temperature. 
Compound 84 (13.5 g, 42.0 mmol, 97%) crystallised, mp 48 OC (lit., 91 52-54 OC). 
(Found: C, 79.19; H, 5.55; C21H1803 requires C, 79.24; H, 5.66 %). 
New data: 8H (400 MHz, CDC13) 5.08 and 5.26 (each 2H, each s, H-8 and 15), 6.90 
(2H, m, H-3 and 5), 7.29 (11H, m, H-4,10 to 14 and 17 to 21), 7.77 (1H, in, H-6); 8C 
(100 MHz, CDC13) 67.0 and 71.0 (C-15 and 8), 114.1 (C-3), 120.9 (C-5), 127.5, 
128.2,128.4,128.6,128.9,132.3 and 133.9 (C-4,6,10 to 14 and 17 to 21), 121.1 (C- 
1), 136.2 and 137.0 (C-9 and 16), 158.6 (C-2), 166.7 (C-7). 
Benzyl 2-benzyloxy-5-methoxybenzoate 85 
32 
13 
A2g 
Me0 
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Compound 85 was prepared from 2-hydroxy-5-methoxybenzoic acid (2.0 g, 
12.1 mmol) and benzyl chloride (4.84 g, 38.6 mmol) in the presence of ignited K2C03 
(7.5 g) by the method used to prepare 84. Recrystallisation from DMF/water provided 
85 as a yellow solid (2.9 g, 70%), mp 43-44 OC. (Found: C, 75.82; H, 5.76; 
C22H2004 requires C, 75.86; H, 5.75%); vmax (KBr disc)/cm-1 1691s (CO), 1606m 
(Ar); 8H (400 MHz, CDC13) 3.69 (3H, s, H-7), 5.01 and 5.27 (each 2H, each s, H-9 
and 16), 6.90 (2H, m, H-3 and 4), 7.23 to 7.48 (11 H, m, H-6,11 to 15 and 18 to 22), 
SC (100 MHz, CDC13) 56.2 (C-7), 67.2 and 72.2 (C-9 and 16), 116.6 and 119.8 (C-3 
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and 6), 127.6,128.2,128.5,128.6 and 128.9 (C-4,11 to 15 and 18 to 22), 121.9 (C-1), 
136.4 and 137.3 (C-10 and 17), 152.8 and 153.8 (C-2 and 5), 166.5 (C-8); m/z (EI) 
348.1363 (M+'). C22H2004 requires 348.1364; m/z (%) 348 (10), 257 (6), 181 (18), 
151 (17), 91 (100), 82 (23), 65 (7). 
2-Benzyloxybenzoic acid 8691 
13 
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Compound 84 (1.2 g, 3.7 mmol) was hydrolysed by heating it at reflux in a 
mixture of MeOH (31 ml) and 40 % NaOH (6 ml) for 2 h. Dilution with water and 
acidification with HC1 precipitated 86 as pale yellow crystals (0.7585 g, 3.6 mmol, 94 
off), mp 64_66 OC (111,, 91 76-78 OC). (Found: C, 72.9; H, 4.84; C 13H 1003 requires C, 
72.89; H, 4.67 %). 
New data: SH (400 HMz, d6-DMSO) 5.2 (2H, s, H-8), 7.01 (1H, m, H-3), 7.20 (1H, 
m, H-5), 7.30,7.40 and 7.50 (6H, three m, H-4, and 10 to 14), 7.62 (IH, m, H-6); SC 
(100 MHz, d6-DMSO) 69.9 (C-8), 114.2 (C-3), 120.7 (C-5), 127.4,127.9,128.7, 
130.9 and 133.2 (C-4,6 and 10 to 14), 157.2 (C-2), 167.7 (C-7), 122.3 (C-1), 137.3 
(C-9). 
2-Benzyloxy-5-methoxybenzoic acid 87 
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Compound 87 was prepared from 85 (2.8 g, 8 mmol) and 40% NaOH (11.8 
ml) in MeOH (65 ml) by the method used to prepare 86. Purification by 
chromatography eluting with EtOAc-hexane (1: 1) containing acetic acid (2%) afforded 
87 as a yellow solid (1.84 g, 90 %), mp 81-84 0C. (Found: C, 70.03; H, 5.45; 
C15H1404 requires C, 69.77; H, 5.42%); vm (KBr disc)/cm71 3234m (CO2H), 
1727s (CO), 1619m (Ar); 8H (400 MHz, CDC13) 3.74 (3H, s, H-7), 5.17 (2H, s, H-8), 
7.01 (2H, m, H-3,4), 7.33 (5H, m, H-10 to 14), 7.61 (1 H, m, H-6); bC (100 MHz, 
CDC13) 56.2 (C-7), 73.3 (C-8), 115.3 and 116.7 (C-3 and 6), 122.4 (C-4), 128.4, 
129.0,129.5 and 129.6(C-10 to 14), 119.0 (C-1), 134.8 (C-9), 151.9 154.9 (C-2 and 
110 
5), 165.5 (C-15); m/z (EI) 258.0893 (M+). C15H1404 requires 258.0894; m/z (%) 
258 (15), 150 (5), 91 (100), 82 (9), 65 (7). 
N-(2-Benzyloxybenzoyl)-L-proline benzyl ester 88 
24 
23 
4 
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Compound 88 was prepared from 86 (0.6 g, 2.80 mmol) and 69 (0.87 g, 4.2 
mmol) in the presence of CDI (0.68 g, 4.2 mmol) by the method used to prepare 73. 
Purification was by column chromatography eluting with hexane-ethyl acetate (1: 1). 
The fractions Rf 0.3 were combined and concentrated in vacuo to yield 88 as a viscous 
oil (0.77 g, 66%). (Found: C, 75.08; H, 6.16; N, 3.35; C26H25NO4 requires C, 75.18; 
H, 6.02; N, 3.37 %); vmax (neat)/cm-1 1751s and 1624s (CO), 1600s (Ar); 8H (400 
MHz, CDC13) 1.66 to 2.19 (4H, m, H-9 and 10), 3.30 and 3.71 (2H, two m, H-8), 4.25 
and 4.63 (1 H, two m, H-11), 5.03 (2H, s, H-20), 5.15 (2H, AB system, J 9.6 Hz, H-13), 
6.78 to 7.44 (14H, m, ArH); 6C (100 MHz, CDC13) 23.3 and 25.0 (C-9), 29.9 and 
31.5 (C-10), 46.6 and 48.4 (C-8), 59.1 and 60.5 (C-11), 66.1 and 67.1 (C-13), 70.8 (C- 
20 ), 113.2 and 113.5 (C-3), 121.7 (C-5), 127.3,128.2,128.3,128.5,128.8,128.9, 
129.0 and 130.9 (C-4,6,22 to 26 and 15 to 19), 127.4 (C-1), 136.3 and 137.2 (C-14 
and 21), 154.8 (C-2), 168.3 (C-7), 172.4 (C-12); m/z (EI) 415.1785 (M+'). 
C26H2504N requires 415.1786; m/z (%) 415 (14), 324 (13), 280 (13), 211 (80), 
188(7), 120 (12), 91 (100), 70 (11), 65(7). 
N-(2-Benzyloxy-5-methoxybenzoyl)-L-proline benzyl ester 89 
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Compound 89 was prepared from 87 (0.9 g, 3.7 mmol) and 69 (1.06 g, 5.2 
mmol) in the presence of CDI (0.84 g, 5.2 mmol) by the method used to prepare 73. 
Purification by column chromatography eluting with hexane-ethyl acetate (1: 1) 
afforded 89 as a viscous oil (1.19 g, 73%). (Found: C, 72.71; H, 6.20; N, 3.14; 
C27H2705N requires C, 72.81; H, 6.06; N, 3.14%); vm (neat)/cm-1 3064w (Ar-H), 
1744s (CO), 1648m (Ar); 8H (400 MHz, CDC13) 1.66 to 2.19 (4H, m, H-10 and 11), 
3.33 and 3.71 (2H, each m, H-9), 3.59 and 3.66 (3H, each s, H-7), 4.31 and 4.63 (1H, 
each m, H-12), 4.94 and 4.96 (2H, each s, H-21), 5.13 (2H, AB system, J 12.4 Hz, H- 
14), 6.71 to 7.32 (13H, m, ArH); SC (100 MHz, CDC13) 23.3 and 25.0 (C-10), 29.9 
and 31.5 (C-11), 46.7 and 48.4 (C-9), 56.0 and 56.1 (C-7), 59.1 and 31.5 (C-11), 46.7 
and 48.4 (C-9), 56.0 and 56.1 (C-7), 59.1 and 60.5 (C-12), 67.0 and 67.1 (C-14), 71.9 
and 72.1 (C-21), 113.4,113.8,115.9,116.8 and 116.9 (C-3,4 and 6), 127.5,128.2, 
128.3,128.5,128.6,128.7,128.8,128.9 and 129.0 (C-1,16 to 20 and 23 to 27), 136.2, 
137.3 and 137.5 (C-15 and 22), 148.8 and 154.5 (C-2 and 5), 167.9 (C-8), 172.3 (C- 
13); m/z (EI) 445.1888 (M+'). C27H2705N requires 445.1887; m/z (%) 445 (14), 
354 (5), 241 (28), 204 (12), 150 (22), 91 (100), 44 (14). 
N-(2-Hydroxybenzoyl)-L-proline 90 
32 OH 489 
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Compound 90 was prepared from 88 (1.34 g, 3.23 mmol) in absolute ethanol 
(15 ml) containing 5% Pd-C (600 mg) by the method used to prepare 76. Trituration 
with petroleum ether afforded 90 as a white solid (0.78 g, 92%), mp 31-33 0C. vmax 
(neat)/cm7l 3489s (OH), 1747s (CO), 1594m (Ar); 6H (400 MHz, CDC13) 1.82,1.98 
and 2.26 (4H, three m, H-9 and 10), 3.67 (2H, in, H-8), 4.15 and 4.60 (1H, two m, H- 
11), 6.74 to 7.44 (4H, m, H-3 to 6), 7.83 (IH, bs, OH or CO2H); 8C (100 MHz, 
CDC13) 24.9 and 26.3 (C-9), 31.1 and 32.5 (C-10), 48.8 and 50.4 (C-8), 58.7 and 60.9 
(C-11), 117.0 and 117.7 (C-3), 120.8 (C-5), 124.8 (C-1), 129.5 and 130.1 (C-6), 132.0 
and 132.9 (C-4), 156.4 (C-2), 170.9 (CO); m/z (EI) 235.0847 (M+'). C 12H 1304N 
requires 235.0849; m/z (%) 235 (33), 217 (10), 190 (28), 121 (100), 93 (17), 70 (100), 
65 (25), 41 (5). 
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Compound 91 was prepared from 89 (0.95 g, 2.14 mmol) in absolute ethanol 
(15 ml) containing 5% Pd-C (680 mg) by the method used to prepare 76. Trituration 
with petroleum ether afforded 91 as a grey solid (0.54 g, 94 %), mp 32 OC; vnm (KBr 
disc)/cm-1 3438s (OH), 1743s (CO), 1583s (Ar); 6H (400 MHz, d4-MeOH) 1.89 and 
2.24 (4H, two m, H-10 and 11), 3.47 (2H, m, H-9), 3.60 and 3.64 (3H, two s, H-7), 
4.33 and 4.46 (IH, two m, H-12), 6.62 to 6.78 (3H, m, ArH); 6C (100 MHz, d4- 
MeOH) 24.0 and 26.2 (C-10), 31.1 and 32.5 (C-11), 48.9 and 50.0 (C-9), 56.6 (C-7), 
60.9 (C-12), 113.8,114.0,118.8 and 118.9 (C-1,3,4 and 6), 148.0,149.0 and 154.5 
(C-2 and 5), 176.5 (CO); m1z (EI) 265.0949 (M+'). C13H1505N requires 265.0948; 
m/z (%) 265 (21), 235 (7), 219 (28), 150 (100), 121 (23), 107 (12), 70 (83). 
Experimental to Chapter 6 
2-Methyl-3-ethoxycarbonyl-5,6-dihydropyran 9292 
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A mixture of potassium carbonate (11.2 g), 99% ethanol (14 ml), 1,3- 
dibromopropane (8.08 g, 40 mmol) and ethyl acetoacetate (5.2 g, 40 mmol) was heated 
with stirring to 60 OC, then heated at reflux overnight. The reaction mixture was 
concentrated in vacuo and the residue was mixed with water (60 ml). The resulting oily 
layer was separated, and the aqueous phase was extracted with ethyl acetate (3 x 50 ml) 
and the ethyl acetate layer was combined with the yellow oil. After drying with sodium 
sulfate the ethyl acetate was evaporated and the residue was fractionally distilled to give 
92 as a colourless oil bp 65-70 OC (>1 mmHg, vacuum pump), (5.15 g, 30.3 mmol, 76 
%). 
New data: SH (400 MHz, CDC13) 1.21 (3H, t, J 7.2 Hz, H-10), 1.75 (2H, m, H-5), 2.15 
(3H, s, H-7), 2.23 (2H, t, J 6.4 Hz, H-4), 3.94 (2H, t, J 4.2 Hz, H-6), 4.11 (2H, q, J 7.2 
Hz, H-9). 
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6-Bromohexan-2-one 9392 
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48% Hydrobromic acid (9.5 ml) was slowly added at room temperature to 92 
(5.1 g, 30 mmol). After standing for 2h at room temperature the mixture was heated to 
reflux for 2 h, then diluted with an equal volumn of iced water. The mixture was 
extracted with chloroform (20 ml x 3), and the organic extracts were washed with 
saturated sodium bicarbonate solution and dried with sodium sulfate. The chloroform 
was evaporated in vacuo, and the residue was fractionally distilled to yield 93 as a 
yellow oil, bp 60-70 OC (> 1 mmHg, vacuum pump), (3.34 g, 18 mmol, 62 %). 
New data: SH (400 MHz, CDC13) 1.65 and 1.79 (each 2H, each m, H-2 or 3), 2.08 
(3H, s, H-6), 2.40 (2H, t, J 7.2 Hz, H-4), 3.34 (2H, t, J 6.4 Hz, H-1); 8C (100 MHz, 
CDC13) 22.6 (C-3), 30.2 (C-6), 32.4 (C-2), 33.6 (C-4), 42.9 (C-1), 208.6 (CO). 
7-(5'-Oxohexyl)-1,3-dimethylzanthine 9492 
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A solution of 1-bromohexan-5-one (3.4 g, 18.9 mmol) in ethanol (30 ml) was 
gradually mixed at the boil with theophylline (5.13 g, 28.5 mmol) in 1M NaOH (40 
ml). After heating at reflux overnight the alcohol was evaporated, and the residual 
aqueous phase was cooled and made alkaline and extracted with chloroform (3 x 60 
ml). The chloroform was evaporated in vacuo and the residue recrystallised from 
isopropanol to yield 94 (1.0 g, 3.6 mmol, 19 %). mp 70-72 OC (lit., 92 75-76 OC). 
New data: 8H (400 MHz, CDC13) 1.49 and 1.82 (each 2H, each It, each J 7.2 Hz, H-9 
or 10), 2.07 (3H, s, H-13), 2.43 (2H, t, J 7.2 Hz, H-11), 3.33 and 3.51 (each 3H, each s, 
H-1 or 3), 4.21 (2H, t, J 7.2 Hz, H-8), 7.49 (1H, s, H-5). 
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A modified version of the literature method93 was used. Compound 94 (0.60 g, 
2.16 mmol) was dissoved in MeOH (20 ml). While cooling in ice, NaBH4 (0.24 g, 
6.48 mmol) was added to the solution portionwise. The reaction mixture was stirred at 
rt for 1 h, then conc. HCl (0.4 ml) was added slowly to quench the reaction. The 
solvent was evaporated in vacuo to give a white solid. By-product NaCl was removed 
by chromatography (Florisil®) eluting with EtOAc-MeOH (10: 1). The fractions Rf 
0.36 were combined and solvent evaporated to yield compound 95 as a white solid (0.3 
g, 1.08 mmol, 50 %) mp 89-90 OC (isopropanol). (Found: C, 55.86; H, 7.22; N, 20.10; 
C13H2203N4 requires C, 55.71; H, 7.14; N, 20.0%); vmax (KBr disc)/cm-1 3475s 
(OH), 1710s, 1649s and 1600w (imidazole ring and CO); 8H (400 MHz, d4-MeOH) 
1.04 (3H, d, J 6.0 Hz, H-13), 1.30 (4H, m, H-9 and 10), 1.81 (2H, m, H-11), 3.26 and 
3.45 (each 3H, each s, H-1 and 3), 3.62 (IH, m, H-12), 4.30 (2H, t, J 6.8 Hz, H-8), 8.27 
(1H, s, H-5); 8C (100 MHz, d4-MeOH) 23.9 (C-13), 28.9 and 31.1 (C-1 and 3), 32.0 
(C-9 or 10), 39.7 (C-11), 49.2 (C-8), 68.6 (C-12), 108.4 (C-4), 142.2 (C-5), 148.1 (C- 
6), 153.1 and 156.4 (C-2 and 7); m/z (EI) 280.1532 (M+'). C13H2003N4 requires 
280.1528; m/z (%) 280 (67), 236 (18), 207 (23), 180 (100), 149(19), 82 (77), 78 (26), 
44(58). 
7-(3'-Oxobutyl)-1,3-dimethylxanthine 9692 
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Theophylline (0.9 g, 4.99 mmol), methylvinyl ketone (0.4 g, 4.99 mmol) and 
dry pyridine (7.5 ml) were heated at reflux overnight. The solvent was removed in 
vacuo and the residue was recrystallized from isopropanol. Compound 96 was a pale 
yellow solid (0.8411 g, 3.4 mmol, 70%), mp 142 OC (lit., 92 144-146 OC). 
New data: SH (400 MHz, CDC13) 2.07 (3H, s, H-11), 3.03 (2H, t, J 6Hz, H-9), 3.33 
and 3.52 (each 3H, each s, H-1 and 3), 4.43 (2H, t, J 6Hz, H-8), 7.62 (IH, s, H-5). 
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Compound 97 was prepared from 96 (0.37 g, 1.48 mmol) and NaBH4(0.14 g, 
3.7 mmol) by the method used to prepare 95. Purification by chromatography eluting 
with EtOAc-MeOH (10: 1) afforded 97 as a white solid (0.19 g, 0.75 mmol, 51 %), mp 
119-120 OC. (Found: C, 52.30; H, 6.39; N, 22.22; C1 IH 1603N4 requires C, 52.38; H, 
6.35; N, 22.22%); vmax (KBr disc)/cm-1 3450s (OH), 1715s and 1596m (imidazole 
ring and CO); 8H (400 MHz, D20) 1.12 (3H, d, J 6.4 Hz, H-11), 1.89 (2H, m, H-9), 
3.20 and 3.39 (each 3H, each s, H-1 and 3), 3.70 (IH, m, H-10), 4.27 (2H, m, H-8), 
7.89 (1H, s, H-5); 6C (100 MHz, D20) 22.4 (C-11), 28.3 and 30.2 (C-1 and 3), 38.9 
(C-9), 44.5 (C-8), 65.1 (C-10), 107.3 (C-4), 143.3 (C-5), 148.9 (C-6), 152.8 and 156.0 
(C-2 and 7); m/z (EI) 252.1222 (M+'). C 11 H 1603N4 requires 252.1222; m/z (%) 
252 (87), 207 (36), 194 (100), 180 (52), 149 (16), 123 (16), 95 (28), 68 (13), 44 (33). 
7-Hexyl-1,3-dimethylxanthine 98 
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Compound 98 was prepared from 1-bromohexane (1.65 g, 10 mmol) and 
theophylline(1.80 g, 10 mmol) together with IM NaOH (15 ml) by the method used to 
prepare 94. Recrystallisation from hexane afforded 98 as white crystals (0.35 g, 14%), 
mp 50 0C. (Found: C, 59.10; H, 7.57; N, 21.20; C13H2002N4 requires C, 59.09; H, 
7.57; N, 21.21%); vmx (KBr disc)/cm-1 1715m, 1646m and 1597m (imidazole ring 
and CO); 8H (400 MHz, CDC13) 0.80 (3H, t, J 6.8 Hz, H-13), 1.24 (6H, s, H-10 to 
12), 1.79 (2H, tt, J 7.2 Hz, H-9), 3.33 (3H, s, H-3), 3.52 (3H, s, H-1), 4.21 (2H, t, J 7.2 
Hz, H-8), 7.46 (IH, s, H-5); 6C (100 MHz, CDC13) 12.9 (C-13), 21.4 (C-12), 25.0 (C- 
11), 26.9 (C-3), 28.7 (C-1), 29.8 (C-10), 30.1 (C-9), 46.3 (C-8), 105.9 (C-4), 139.7 (C- 
5), 147.9 (C-6), 150.7 and 154.1 (CO); m/z (EI) 264.1587 (M+'). C13H2002N4 
requires 264.1588; m/z (%) 264 (100), 235 (10), 221 (14), 207 (22), 180 (80), 123 
(12), 95 (16), 55 (8). 
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Compound 99 (1.143 g, 3.8 mmol, 76%) was obtained from theophylline (0.9 
g, 5 mmol) and 2-bromoacetophenone (1 g, 5 mmol) in the presence of NaH (60% 
suspension, 0.3 g, 7.5 mmol) in DMF (50 ml) with stirring overnight at room 
temperature. DMF was evaporated off, and the residual solid was collected and 
recrystallised from EtOH, mp 184 OC (lit., 94 mp 190-191 OC). 
New data: SH (400 HMz, d6-DMSO) 3.16 and 3.47 (each 3 H, each s, H-1 or 3), 5.96 
(2H, s, H-8), 7.60 to 7.77 (6 H, m, H-5 and ArH); SC (100 HMz, d6-DMSO) 27.7 and 
29.8 (C-1 and 3), 52.9 (C-8), 106.9 (C-4), 128.4,129.4 and 134.6 (C-11 to 15), 134.4 
(C-10), 143.7 (C-5), 148.3 (C-6), 151.4 and 154.8 (C-2 and 7), 192.8 (C-9). 
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Compound 100 was prepared from theophylline (0.7 g, 3.9 mmol) and ethyl 
bromoacetate (0.65 g, 3.9 mmol) in the presence of NaH (60 % suspension, 0.21 g, 5.0 
mmol) by the modified method used to prepare 99. DCM was added to the reaction 
mixture to precipitate the unreacted theophylline which was filtered off, and the filtrate 
was concentrated in vacuo to give a dark oil. Recrystallisation from isopropanol give 
100 (0.19 g, 0.72 mmol, 19%) as a grey solid, mp 136-139 0C. (Found: C, 49.45; H, 
5.38; N, 21.01; C 11 H 14O4N4 requires C, 49.62; H, 5.26; N, 21.05%); vmax (KBr 
disc)/cm-1 1760m, 1636m (imidazole ring and CO); 8H (400 MHz, CDC13) 1.24 (3H, 
t, J 7.2 Hz, H-11), 3.31 and 3.53 (each 3H, each s, H-1 and 3), 4.20 (2H, q, J 7.2 Hz, 
H-10), 5.01 (2H, s, H-8), 7.53 (1H, s, H-5); 8C (100 MHz, CDC13) 14.4 (C-11), 28.2 
and 30.1 (C-1 and 3), 47.7 (C-10), 62.7 (C-8), 107.5 (C-4), 142.2 (C-5), 148.9 (C-6), 
152.0 and 155.6 (C-2 and 7), 167.4 (C-9); m/z (EI) 266.1016 (M+'). Cl IH 1404N4 
requires 266.1017; m/z (%) 266 (100), 252 (18), 220 (59), 193 (58), 152 (13), 109 
(36), 81 (24), 67 (18). 
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Compound 101 was prepared from theophylline (2.0 g, 11 mmol) and 2- 
bromomethyl-1,3-dioxolane (1.86 g, 11 mmol) in the presence of NaH (60% 
suspension, 0.57 g) by the modified method used to prepare 100. Recrystallisation 
from EtOH provided 101 as pale yellow needles (1.61 g, 6 mmol, 55 %), mp 137-138 
0C. (Found: C, 49.80; H, 5.29; N, 21.04; C 11 H 1404N4 requires C, 49.62; H, 5.26; N, 
21.05%); vmax (KBr disc)/cm-1 1760m, 1636m (imidazole ring and CO); 8H (400 
MHz, CDC13) 3.34 and 3.52 (each 3H, each s, H-1 and 3), 3.79 (4H, m, H-10 and 11), 
4.51 (2H, d, J 3.2 Hz, H-8), 5.15 (111, t, J 3.2 Hz, H-9), 7.58 (IH, s, H-5); 6C (100 
MHz, CDC13) 28.3 and 30.1 (C-1 and 3), 48.3 (C-10 and 11), 65.8 (C-8), 101.2 (C-9), 
107.7 (C-4), 142.6 (C-5), 148.7 (C-6), 152.0 and 155.7 (C-2 and 7); m/z (EI) 
266.1014 (M+'). C 11 H 1404N4 requires 266.1013; m/z (%) 266 (10), 193 (6), 180 
(5), 149 (2), 109 (5), 73 (100). 
7,7'-Methylenebis(theophylline) 10295 
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Sodium hydride (60% suspension, 0.17 g, 4.2 mmol) and dibromomethane 
(0.24 g, 1.4 mmol) were added to a solution of theophylline (0.5 g, 2.8 mmol) in DMF 
(20 ml). The mixture was stirred at room temperature overnight then heated at 70 OC 
for 3 h. The resulting mixture was poured into water to give 102 as a white solid (0.36 
g, 0.97 mmol, 69 %), mp 327-328 OC (lit., 95 mp > 300 OC). 8H (400 MHz, CDC13) 
3.34 and 3.49 (each 6H, each s, H-1 and 3), 6.66 (2H, s, H-8), 8.29 (2H, s, H-5). 
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Compound 103 (0.41 g, 1.07 mmol, 77%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,2-dibromoethane (0.26 g, 1.4 mmol) in the presence of NaH (60 % 
suspension, 0.17 g, 4.2 mmol) by the method used to prepare 102, mp 335 OC (lit., 95 
mp > 300 OC); m/z (EI) 386.1453 (M+'). C16H1804N8 requires 386.1455; m/z (%) 
386 (48), 278 (21), 221 (11), 206 (100), 180 (46), 122 (20), 95 (17), 67 (8). 
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Compound 104 (0.30 g, 0.75 mmol, 54%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,3-dibromopropane (0.28 g, 1.4 mmol) in the presence of NaH 
(60% suspension, 0.17 g, 4.2 mmol) by the modified method used to prepare 102, nip 
268-270 OC (lit., 95 mp 283-285 OC); m/z (EI) 400.1608 (M+'). C17H2004N8 
requires 400.1608; m/z (%) 400 (63), 386 (7), 207 (100), 194 (65), 180 (15), 109 (17), 
82 (35), 67 (12). 
7,7'-(1,4-Butanediyl)bis(theophylline) 10595 
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Compound 105 (0.28 g, 0.70 mmol, 55%) was prepared from theophylline 
(0.45 g, 2.5 mmol) and 1,4-dibromobutane (0.27 g, 1.25 mmol) in the presence of NaH 
(60% suspension, 0.15 g, 3.8 mmol) by the method used to prepare 102, mp 280 OC 
(lit., 95 mp 297-299 OC); 8H (400 MHz, CDC13) 1.86 (4H, tt, J 6.4 Hz, H-9), 3.33 and 
3.52 (each 6H, each s, H-1 and 3), 4.26 (4H, t, J 6.4 Hz, H-8), 7.51 (2H, s, H-5). 
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Compound 106 (0.13 g, 0.31 mmol, 22%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,5-dibromopentane (0.32 g, 1.4 mmol) in the presence of NaH (60% 
suspension, 0.17 g, 4.2 mmol) by the method used to prepare compound 102, mp 221- 
223 OC (lit., 95 mp 230-232 OC); 8H (400 MHz, CDC13) 1.30 (2H, tt, J 7.6 Hz, H-10), 
1.88 (4H, tt, J 7.6 Hz, H-9), 3.33 and 3.52 (each 6H, each s, H-i and 3), 4.21 (4H, t, J 
7.2 Hz, H-8), 7.49 (2H, s, H-5). 
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0 
8 10 N 
o 
\N 
I 
)5 N NýNX1, 
N 
/1@ 
13 
T 
Compound 107 (0.43 g, 0.97 mmol, 69%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,6-dibromohexane (0.34 g, 1.4 mmol) in the presence of NaH (60% 
suspension, 0.17 g, 4.2 mmol) by the method used to prepare compound 102, mp 232- 
235 OC (1it, 95 mp 243-245 OC); 8H (400 MHz, CDC13) 1.30 (4H, m, H-10), 1.82 
(4H, m, H-9), 3.33 and 3.51 (each 6H, each s, H-1 and 3), 4.19 (4H, t, J 7.2 Hz, H-8), 
7.46 (2H, s, H-5). 
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Compound 108 (0.47 g, 0.95 mmol, 68%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,10-dibromodecane (0.42 g, 1.4 mmol) in the presence of NaH 
(60% suspension, 0.17 g, 4.2 mmol) by the method used to prepare compound 102, mp 
161-163 OC (lit., 95 mp 169-171 OC); SH (400 MHz, CDC13) 1.20 (12H, m, H-10 to 
120 
12), 1.80 (4H, m, H-9), 3.33 and 3.51 (each 6H, each s, H-1 and 3), 4.20 (4H, t, J 7.2 
Hz, H-8), 7.46 (2H, s, H-5). 
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Compound 109 (0.23 g, 0.57 mmol, 41%) was prepared from theophylline (0.5 
g, 2.8 mmol) and 1,4-dibromo-2-butene (0.30 g, 1.4 mmol) in the presence of NaH 
(60% suspension, 0.17 g, 4.2 mmol) by the method used to prepare 102, mp 292-293 
OC. (Found: C, 52.21; H, 4.89; N, 27.04; C18H2004N8 requires C, 52.39; H, 4.85; N, 
27.17 %); vmax (KBr disc)/cm-1 3117m (Ar-H), 1708s, 1646s and 1602m (imidazole 
ring and CO); m/z (EI) 412.1609 (M+'). C18H2004N8 requires 412.1611; m/z (%) 
412 (33), 232 (100), 180 (13), 147 (33), 121 (21), 94 (16), 80 (8), 67 (7). 
7,7'-o-Xylylenebis(theophylline) 110 
Compound 110 (0.44 g, 0.94 mmol, 75%) was prepared from theophylline 
(0.45 g, 2.5 mmol) and a, a-dibromo-o-xylene (0.33 g, 1.25 mmol) in the presence of 
NaH (60% suspension, 0.15 g, 3.8 mmol) by the method used to prepare 102, mp 298 
0C. (Found: C, 56.99; H, 4.71; N, 23.91; C22H2204N8 requires C, 57.14; H, 4.76; N, 
24.24%); vmax (KBr disc)/cm713112m (Ar-H), 1719s and 1602m (imidazole ring, Ar 
and CO); 8H (400 MHz, CDC13) 3.29 and 3.51 (each 6H, each s, H-1 and 3), 5.59 
(4H, s, H-8), 7.04 and 7.28 (each 2H, each m, ArH), 7.46 (2H, s, H-5); 8C (100 MHz, 
CDC13) 28.3 and 30.2 (C-1 and 3), 47.5 (C-8), 107.3 (C-4), 129.3 and 129.8 (C-10 
and 11), 133.6 (C-9), 141.6 (C-5), 149.3 (C-6), 151.9 and 155.6 (C-7); m/z (EI) 
462.1762 (M+'). C22H2204N8 requires 462.1760; m/z (%) 462 (70), 282 (100), 281 
(30), 198 (35), 130 (33), 104 (22), 78 (7). 
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Compound 111 (0.50 g, 1.08 mmol, 87%) was prepared from theophylline 
(0.45 g, 2.5 mmol) and a, a'-dibromo-m-xylene (0.33 g, 1.25 mmol) in the presence of 
NaH (60% suspension, 0.15 g, 3.8 mmol) by the method used to prepare 102, mp 265 
OC; vmax (KBr disc)/cm-1 3110m (Ar-H), 1731s (imidazole ring, Ar and CO); 8H 
(400 MHz, CDC13) 3.33 and 3.50 (each 6H, each s, H-1 and 3), 5.40 (4H, s, H-8), 7.19 
to 7.31 (4H, m, Ar-H), 7.51 (2H, s, H-5); 8C (100 MHz, CDC13) 28.3 and 30.1 (C-1 
and 3), 50.3 (C-8), 107.2 (C-4), 128.0,128.4 and 130.2 (C-10,11 and 12), 136.8 and 
138.5 (C-9), 141.1 (C-5), 149.3 (C-6), 151.9 and 155.6 (C-2 and 7); m/z (EI) 
462.1765 (M+'). C22H2204N8 requires 462.1766; m/z (%) 462 (90), 282 (100), 198 
(18), 171 (8), 130 (9), 104 (27), 78 (9). 
7,7' p-Xylylenebis(theophylline)112 
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Compound 112 (0.48 g, 1.04 mmol, 84%) was prepared from theophylline 
(0.45 g, 2.5 mmol) and a, a'-dibromo-p-xylene (0.33 g, 1.25 mmol) in the presence of 
NaH (60% suspension, 0.15 g, 3.8 mmol) by the method used to prepare 102, mp > 
340 OC; vmax (KBr disc)/cm-1 3104m (Ar-H), 1727s and 1597m (imidazole ring, Ar 
and CO); m/z (EI) 462.1767 (M+'). C22H2204N8 requires 462.1770; m/z (%) 462 
(15), 282 (100), 231 (3), 185 (4), 104 (38), 78 (5). 
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Ethyl 4-methoxybenzoate 11397 
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To a stirring suspension of p-anisic acid (3.0 g, 19.7 mmol) in EtOH (18 ml) was added 
concentrated H2SO4 (0.4 ml) dropwise and the mixture was heated at reflux for 24 h. The 
EtOH was evaporated and the residue was taken into EtOAc (50 ml). The EtOAc solution was 
washed with 1M NaOH (2 x 25 ml), water (25 ml) and brine (10 ml) before drying over 
MgSO4. Concentration in vacuo gave 113 as a colourless oil (3.11 g, 17.3 mmol. 88%) pure 
enough for synthetic work without further purification. SH (400 MHz, CDC13) 1.30 (3H, t, J 
7.2 Hz, H-9), 3.78 (3H, s, OCH3), 4.27 (2H, q, J 7.2 Hz, H-8), 6.84 (2H, m, H-3 and 5). 7.92 
(2H, m, H-2 and 6); SC (100 MHz, CDC13) 13.4 (C-9), 54.4 (OMe), 59.6 (C-8), 112.5 (C-3 
and 5), 121.9 (C-1), 130.5 (C-2 and 6), 162.2 (C-4), 165.4 (CO). 
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O OH 
2 
3ý78ý 
MeO 
b 
OMe 
S 
A solution of 4-methoxyacetophenone (1.17 g, 7.57 mmol) in dry toluene (10 ml) was 
added dropwise to a stirred suspension of NaH (0.43 g, 60% dispersion, 7.57 mmol) in dry 
toluene (50 ml) at rt. After 2 min a solution of ethyl ester 113 (1.50 g, 8.33 mmol) in dry 
toluene (5 ml) was introduced dropwise at rt, and the mixture was heated at reflux for 24 h. 
After cooling to rt, the reaction was quenched by the cautious addition of 10% HCl (40 ml) and 
the mixture was extracted with EtOAc (2 x 50 ml). The combined organic layers were washed 
with water (60 ml) and brine (50 ml) before drying over MgSO4. Concentration in vacuo gave a 
yellow solid which was recrystallised from EtOH affording 114 as bright yellow crystals (0.60 
g, 2.11 mmol, 28 %). mp 106-108 OC (lit., 
97 108 0C); 8H (400 MHz, CDC13) 3.80 (6H, s, 
OCH3), 6.65 (1H, s, H-8), 6.88 (4H, in, H-3 and 5), 7.91 (4H, m, H-2 and 6); 8C (100 MHz, 
CDC13) 54.4 (OCH3), 90.5 (C-8), 112.9 (C-3 and 5), 127.2 (C-1), 128.1 (C-2 and 6), 161.9 
(C-4), 183.6 (CO). 
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1,3-Bis-(4-hydroxyphenyl)propane 11599 
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A solution of compound 114 (0.34 g, 1.19 mmol) in EtOH-EtOAc (4: 1) (60 ml) 
containing Pd/C (10%, 1.0 g) was shaked under 7 atm of hydrogen at 28 OC for 5 h. The 
mixture was filtered through Celite® and concentrated in vacuo to give a coloureless oil (0.25 g) 
which solidified to white crystals on standing. The crude methyl ether was taken up in glacial 
AcOH (2.5 ml). 48% HBr (5 ml) was added to the AcOH solution and the mixture was heated 
at reflux for 4 h. the solvent was evaporated and the residue was taken up in EtOAC (10 ml). 
The EtOAC solution was washed with saturated NaHCO3 (3 x5 ml), water (5 ml) and brine (5 
ml) before drying over MgSO4. Concentration in vacuo to give a yellow oil which was then 
washed with petroleum ether affording crude 115 as a yellow solid. Recrystallisation from 
EtOAc yielded compound 115 as a yellow solid (0.10 g, 0.44 mmol, 37%), mp 105-106 OC 
(lit,, 99 108-109 °C); SH (400 MHz, CDC13) 1.79 (2H, m, H-8), 2.48 (4H, t, J 7.8 Hz, H-7), 
4.76 (2H, bs, OH), 6.68 (4H, m, H-3 and 5). 6.96 (4H, m, H-2 and 6); SC (100 MHz, CDC13) 
33.8 (C-8), 34.8 (C-7), 115.5 (C-3 and 5), 129.9 (C-2 and 6). 135.0 (C-1), 153.8 (C-4). 
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A mixture of triphenylphosphine hydrobromide (4.08 g, 11.9 mmol) and 3,4- 
dimethoxybenzyl alcohol (2.0 g, 11.9 mmol) in dry acetonitrile (120 ml) was heated at reflux 
overnight. The mixture was concentrated in vacuo to give a pale yellow solid which was 
recrystallised from ethanol affording compound 116 as white crystals (5.3 g, 95%), m. p. 235 
OC (lit., 8 235-237 0C). SH (400 MHz, CDC13) 3.45 and 3.72 (each 3H, each s, OCHS), 5.22 
(2H, d, JH_p 13.8 Hz, CH2), 6.52-6.75 (3H, m, H-2,5 and 6), 7.53-7.71 (15H, M, PPh3). 
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A mixture of triphenylphosphine hydrobromide (3.5 g, 10.1 mmol) and 3,4,5- 
trimethoxybenzyl alcohol (2.0 g, 10.1 mmol) in dry acetonitrile (140 ml) was heated at reflux 
overnight. Concentration in vacuo gave a pale yellow solid which was recrystallised from 
ethanol affording 117 as white crystals (4.8 g, 9.18 mmol, 90%), mp 232 OC (lit., 100 234-236 
OC); 8H(400 MHz, CDC13) 3.43 (6H, s, OCHS), 3.69 (3H, s, OCHS), 5.31 (2H, d, JH_p 14.0 
Hz, CH2), 6.42 (2H, d, J 2.8 Hz, ArH), 7.51-7.71 (15H, m, PPh3). 
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A solution of 3-(3,4-dimethoxyphenyl)propionic acid (8.7 g, 42.8 mmol) in dry THE 
(20 ml) was added dropwise to a stirring slurry of LiAIH4 (2.44 g, 64.2 mmol) and THE (100 
ml) at 0 0C. After stirring at rt for 5h the reaction was quenched by the cautious addition of 
moist ether followed by 1M HC1 till the layers were separated. The aqueous layer was extracted 
with EtOAc (2 x 100 ml) and the combined organic layers were washed with brine (50 ml) 
before drying over MgSO4. Concentration in vacuo afforded compound 118 as a viscous oil 
which was satisfactory for synthetic work without further purification (7.7 g, 94%), bp 159 
OC > 
1 mmHg (lit., 8 150-152 OC >1 mmHg, vacuum pump); SH (400 MHz, CDC13) 1.52 (1H, bs, 
OH), 1.80 (2H, m, H-8), 2.58 (2H, t, J 7.9Hz, H-7), 3.60 (2H, t, J 6.4 Hz, H-9), 3.78 and 3.79 
(each 3H, each s, OCHS), 6.65-6.73 (3H, m, ArH). 
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A solution of 3-(3,4,5-trimethoxyphenyl)propionic acid (3.0 g, 12.5 mmol) in dry THE 
(10 ml) was added dropwise to a stirred suspension of LiAIH4 (0.71 g, 18.8 mmol) in THE (40 
ml) at 0 0C. After stirring at rt for 5h the reaction was quenched by the cautious addition of 
water and ether followed by 1M HCl till the layers were separated. The aqueous layer was 
extracted with EtOAc (2 x 80 ml) and the combined organic layers were washed with brine (50 
ml) before drying over MgSO4. Concentration in vacuo afforded 119 as a colourless oil which 
was satisfactory for synthetic work without further purification (2.4 g, 10.62 mmol, 85%). bp 
148-158 OC (> 1 mmHg, vacuum pump) [lit., 102 b. p. 120-1300C (1 mmHg)]; 8H(400 MHz, 
125 
CDC13) 1.75 (1H, bs, OH), 1.81 (2H, m, H-8), 2.58 (2H, t, J 8.0 Hz, H-7), 3.61 (2H, t, J 6.4 Hz, 
H-9), 3.74 (3H, s, OCH3), 3.77 (6H, s, OCH3), 6.35 (2H, s, ArH). 
3-(3,4-Dimethoxyphenyl)propionaldehyde 120104 
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A solution of DMSO (6.7 g, 6.1 ml, 85.6 mmol) in dry DCM (25 ml) was added 
dropwise to a stirred solution of oxalyl chloride (5.0 g, 3.4 ml, 39.2 mmol) in dry DCM (180 
ml) at -60 0C. After 2 min a solution of alcohol 118 (7.0 g, 35.7 mmol) in dry DCM (50 ml) 
was introduced dropwise at the same temperature and stirring was continued for 30 min. Et3N 
(18.1 g, 24.9 ml, 178.9 mmol) was added dropwise to the white cloudy solution and the mixture 
was allowed to warm to rt over lh. Water (250 ml) was added and the resultant two layers were 
separated and the aqueous layer was further extracted with DCM (150 ml). The combined 
organic layers were washed with 10% HCl (100 ml) and brine (150 ml) before drying over 
MgSO4. Concentration in vacuo afforded compound 120 as a light yellow oil (6.7 g, 97%) pure 
enough to be used without further purification. 6H(400 MHz, CDC13) 2.68 and 2.83 (each 2H, 
each t, J 7.2 Hz, H-7 and 8), 3.77 and 3.79 (each 3H, each s, CH3O), 6.64-6.73 (3H, m, ArH), 
9.74 (1H, s, CHO). 
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A solution of DMSO (0.92 g, 0.84 ml, 11.8 mmol) in dry DCM (2 ml) was added 
dropwise to a stirred solution of oxalyl chloride (0.69 g, 0.47 ml, 5.4 mmol) in dry DCM (35 
ml) at -60 0C. After 2 min a solution of alcohol 119 (1.1 g, 4.9 mmol) in dry DCM (5 ml) was 
introduced dropwise at the same temperature and stirring was continued for 30 min. Et3N (2.49 
g, 3.4 ml, 24.5 mmol) was added dropwise to the white cloudy solution and the mixture was 
allowed to warm to rt over 1 h. Water (30 ml) was added and the resultant two layers were 
separated and the aqueous layer was further extracted with DCM (30 ml). The combined 
organic layers were washed with 10% HCl (10 ml) and brine (15 ml) before drying over 
MgSO4. Concentration in vacuo afforded 121 as a yellow oil (1.08 g, 98%) pure enough to be 
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used without further purification. 8H(400 MHz, CDC13) 2.71 and 2.83 (each 2H, each in, H-7 
and 8), 3.72 (3H, s, OCHS), 3.77 (6H, s, OCHS), 6.34 (2H, s, ArH), 9.73 (1H, s, CHO). 
1,4-Bis-(3,4-dimethoxyphenyl)but-l-ene 1228 
To a stirred suspension of phosphonium salt 116 (14.9 g, 30.2 mmol) in dry THE (250 
ml) was added n-butyl lithium (15.8 ml, 2.1 M in hexanes, 33.2 mmol) dropwise at 0 0C. After 
stirring the dark red solution for a further 15 min aldehyde 120 (5.5 g, 28.5 mmol) in THE (40 
ml) was introduced dropwise at the same temperature. The resultant fawn coloured suspension 
was stirred at 0 OC for 30 min then allowed to warm to rt and stirred for a further 3h before 
pouring into iced water (500 ml). The mixture was extracted into ethyl acetate (3 x 250 ml) and 
the combined organic layers were washed with brine (200 ml) before drying over MgSO4. 
Concentration in vacuo gave a dark yellow gum which became a mixture of crystals and sticky 
oil after leaving at rt overnight. The mixture was stirred with MeOH (150 ml) at rt for 2h. The 
yellow suspension was filtered and washed thoroughly with MeOH affording 122 as a yellow 
solid (4.7 g, 50%, E: Z = 9). Concentration of the filtrate in vacuo gave a yellow oil which was 
purified by silica gel column chromatography affording more of 122 (2.1 g, 22%, E: Z = 2). mp 
60 OC (lit., 8 58 0C). 8H(400 MHz, CDC13) (E)-isomer: 2.42 (2H, m, H-9), 2.66 (2H, m, H-10), 
3.80 (12H, M, CH3O), 6.05 (1H, dt, J 15.8 Hz and 6.8 Hz, H-8), 6.29 (1H, in, H-7), 6.64-6.82 
(6H, m, ArH); (Z)-isomer. 2.58 (2H, m, H-9), 2.66 (2H, in, H-10), 3.80 (12H, m, CH3O), 5.55 
(1H, dt, J 11.6 Hz and 6.8 Hz, H-8), 6.29 (1H, m, H-7), 6.64-6.82 (6H, m, ArH). 
1,4-Bis-(3,4,5-trimethoxyphenyl)but-l-ene 123 
n-Butyl lithium (3.5 ml, 1.6 M in hexanes, 5.6 mmol) was added dropwise to a stirred 
suspension of phosphonium salt 117 (2.69 g, 5.1 mmol) in dry THE (30 ml) at 0 0C. After 
stirring the dark red solution for a further 15 min, aldehyde 121 (1.1 g, 4.9 mmol) in THE (6 
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ml) was introduced dropwise at the same temperature. The resultant yellow suspension was 
stirred at 0 OC for 30 min then allowed to warm to rt and stirred for a further 3h before pouring 
into iced water (50 ml). The mixture was extracted into ethyl acetate (3 x 40 ml) and the 
combined organic layers were washed with brine (20 ml) before drying over MgSO4. 
Concentration in vacuo gave a dark yellow gum which became a mixture of crystals and sticky 
oil after leaving at rt overnight. The mixture was purified by column chromatography to give 
123 as a mixture of geometrical isomers (0.61 g, 1.57 mmol, 32%, Z: E = 1); mp 98 °C; vmax 
(neat)/cm-12937s (OCHS), 1588s (C=C); 8H(400 MHz, CDC13) (E)-isomer: 2.44 (2H, m, H- 
9), 2.65 (2H, m, H-10), 3.75 (18H, in, OCHS), 6.11 (1H, dt, J 15.8 Hz and 6.8 Hz, H-8), 6.28 
(1 H, m, H-7), 6.33-6.49 (4H, m, ArH); (Z)-isomer: 2.61 (2H, m, H-9), 2.65 (2H, m, H-10), 3.75 
(18H, m, OCHS), 5.59 (1H, dt, J 11.6 Hz and 6.8 Hz, H-8), 6.28 (1H, m, H-7), 6.33-6.49 (4H, 
m, ArH); 8C(100 MHz, CDC13) 29.9,33.8 and 35.3 (C-9 and 10), 55.1 (OCH3), 102.0,102.4, 
104.3,104.4,104.9,105.5,128.3,128.6 and 129.4 (CH), 129.4,130.4,132.4,135.1,136.5, 
150.5,151.8,152.1,152.3 and 152.4 (C); m/z (EI) 388.1884 (M+). C22H2806 requires M 
388.1882; m/z (%) 388 (45), 360 (12), 345 (8), 207 (86), 181 (100), 176 (34), 149(7), 106 (5). 
1,4-Bis-(3,4-dimethoxyphenyl)butane 124104 
Palladium on charcoal (10%, 1.0 g) was added to a stirred solution of 122 in EtOAc- 
MeOH (1: 5) (370 ml) and the mixture was stirred under a hydrogen balloon at rt for 24 h. The 
mixture was filtered through Celite®. Concentration in vacuo gave a white solid which was 
recrystallised from aqueous MeOH affording 124 as white crystals (3.9 g, 92%), mp 89 OC 
(lit., 104 90-910C); 6H(400 MHz, CDC13) 1.60 (4H, m, H-8), 2.51 (4H, t, J 6.8 Hz, H-7), 3.77 
and 3.78 (each 6H, each s, OCHS), 6.62-6.72 (6H, m, ArH). 
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1,4-Bis-(3,4,5-trimethoxyphenyl)butane 125 
Pd/C (10 %I 0.2 g) was added to a stirred solution of 123 (0.41 g, 1.06 mmol) in 
EtOAc-MeOH (1: 4) (40 ml) and the mixture was stirred under a hydrogen balloon at rt for 24 
h. The mixture was filtered through Celite®. Concentration in vacuo gave a white solid which 
was recrystallised from aqueous MeOH affording 125 as white crystals (0.36 g, 86 %), mp 96 
OC. (Found: C, 67.79; H, 7.79; C22H3006 requires C, 67.69; H, 7.6 %); vmax (KBr disc)/cm-1 
2932s (OCHS), 1587s (Ar); 8H (400 MHz, CDC13) 1.60 (4H, m, H-8), 2.52 (4H, t, J 6.8 Hz, 
H-7), 3.75-3.79 (18H, m, OCH3), 6.31 (4H, s, ArH); 8C(100 MHz, CDC13) 31.5 (C-8), 36.6 
(C-7), 56.4 and 61.2 (OCH3), 105.7 (C-2 and 6), 136.4 and 138.7 (C-1 and 4), 153.5 (C-3 and 
5); m/z (EI) 390.2044 (M+). C22H30O6 requires M 390.2046; m/z (%) 390 (23), 362 (25), 282 
(12), 208 (4), 181 (100), 151 (10), 83 (17). 
1,4-Bis-(3,4-dihydroxyphenyl)butane 126106 
A mixture of compound 124 (1.8 g, 5.5 mmol), 48% HBr (30 ml) and glacial AcOH (12 
ml) was heated at reflux under N2 for 6 h. After cooling to rt the mixture was poured into water 
(300 ml) and extracted with EtOAc (2 x 200 ml). The organic layers were decolourised by 
activated carbon and washed with brine (2 x 60 ml), dried over MgSO4 and concentrated in 
vacuo to give a light brown solid. Recrystallisation from ether-hexane afford 126 as brown 
crystals (1.1 g, 72%), mp 139 OC (lit., 
106 136-138 0C). 6H(400 MHz, d6-DMSO) 1.47 (4H, 
bs, H-8), 2.40 (4H, t, J 6.2 Hz, H-7), 6.38-6.62 (6H, m, ArH), 8.60 (4H, bs, OH). 
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1,4-Bis-(3,4,5-trihydroxyphenyl)butane 127 
A mixture of 125 (0.13 g, 0.33 mmol), 48% HBr (3.5 ml) and glacial AcOH (1.4 ml) 
was heated at reflux under N2 for 6 h. After cooling to rt the mixture was poured into water (30 
ml) and extracted with EtOAc (2 x 20 ml). The organic layers were decolourised by activated 
carbon and washed with brine (10 ml), dried over MgSO4 and concentrated in vacuo to give a 
light brown solid. Recrystallisation from ether-hexane afforded 127 as yellow crystals (0.073 g, 
72%), mp 191-192 0C. (Found: C, 62.50; H, 6.23; C16H1806 requires C, 62.34; H, 6.49%). 
vmax (KBr disc)/cm71 3455s (OH), 1611 s (Ar); 8H(400 MHz, d6-DMSO) 1.36 (4H, in, H-8), 
2.32 (4H, m, H-7), 6.06 (4H, s, H-2 and 6), 7.70 (2H, bs, OH), 8.57 (4H, bs, OH); 8C(100 
MHz, d6-DMSO) 31.1 (C-8), 35.0 (C-7), 107.3 (C-2 and 6), 131.0 and 132.7 (C-1 and 4), 
146.2 (C-3 and 5); m/z (EI) 306.1100 (M+). C16H1806 requires M 306.1096; m/z (%) 306 
(65), 246 (5), 178 (14), 139 (100), 122 (5), 65 (7), 53 (10). 
N-(4-Methoxybenzyl)-4-methoxyphenylacetamide 128 
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A mixture of 4-methoxyphenylacetic acid (0.8 g, 4.81 mmol) and 4- 
methoxybenzylamine (0.59 g, 0.56 ml, 4.33 mmol) was heated with stirring under nitrogen at 
160 OC for 4 h. The brown solid formed dissolved in CH2C12 and the organic solution was 
washed successively with saturated NaHCO3 (10 ml), 5% citric acid (10 ml), water (10 ml) and 
brine (10 ml) before drying over MgSO4. Concentration in vacuo gave 128 as a yellow solid 
which was recrystallised from ethyl acetate providing 128 as yellow crystals (1.0 g, 81%), rap 
136-138 °C. (Found: C, 71.61; H, 6.73; N, 4.88; C17H19NO3 requires C, 71.58; H, 6.67; N, 
4.91 %). vmu (KBr disc)/cm-1 3284s (CONH), 2834m (OCHS), 1644s (CO), 1609s (Ar). SH 
(400 MHz, CDC13) 3.47 (2H, s, H-9), 3.70 and 3.71 (each 3H, each s, OCH3), 4.25 (2H, d, J 
5.6 Hz, H-7), 5.60 (IH, bs, NH), 6.78 (4H, m, H-3,5,12 and 14), 7.06 (4H, m, H-2,6,11 and 
15); SC (100 MHz, CDC13) 41.9 and 42.0 (C-7 and 9), 54.2 (OCHS), 113.0 and 113.4 (C-12, 
14,3 and 5), 125.7 and 129.2 (C-1 and 15), 127.9 and 129.5 (C-2,6,11 and 15), 157.8 and 
130 
157.9 (C-4 and 13), 170.2 (CO). m/z (EI) 285.1363 (M+). C17H1903N requires M 
285.1361; m/z (%) 285 (20), 227 (3), 177 (4), 121 (100), 91 (5), 78 (8), 77 (7). 
N-(3,4-Dimethoxybenzyl)-3,4-dimethoxyphenylacetamide 1298 
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Compound 129 was prepared from (3,4-dimethoxyphenyl)acetic acid (0.8 g, 4.07 mmol) 
and veratrylamine (0.61 g, 0.55 ml, 3.67 mmol) by the method used to prepare 128. 
Recystallisation from ethyl acetate afforded 129 as a yellow solid (1.14 g, 90%), mp 130-132 
°C (lit., 8 127-129 °C); 6H (400 MHz, CDC13) 3.49 (2H, s, H-9), 4.27 (2H, d, J 5.6 Hz, H-7), 
3.78 (9H, s, OCHS)03.79 (3H, s, OCHS), 4.27 (2H, d, J 5.4 Hz, H-7), 5.63 (1H, bs, NH), 6.64 
6.76 (6H, m, ArH). 
N (4-Hydroxybenzyl)-4-hydroxyphenylacetamide 130 
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The procedure of McOmie et al. 107 was modified as follows. To a stirred solution of 
128 (2.0 g, 7.0 mmol) in dry CH2C12 (250 ml) was added boron tribromide (28.1 ml, 28.07 
mmol, 1M in DCM) dropwise at -78 0C. This was stirred for 1h then allowed to reach 0 OC 
and stirred for 2.5 h before pouring into iced water (50 ml). The mixture was stirred for 1h and 
the two layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 150 ml), 
and the initial organic layer was concentrated in vacuo to give a yellow solid which was 
combined with the ethyl acetate extracts. The ethyl acetate solution was washed with saturated 
NaHCO3 (2 x 150 ml), water (150 ml) and brine (150 ml) before drying over MgSO4. 
Concentration in vacuo gave a yellow solid which was recrystallised from ethyl acetate 
affording 130 as yellow crystals (1.66 g, 92%), mp 171-173 °C. (Found: C, 70.12; H, 5.77; N, 
5.29; C15H15NO3 requires C, 70.04; H, 5.84; N, 5.45 %). vmax (KBr disc)/cm-1 3349m and 
3239m (OH and CONH), 1648s (CO), 161 1s and 1598s (Ar). 6H (400 MHz, d4-MeOH) 3.30 
(2H, s, H-9), 4.13 (2H, s, H-7), 6.62 (4H, m, H-3,5,12 and 14), 6.96 (4H, m, H-2,6,11, and 
15); 8C (100 MHz, d4-MeOH) 43.5 and 44.2 (C-7 and 9), 116.6 and 116.7 (C-3,5,12 and 14), 
128.1 and 131.0 (C-1 and 10), 130.4 and 131.5 (C-2,6,11 and 15), 157.8 and 158.1 (C-4 and 
131 
13), 174.8 (CO). m/z (EI) 257.1051 (M+). C15H1503N requires M 257.1050; mlz (%) 257 
(27), 199 (2), 163 (3), 121 (7), 107 (100), 77 (12), 51 (2). 
N-(3,4-Dihydroxybenzyl)-3,4-dihydroxyphenylacetamide 1318 
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To a stirred solution of 129 (0.4 g, 1.16 mmol) in dry CH2C12 (10 ml) was added BBr3 
(8.1 ml, 8.1 mmol, 1M in CH2C12) dropwise at -78 °C. This was stirred for 1h then allowed to 
reach 0 °C and stirred for 2.5 h before pouring into iced water (30 ml). The mixture was stirred 
for 1h and the two layers were separated. The aqueous layer was extracted with EtOAc (3 x 30 
ml). The combined EtOAc extracts were extracted into saturated NaHCO3 (40 ml) which was 
then acidified by 10 % HCI, and re-extracted with EtOAc (3 x 40 ml). The EtOAc solution was 
washed with brine (30 ml), dried over MgSO4 and concentrated to give 131 as a dark brown 
solid (0.29 g, 1.0 mmol, 87%), mp 177-179 °C (EtOAc-EtOH) (lit., 
8 179-182 °C); SH (400 
MHz, d6-DMSO) 3.23 (2H, s, H-9), 4.11 (2H, d, J 5.6 Hz, H-7), 6.42-6.73 (6H, m, ArH), 8.25 
(1 H, t, J 5.6 Hz, NH), 8.8 (4H, bs, OH). 
N-(4-Hydroxybenzyl)-4-hydroxyphenylthioethanamide 132 
1l 
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To a stirred solution of 130 (0.12 g, 0.467 mmol) in DME (5 ml) was added Lawesson's 
reagent (0.25 g, 0.63 mmol) portionwise. The resultant suspension was heated at reflux 
overnight. After cooling to rt, the reaction mixture was poured into water (25 ml) and extracted 
with EtOAc (3 x 25 ml). The combined organic extracts were washed successively with 
saturated NaHCO3 (3 x 25 ml), water (25 ml) and brine (25 ml) before drying over MgSO4. 
The solvent was evaporated and the residue was purified by chromatography to give 132 as a 
yellow solid (0.02 g, 0.072 mmol, 16%), mp 134-137 cC (EtOAc). vmax (KBr disc)/cm-1 3379s 
(OH and CSNH), 1608s (Ar), 1511 m (CSN). SH (400 MHz, d4-MeOH) 3.76 (2H, s, H-9), 
4.58 (2H, s, H-7), 6.62 (4H, m, H-3,5,12 and 14), 7.04 (4H, m, H-2,6,11 and 15); SC (100 
MHz, d4-MeOH) 50.8 (C-9), 52.7 (C-7), 116.6 and 116.7 (C-3,5,12 and 14), 129.3 and 129.6 
(C-1 and 10), 130.9 and 131.3 (C-2,6,11 and 15), 157.9 and 158.4 (C-4 and 13), 204.5 (CS). 
132 
m/z (EI) 273.0824 (M+). C 15H 15O2NS requires M 273.0824; m/z (%) 273 (30), 257 (3), 199 
(4), 167 (9), 133 (10), 107 (100), 77 (18), 44 (10). 
N-(4-Methoxyphenyl)-4-methoxyphenylpropanamide 134 
12 OMe 11 
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A mixture of 3-(4-methoxyphenyl)propionic acid (1.0 g, 5.58 mmol) and p-anisidine 
(0.69 g, 5.58 mmol) was heated with stirring under nitrogen at 160 OC for 4 h. The dark solid 
formed dissolved in CH2C12 and the organic solution was washed successively with saturated 
NaHCO3 (10 ml), 5% citric acid (10 ml), water (10 ml) and brine (10 ml) before drying over 
MgSO4. Concentration in vacuo gave 134 as a dark purple solid which was pure enough for 
use without further purification (1.06 g, 67 %), mp 154-155 OC (EtOAc). (Found: C, 71.36; H, 
6.74; N, 4.96; C 17H 19NO3 requires C, 71.58; H, 6.67; N, 4.91 %). vmax (KBr disc)/cm-1 
3309m (CONH), 2953m (OCHS), 1656s (CO), 1601 (Ar). SH (400 MHz, CDC13) 2.52 (2H, t, 
J 7.4 Hz, H-8), 2.91 (2H, t, J 7.4 Hz, H-9), 3.70 and 3.71 (6H, each s, OCH3), 6.75 (4H, m, H- 
3,5,12 and 14), 7.06 (2H, d, J 8.6 Hz, H-11 and 15), 7.25 (2H, m, H-2 and 6); SC (100 MHz, 
CDC13) 29.8 (C-8), 38.6 (C-9), 54.3 and 54.4 (OCH3), 113.0,113.1 and 120.9 (C-3,5,12,14, 
2 and 6), 128.3 (C-11 and 15), 129.8 and 131.7 (C-1 and 10), 155.4 and 157.1 (C-4 and 13), 
169.3 (CO); m/z (EI) 285.1363 (M+). C17H19O3N requires M 285.1361; m/z (%) 285 (60), 
227 (15), 123 (100), 121 (38), 108 (25), 83 (12), 77 (6). 
N-(4-Hydroxyphenyl)-4-hydroxyphenylpropanamide 135 
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BBr3 (8.42 ml, 8.42 mmol, 1M in DCM) was added dropwise to a stirred solution of 
134 (0.64 g, 2.24 mmol) in DCM (16 ml) at -78 °C. The brown suspension was stirred for 1h 
and then allowed to reach 0 °C and stirred for 2.5 h. The reaction mixture was poured into iced 
water (30 ml) and shaken for 20 min. The resulting suspension was filtered affording 135 as a 
grey solid (0.53 g, 91%) pure enough to use without further purification, mp 190 °C. vm 
(KBr disc)/cm71 3148s (OH and CONH), 1654s (CO), 1601s (Ar). 8H (400 MHz, d4-MeOH) 
2.45 (2H, t, J 7.4 Hz, H-8), 2.78 (2H, t, J 7.4 Hz, H-9), 6.60 (4H, m, H-3,5,12 and 14), 6.94 
(2H, m, H-11 and 15), 7.14 (2H, m, H-2 and 6); SC (100 MHz, d4-MeOH) 32.6 (C-8), 40.5 
133 
(C-9), 116.5,116.6 and 124.0 (C-2,6,3,5,12 and 14), 130.8 (C-11 and 15), 131.9 and 133.4 
(C-1 and 10), 155.8 and 157.2 (C-4 and 13), 174.1 (CO); Found: [M+H]+ (FAB) 258.1133. 
C 15H 1603N requires 258.1136. 
N-[2-(3,4-Dimethoxyphenyl)ethyl]-3,4-dimethoxyphenylacetamide 136 
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Compound 136 (1.70 g, 93%) was prepared from (3,4-dimethoxyphenyl)acetic acid (1.0 
g, 5.10 mmol) and 3,4-dimethoxyphenethylamine (0.92 g, 0.86 ml, 5.10 mmol) by the method 
used to prepare 128, mp 102-103 °C. (Found: C, 66.63; H, 7.05; N, 3.92; C20H25NO5 
requires C, 66.85; H, 6.96; N, 3.90%). vm (KBr disc)/cm-1 3323m (CONH), 2837m and 
2915m (OCHS), 1649s (CO), 1607s (Ar). 8H (400 MHz, CDC13) 2.61 (2H, t, J 6.8 Hz, H-10), 
3.37 (2H, m, H-9), 3.40 (2H, s, H-7), 3.75 (6H, s, OCH3), 3.77 (3H, s, OCH3), 3.78 (3H, s, 
OCHS), 5.38 (1H, bs, NH), 6.44-6.73 (6H, m, ArH); 8C (100 MHz, CDC13) 35.4 (C-10), 41.1 
(C-9), 43.8 (C-7), 56.1,56.2 and 56.3 (OCHS), 111.5,111.8,112.1 and 112.8 (C-2,5,12 and 
15), 120.9 and 121.9 (C-6 and 16), 127.6 and 131.4 (C-1 and 11), 148.0,148.7,149.4 and 
149.6 (C-3,4,13 and 14), 171.6 (CO). m/z (EI) 359.1729 (M+). C20H2505N requires M 
359.1725; m/z (%) 359 (18). 195 (5), 164 (100), 151 (38), 107 (5). 
N-[2-(3,4-dihydroxyphenyl)ethyl j-3,4-dihydroxyphenylacetamide 137 
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Compound 137 (0.56 g, 66 %) was prepared from 136 (1.0 g, 2.79 mmol) and BBr3 
(19.5 ml, 19.5 mmol, 1M in DCM solution) by the method used to prepare 131, mp 38 °C. 
vmax (KBr disc)/cm-1 3418s (OH and CONH), 1600s (Ar). 6H (400 MHz, d4-MeOH) 2.49 
(2H, t, J 7.2 Hz, H-10). 3.22 (4H, m, H-7 and 9), 6.54 (6H, m, ArH); 8C (100 MHz, d4-MeOH) 
36.2 (C-10), 42.9 (C-9), 43.8 (C-7), 116.8,116.9,117.2 and 117.7 (C-2,5,12 and 15), 121.6 
and 122.0 (C-6 and 16), 128.6 and 132.3 (C-1 and 11), 145.2,145.8,146.6 and 146.8 (C-3,4, 
13 and 14), 175.1 and 175.2 (CO); Found: [M+H]+ (FAB) 304.1188. C 16H 1805N requires 
304.1191. 
134 
N-(3,4-dimethoxyphenyl)-3,4-dimethoxyphenylbutanamide 138 
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A solution of 4-(3,4-dimethoxyphenyl)butyric acid (1.22 g, 5.35 mmol) and EDCI (1.03 
g, 5.35 mmol) in dry DCM (50 ml) was stirred at rt for 10 min before DMAP (72.7 mg, 0.59 
mmol) was added. After stirring the mixture for a futher 15 min, 3,4-dimethoxyaniline (0.85 g, 
5.6 mmol) was added and the brown mixture was stirred at rt for 24 h. The reaction mixture was 
washed successively with saturated NaHCO3 (3 x4 ml), 5% citric acid (3 x 40 ml), water (40 
ml) and brine (20 ml) before drying over MgSO4. Concentration in vacuo gave a brown solid 
which was recrystallised from MeOH affording the compound 138 as grey fluffy crystals (1.02 
g, 2.84 mmol, 53 %), mp 107-109 °C (EtOAc). (Found: C, 66.74; H, 7.06; N, 3.95; 
C20H25NO5 requires C, 66.85; H, 6.96; N, 3.90%). vmax (KBr disc)/cm-l 3299m (CONH), 
2937m (OCHS), 1657s (CO), 1603s (Ar). SH (400 MHz, CDC13) 1.97 (2H, tt, J 7.4 Hz, H-9), 
2.26 (2H, t, J 7.4 Hz, H-8), 2.59 (2H, t, J 7.4 Hz, H-10), 3.77,3.78 and 3.79 (12H, each s, 
OCHS), 6.65-7.30 (6H, m, ArH); SC (100 MHz, CDC13) 26.0 (C-9), 33.7 (C-8), 35.6 (C-10), 
54.8,54.9 and 55.1 (OCHS), 103.8,110.2,110.3,110.6,110.8 and 119.3 (C-2,5,6,12,15 and 
16), 130.6 and 132.9 (C-1 and 11), 144.7,146.3,147.9 and 148.0 (C-3,4,13 and 14), 169.9 
(CO). ndz (EI) 359.1729 (M+). C20H2505N requires 359.1725; m/z (%) 360 (20), 359 (80), 
195 (100), 153 (40), 151 (35), 110 (8), 83 (14). 
N-(3,4-dihydroxyphenyl)-3,4-dihydroxyphenylbutanamide 139 
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To a stirred solution of 138 (0.6 g, 1.67 mmol) in dry CH2C12 (15 ml) was added BBr3 
(11.7 ml, 11.70 mmol, 1 M in CH2C12) dropwise at -78 °C. The reaulting brown mixture was 
stirred for 1h and then allowed to warm to 0 OC and stirred for 2.5 h before pouring into iced 
water (30 ml). After shaking the mixture for 20 min, a grey solid precipitated between the 
aqueous and the DCM layers. The solid was filtered off and recrystallised from EtOAc-EtOH 
to give 139 as a brown solid (0.25 g, 50%), mp 56 °C. vmax (KBr disc)/cm71 3387s (OH and 
CONH), 1646s (CO and Ar). 8H (400 MHz, d4-MeOH) 1.90 (2H, m, H-9), 2.34 (2H, t, J 7.6 
Hz, H-8), 2.53 (2H, t, J 7.6 Hz, H-10), 6.47-7.17 (6H, m, ArH); 6C (100 MHz, d4-MeOH) 29.4 
(C-9), 36.1 (C-8), 37.5 (C-10), 110.6,114.0,116.5,116.8,117.0 and 121.2 (C-2,5,6,12,15 
and 16), 132.2 and 134.9 (C-1 and 11), 143.9,144.8,146.5 and 146.6 (C-3,4,13 and 14), 
174.9 (CO). Found: [M+H]+ (FAB) 304.1191 C 16H 18O5N requires 304.1197. 
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The procedure of Koßmehl et al. 110 was modified as follows. Thiophene (0.5 g, 6 
mmol) was dissolved in dry THE (7 ml) under nitrogen. After the addition of n-butyl lithium 
(2.4 ml, 2.5 M in hexane, 6 mmol) the resulting mixture was heated at reflux for 2 h. After 
cooling to -60 OC a solution of 1,4-dibromobutane (0.28 ml, 2.4 mmol) was added dropwise to 
the reaction mixture which was stirred for 2h then allowed to warm to rt and stirred for a 
further 5 h. Finally the mixture was heated at reflux for 5h to complete the reaction before 
pouring into iced water (15 ml). The mixture was neutralised with 10% HCl and extracted with 
diethyl ether (3 x 15 ml). The combined organic layers were washed with water (20 ml) and 
brine (20 ml) before drying over MgSO4. Concentration in vacuo gave a black oil which was 
purified by silica-gel column chromatography, eluting with hexane. The fractions Rf0.3 were 
combined and concentrated in vacuo to yield 140 as a light yellow oil (0.25 g, 1.12 mmol, 
47%). SH (400 MHz, CDC13) 1.69 (4H, m, H-7), 2.79 (4H, in, H-6), 6.70 (2H, in, H-3), 6.83 
(2H, m, H-4), 7.02 (2H, m, H-5). 
N (4-Methoxybenzyl)thiophene-2-acetamide 141 
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A mixture of thiophene-2-acetic acid (0.8 g, 5.63 mmol) and 4-methoxybenzylamine 
(0.69 g, 0.66 ml, 5.07 mmol) was heated with stirring under nitrogen at 160 OC for 4 h. The 
brown solid formed was dissolved in CH2C12 and the organic solution was washed successively 
with saturated NaHCO3 (10 ml), 5% citric acid (10 ml), water (10 ml) and brine (10 ml) before 
drying over MgSO4. Concentration in vacuo gave 141 as a brown solid which was pure enough 
for use without further purification (1.28 g, 4.4 mmol, 79 %), mp 95-97 0C. (Found: C, 64.47; 
H, 5.81; N, 5.30; C14H1502NS requires C, 64.37; H, 5.75; N, 5.36%); v,,, ax (KBr disc)/cm-4 
3256s (CONH), 2841m (OCHS), 1658s (CO), 1611s (Ar). 8H(400 MHz, CDC13) 3.71 (3H, s, 
OCHS)03.73 (2H, s, H-6), 4.28 (2H, d, J 5.6 Hz, H-8), 5.82 (1H, bs, NH), 6.74-7.19 (7H, m, 
aromatic H); 8C(100 MHz, CDC13) 36.5 (C-6), 42.1 (C-8), 54.3 (OCH3), 113.0 (C-11 and 13), 
124.6,125.3 and 125.4 (C-3 to 5), 127.9 (C-10 and 14 ), 129.0 and 135.1 (C-2 and 9), 157.9 
136 
(C-12), 168.6 (CO); mlz (EI) 261.0823 (M+). C14H1502NS requires 261.0823; m/z (%) 261 
(24), 203 (3), 177 (12), 121 (100), 97 (12), 82 (9), 78 (6). 
N-(3,4-Dimethoxybenzyl)thiophene-2-acetamide 142 
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Compound 142 was prepared from thiophene-2-acetic acid (0.8 g, 5.63 mmol) and 
veratrylamine (0.85 g, 0.76 ml, 5.07 mmol) by the method used to prepare 128. 
Recrystallisation from ethyl acetate afforded 142 as a yellow solid, mp 91-92 0C. (Found: C, 
61.73; H, 5.82; N, 4.77; C15H1703NS requires C, 61.86; H, 5.84; N, 4.81 %); vmax (KBr 
disc)/cm71 3294s (CONH), 2832m (OCH3), 1656s (CO), 1593s (Ar). 8H(400 MHz, CDC13) 
3.75 and 3.76 (6H, two s, OCH3), 3.78 (2H, s, H-6), 4.29 (2H, d, J 5.6 Hz, H-8), 5.86 (1H, bs, 
NH), 6.66-7.17 (6H, m, aromatic H); SC (100 MHz, CDC13) 36.6 (C-6), 42.4 (C-8), 54.8 and 
54.9 (OCHS), 109.7 and 110.1 (C-11 and 14), 118.7 (C-10), 124.6,126.3 and 126.4 (C-3 to 5), 
129.5 (C-2), 135.1,147.4 and 148.1 (C-9,12 and 13), 168.6 (CO); m/z (EI) 291.0926 (M+). 
C15H1703NS requires 291.0923; m/z (%) 291 (50), 193 (5), 176 (7), 151 (100), 97 (14), 65 
(3). 
N-(4-Hydroxybenzyl)thiophene-2-acetamide 143 
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The procedure of McOmie et al. 107 was modified as follows. To a stirred solution of 
141 (0.5 g, 1.9 mmol) in dry CH2C12 (18 ml) was added boron tribromide (3.8 ml, 3.8 mmol, 
iM in DCM) dropwise at -78 0C. This was stirred for 1h then allowed to reach 0 OC and 
stirred for 2.5 h before pouring into iced water (50 ml). The mixture was stirred for 1h and the 
two layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 30 ml), and 
the organic layer was concentrated in vacuo to give a yellow solid which was combined with the 
ethyl acetate extracts. The ethyl acetate solution was washed with saturated NaHCO3 (2 x 50 
ml), water (50 ml) and brine (50 ml) before drying over MgSO4. Concentration in vacuo gave a 
brown solid which was recrystallised from ethyl acetate affording 143 as colourless crystals 
(0.34 g, 72%), mp 115-117 0C. vnm (KBr disc)/cm-1 3395m and 3200s (OH and CONH), 
1652s (CO). 8H(400 MHz, d6-DMSO) 3.67 (2H, s, H-6), 4.15 (2H, d, J 5.6 Hz, H-8), 6.68- 
137 
7.36 (7H, m, aromatic H), 8.45 and 9.29 (2H, m and bs, NH and OH); 8C (100 MHz, d6- 
DMSO) 36.9 (C-6), 42.2 (C-8), 115.4 (C-11 and 13), 125.1,126.3 and 126.9 (C-3 to 5), 129.0 
(C-10 and 14 ), 129.7 and 138.1 (C-2 and 9), 156.6 (C-12), 169.2 (CO); m/z (EI) 247.0664 
(M+)" C13H13O2NS requires 247.0661; m/z (%) 247 (17), 163 (15), 120 (4), 107 (100), 97 
(22), 77 (9), 49 (4). 
N-(3,4-Dihydroxybenzyl)thiophene-2-acetamide 144 
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Compound 144 was prepared from 142 (0.35 g, 1.2 mmol) and BBr3 (4.8 ml, 4.8 mmol, 
IM solution in DCM) by the method used to prepare 130. Recystallisation from ethyl acetate- 
hexane afforded 144 as a yellow solid (0.24 g, 76%), mp 105 0C. vmax (KBr disc)/cm-1 3481 Is 
and 3170s (OH and CONH), 1652s (CO), 1600s (Ar). 8H(400 MHz, d6-DMSO) 3.67 (2H, s, 
H-6), 4.09 (2H, d, J 5.6 Hz, H-8), 6.46-7.36 (6H, m, H-10,13,14 and 3 to 5), 8.40-8.85 (3H, in, 
NH and OH); SC (100 MHz, d6-DMSO) 36.8 (C-6), 42.4 (C-8), 115.4 and 115.6 (C-10 and 
13), 118.7 (C-14), 125.1,126.3 and 126.8 (C-3 to 5), 130.3 (C-2), 138.1 (C-9), 144.6 and 
145.5 (C-11 and 12) 169.1 (CO); m/z (EI) 263.0613 (M+). C 13H 1303NS requires 263.0610; 
m/z (%) 263 (30), 179 (15), 123 (100), 97 (27), 77 (9), 51 (4). 
Methoxymethyl phenyl ether 145111 
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The method of Schlosser and his coworkers 111 was modified as follows. A solution of 
phenol (5.16 g, 54.8 mmol) in dry DMF (10 ml) was added into a slush of NaH (60% 
dispersion, 2.43 g, 60.9 mmol) in dry DMF (30 ml). After stirring for 30 min chloromethyl 
methyl ether (3.2 ml, 3.42 g, 42.5 mmol) was added dropwise at 0 0C. After stirring for 3h at it, 
the resultant grey suspension was poured into water (150 ml), which was extracted with hexane 
(3 x 100 ml). The combined organic extracts were washed with 1M NaOH (100 ml), water (2 x 
100 ml) and brine (100 ml) before drying over Na2SO4. Concentration in vacuo gave a 
colourless oil which was distilled under reduced pressure to yield 145 as a colourless oil (3.69 
g, 26.74 mmol, 63%), bp 74-75 °C (> 1 mmHg, vacuum pump) (lit., 111 bp 63-65°C at 8 
mmHg). 8H (400 MHz, CDC13) 3.41 (3H, s, H-8), 5.10 (2H, s, H-7), 6.96 (3H, m, H-2,4 and 
6), 7.21 (2H, m, H-3 and 5). 
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Tris (2-methoxymethyleneoxyphenyl)phosphine 146111 
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To an ice-cooled solution of 145 (4.0 g, 28.99 mmol) and N, N, N', N'- 
tetramethylethylenediamine (6.74 g, 8.7 ml, 57.98 mmol) in dry THE (55 ml) was added n-butyl 
lithium (24 ml, 2.5 M in hexanes, 60.87 mmol) dropwise. After stirring the dark red solution for 
2h at 25 °C, triphenyl phosphite (6.60 g, 5.6 ml, 21.26 mmol) was added dropwise at 0 °C. The 
resultant yellow solution was stirred at 25 OC for 16 h. The solvent was evaporated and the 
residue was purified by silica gel column chromatography to give a white solid which was 
recrystallised from EtOAc to yield 146 as white crystals (3.24 g, 7.32 mmol, 76%), mp 125-126 
OC (lit., l 11 128-129 °C). 6H (400 MHz, CDC13) 3.16 (9H, s, H-8), 5.03 (6H, s, H-7), 6.73 
(3H, m, H-2), 6.83 (3H, m, H-4), 7.04 and 7.22 (each 3H, each m, H-3 or 5). 
2-(3,4-Dimethoxyphenyl)ethanol 147115 
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Compound 147 (2.91 g, 75%) was prepared from (3,4-dimethoxyphenyl)acetic acid (4.0 
g, 20.39 mmol) and LiAIH4 (1.55 g, 40.78 mmol) by the method used to prepare 118, mp 43- 
44 oC (lit,, 115 mp 44-45 OC). 6H (400 MHz, CDC13) 1.41 (1H, bs, OH), 2.75 (2H, t, J 6.4 Hz, 
H-7), 3.77 (2H, t, J 6.4 Hz, H-8), 3.79 and 3.81 (6H, two s, OCHS), 6.68-6.77 (3H, m, ArH). 
2-(3,4-Dimethoxyphenyl)ethyl bromide 149114 
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To a stirred solution of alcohol 147 (1.50 g, 8.24 mmol) and CBr4 (3.42 g, 10.30 mmol) 
in CH2C12 (25 ml) was added Ph3P (3.25 g, 12.36 mmol) portionwise with ice-bath cooling. 
After addition was complete, the mixture was stirred for 40 min, whereupon the solvent was 
removed in vacuo. Ether (50 ml) was added and the white precipitate was filtered off. The 
filtrate was concentrated in vacuo and the residue was purified by column chromatography to 
give a pale yellow solid (1.49 g, 6.07 mmol, 74%), mp 50-510C (EtOH) (lit., 
114 47-50 OC). SH 
139 
(400 MHz, CDC13) 3.02 (2H, t, J 7.6 Hz, H-7), 3.47 (2H, t, J 7.6 Hz, H-8), 3.79 and 3.81 (each 
3 H, each s, OCH3), 6.66-6.76 (3H, m, ArH). 
2-(3,4-Dimethoxyphenyl)ethyltris(o-methoxymethyleneoxyphenyl)phosphonium bromide 150 
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A mixture of compound 149 (1.00 g, 4.08 mmol) and 146 (1.0 g, 2.26 mmol) in EtOH 
(30 ml, distilled over Na2CO3) was heated at reflux for 8 h. The solvent was evaporated and the 
residue was washed with ether (3 x 100 ml). The white precipitate was recrystallised from 
EtOAc to yield 150 (1.05 g, 1.53 mmol, 68%), mp 140-142 °C. 8H (400 MHz, CDC13) 2.83 
(2H, m, H-10), 2.99 (9H, s, H-8), 3.70 (2H, m, H-9), 3.73 and 3.80 (each 3H, each s, H-17 or 
18), 5.05 (6H, s, H-7), 6.37-6.81 (3H, m, H-12,15 and 16), 7.19-7.67 (12H, m, H-3 to 6); 8C 
(100 MHz, CDC13) 23.7 (C-10), 28.3 (C-9), 55.7 (C-8), 54.9 and 55.5 (C-17 and 18), 93.8 (C- 
7), 105.1 (C-1, Jcp 90 Hz), 110.1,111.1 and 114.0 (C-12,15 and 16), 118.9,121.7,121.8, 
134.2 and 135.9 (C-3 to 6), 131.1(C-2, Jcp 10 Hz), 146.8,148.1 and 158.4 (C-11,13 and 14). 
Found: [M+H]+ (FAB), 607.2458. C34H40O8P requires 607.2455. 
3,4-Dimethoxyphenylacetaldehyde 148115 
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`ý6 
8 
CHO 
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To a stirred suspension of pyridinium chlorochromate (1.61 g, 7.47 mmol) in CH2C12 
(10 ml) was added 147 (0.8 g, 4.4 mmol) in CH2C12 (10 ml). After being stirred at 23 OC for 2 
h, the reaction mixture was poured into dry ether (150 ml), and the precipitate was filtered off. 
The filtrate was concentrated in vacuo and the residue was purified by chromatography to give 
148 as a colourless oil (0.23 g, 1.24 mmol, 29 %). 8H (400 MHz, CDC13) 3.55 (2H, s, H-7), 
3.81 (6H, s, OCHS), 6.32-6.80 (3H, m, H-2,5 and 6). 9.62 (1H, s, H-8). 
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Pyridine (1.2 g, 1.2 ml, 14.6 mmol) was added dropwise at 0 OC to a stirred solution of 
126 (1.0 g, 3.3 mmol) and N-(tert-butoxycarbonyl)glycine (2.6 g, 14.6 mmol) in dry EtOAc (80 
ml). After the addition was complete the mixture was stirred for a further 5 min before DCC 
(3.0 g, 14.6 mmol) was added and the mixture was allowed to warm to rt. After stirring for 24 h 
the precipitated DCU was removed through Celite®, and the filtrate was stored in a freezer for 
12 h to precipitate further DCU which was filtered off through Celite®. The solution was 
washed successively with 5% citric acid (2 x 60 ml), 5% NaHCO3 (80 ml), water (100 ml) and 
brine (80 ml) before drying over MgSO4. The organic solution was concentrated affording the 
glycine ester 152 as white crystals (2.4 g, 80%), mp 101-104 0C. vmax (KBr disc)/cm-1 1681s 
(carbamate), 1783s (ester); 8H(400 MHz, CDC13) 1.38 and 1.39 (36H, two s, H-13 to 15), 1.48 
(4H, m, H-8), 2.47 (4H, in, H-7), 4.04 (8H, m, H-10), 6.45-7.02 (6H, m, ArH); SC(100 MHz, 
CDC13) 28.7 (C-13 to 15), 31.0 (C-8), 35.3 (C-7), 42.7 (C-10), 80.6 (C-12), 123.2,123.3 and 
127.2 (C-2,5 and 6), 138.5,140.0 and 141.9 (C-1,3 and 4), 156.6 (C-11), 168.5 (C-9). 
Found: [M+Na]+ (FAB), 925.4058. C44H62N4016Na requires 925.4057. 
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Glycine ester tetrahydrochloride salt 153 
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Dry HC1 was bubbled into a solution of 152 (250 mg, 0.28 mmol) under nitrogen in dry 
EtOAc (4 ml) at 0 OC for 3 min. A white solid precipitated from the reaction mixture which was 
allowed to warm to rt and stirred for a further 2h. The mixture was filtered and the solid was 
washed thoroughly with EtOAc affording 153 as a white solid (0.12 g, 88%), mp 192-195 0C. 
vm (KBr disc)/cm-1 1774s (ester), 1594s (Ar); 6H(400 MHz, D20) 1.52 (4H, in, H-8), 2.52 
(4H, m, H-7), 4.22 (8H, m, H-10), 6.44-7.22 (6H, m, ArH); 8C(100 MHz, D20) 30.1 (C-8), 
34.5 (C-7), 40.5 (C-10), 117.6,122.7, and 128.5 (C-2,5 and 6), 138.5,140.4 and 144.2 (C-1,3 
and 4), 167.2 (CO). Found: [M+H]+ (FAB) 503.2146. C24H31N40g requires 503.2150. 
1,4-Bis-(4,5-dimethoxy-2-nitrophenyl)butane 154 
02 oMe 
M32' 
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Concentrated nitric acid (70%) (0.30 ml, d 1.42,6.85 mmol) was added dropwise at rt to 
a stirred solution of 124 (300 mg, 0.91 mmol) in glacial AcOH (4.3 ml). The resultant yellow 
suspension was stirred for 2 h. After water (27 ml) was added to the reaction mixture, the 
suspension was extracted with CHC13 (3 x 25 ml) and the combined organic layers were 
washed. with saturated Na2CO3 (40 ml), water (40 ml) and brine (40 ml) before drying over 
MgSO4. Concentration in vacuo gave a solid which was satisfactory for synthetic work without 
further purification (0.343 g, 0.81 mmol, 89 %), mp 170 0C. (Found: C, 56.92; H, 5.79; N, 
6.49; C20H2408N2 requires C, 57.14; H, 5.71; N, 6.67 %); vniax (KBr disc)/cm71 1616m (Ar), 
1327m and 1525s (NO2); SH (400 MHz, CDC13) 1.68 (4H, it, J 7.0 Hz, H-8), 2.91 (4H, t, J 7.0 
Hz, H-7), 3.86 and 3.90 (12H, two s, OCH3), 6.64 (2H, s, H-2), 7.52 (2H, s, H-5); SC(100 
MHz, CDC13) 31.0 (C-8), 33.9 (C-7), 56.7 and 56.8 (OCHS), 108.6 (C-2), 113.6 (C-5), 133.3, 
141.4,147.5 and 153.4 (C-1,3,4 and 6); m/z (EI) 420.1534 (M+). C2OH24OgN2 requires 
142 
420.1535; m/z (%) 420 (55), 375 (20), 325 (10), 206 (65), 180 (100), 151 (50), 136(14), 77 
(12). 
1,4-Bis-(2-amino-4,5-dimethoxyphenyl)butane 155 
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A solution of 154 (0.26 g, 0.62 mmol) in CH2C12-EtOH (2: 1) (25 ml) containing 10% 
Pd-C (0.1 g) was stirred under 3.5 atm of hydrogen at 25 OC for 5 h. The mixture was filtered 
through Celite. ® Concentration in vacuo gave a black solid (0.13 g, 0.36 mmol, 58 %), mp 149- 
150 0C. vmax (KBr disc)/cm-1 1613 m (Ar), 3383 m (NH2); 8H(400 MHz, d6-DMSO) 1.52 
(4H, m, H-8), 2.38 (4H, m, H-7), 3.60 and 3.65 (12H, two s, OCHS), 4.57 (4H, bs, NH2), 6.32 
(2H, s, H-5), 6.52 (2H, s, H-2); 8C(100 MHz, d6-DMSO) 29.1 (C-8), 30.2 (C-7), 55.7 and 
57.0 (OCH3), 101.9 (C-5), 115.5 (C-2), 118.8 (C-1), 138.2,141.4 and 148.0 (C-3,4 and 6); 
m/z (EI) 360.2047 (M+). C20H2804N2 requires 360.2044; m/z (%) 360 (50), 330 (8), 206 
(10), 166 (100), 122 (15), 82 (9), 57 (5). 
1,4-Bis-(2-amino-4,5-dihydroxyphenyl)butane dihydrobromide 156 
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A mixture of 155 (0.2 g, 0.55 mmol) and 48% HBr (7 ml) was heated at reflux under 
N2 for 4 h. After cooling to rt the precipitated brown solid was collected on suction to yield 156 
as a brown solid (0.21 g, 0.47 mmol, 84%), mp > 330 °C. vmax (KBr disc)/cm71 3485s (OH), 
1635s (Ar); 8H(400 MHz, D20) 1.52 (4H, m, H-8), 2.48 (4H, m, H-7), 6.76 and 6.77 (4H, two 
s, ArH); &C(100 MHz, D20) 29.2 and 29.3 (C-7 and 8), 111.5 (C-5), 117.7 (C-2), 120.1 (C-1), 
128.5,143.1 and 144.9 (C-3,4 and 6); Found: [M (-2HBr) + H]+ (FAB), 305.1497. 
C16H2104N2 requires 305.1493. 
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(meso)-1,4-Bis-(3,4-dimethoxyphenyl)-2,3-dimethylbutane 538 
2 
The procedure of Perry et al. was modified as follows. 62 A solution of KOH (0.21 g, 
3.75 mmol) in MeOH (0.65 ml) and water (1 ml) was added dropwise to a stirred solution of 
NDGA (0.25 g, 0.83 mmol) in MeOH (2 ml). To the resultant brown solution was added 
dimethyl sulfate (0.84 g, 0.63 ml, 6.66 mmol) dropwise and the mixture was stirred for a further 
23 h ensuring the mixture was maintained at pH 8-9 by periodic addition of more KOH 
solution. Ammonia solution (35%, 5 ml) was added to the tan coloured suspension and the 
mixture was stirred for a further 30 min. The resultant mixture was extracted with EtOAc (30 
ml) and the organic extracts were washed with water (10 ml) and brine (10 ml) before drying 
over MgSO4. Concentration in vacuo gave a yellow coloured solid (0.25 g, 0.71 mmol, 86 %), 
mp 99-100 °C (MeOH-H20) (lit., 8 100-102 OC). SH (400 MHz, CDC13) 0.75 (6H, d, J 6.6 
Hz, H-9), 1.70 (2H, m, H-8), 2.23 (2H, dd, J 13.4 Hz and 9.2 Hz, H-7), 2.68 (2H, dd, J 13.4 Hz 
and 4.9 Hz, H-7), 3.78 (12H, two s, OCH3), 6.58-6.72 (6H, m, ArH). 
(meso)-1,4-Bis-(3,4-dimethoxy-6-nitrophenyl)-2,3-dimethylbutane 1578 
Compound 157 was prepared from 53 (1.0 g, 2.79 mmol) and 68% HNO3 (0.67 ml, 
10.32 mmol) in glacial acetic acid (8 ml) by the method used to prepare 154. Recrystallisation 
from MeOH afforded 157 as yellow crystals (1.15 g, 92 %), mp 149-150 cC (lit, 8 150-151 
OC). 6H (400 MHz, CDC13) 0.80 (6H, d, J 6.8 Hz, H-9), 1.80 (2H, m, H-8), 2.60 (2H, dd, J 
13.0 Hz and 9.5 Hz, H-7), 3.29 (2H, dd, 113.0 Hz and 4.1 Hz, H-7), 3.86 and 3.91 (12 H, two 
s, OCHS), 6.68 (2H, s, H-2), 7.54 (2H, s, H-5). 
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(meso)-1,4-Bis-(3,4-dihydroxy-6-aminophenyl)-2,3-dimethylbutane dihydrobromide 1588 
NH3 
A solution of 157 (1.10 g, 2.46 mmol) in DCM-EtOH (1: 1) (40 ml) containing 10% 
Pd/C (0.5 g) was stirred under 6 atm of hydrogen at 25 OC for 7.5 h. The mixture was filtered 
through Celite®. Concentration in vacuo gave a semi-solid (0.8 g, 84%) which was dissolved in 
48% HBr (9 ml). The mixture was heated at reflux for 3h and the resultant brown precipitate 
was collected to give 158 as a brown solid (0.72 g, 75%), mp > 250 °C (lit., 
8 mp>250 °C). 6H 
(400 MHz, D20) 0.74 (6H, d, J 6.6 Hz, H-9), 1.75 (2H, m, H-8), 2.31 (2H, dd, J 14.6 Hz and 
10.1 Hz, H-7), 2.66 (2H, dd, J 14.6 Hz and 4.5 Hz, H-7), 6.75 and 6.80 (4H, two s, ArH). 
1,6-Bis-(3,4-dimethoxyphenyl)hexane-1,6-dione 159117 
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Powdered A1C13 (4.05 g, 30.37 mmol) was added in portions to a stirred solution of 
veratrole (3.5 g, 25.33 mmol) in dry CH2C12 (50 ml) under nitrogen at 0 OC. After the addition 
was complete, adipoyl dichloride (2.78 g, 2.2 ml, 15.2 mmol) was added dropwise and the 
mixture was stirred at 0 OC for a further 4 h. The yellow suspension was poured into a flask 
containing iced water (180 ml) and concentrated HCl (7 ml) and the mixture was stirred for 1h 
with more CH2C12 added to ensure two homogenous layers. The layers were separated and the 
aqueous layer was further extacted with CH2C12 (2 x 30 ml). The combined organic layers were 
washed with saturated NaHCO3 (2 x 50 ml), water (50 ml) and brine (60 ml) before drying over 
MgSO4. Concentration in vacuo gave a yellow solid which was recrystallised from ethyl acetate 
affording compound 159 as pale yellow crystals (3.2 g, 8.3 mmol, 66%), mp 139-140 OC 
(lit., 117 149-150 OC). 8H(400 MHz, CDC13) 1.4 (4H, m, H-9), 2.91 (4H, in, H-8), 3.86 (6H, s, 
OCHS), 3.87 (6H, s, OCHS) 6.84 (2H, m, H-5), 7.45 (2H, d, J2 Hz, H-2), 7.52 (2H, m, H-6). 
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1,6-Bis-(3,4-dimethoxyphenyl)hexane 160117 
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Pd/C (10%, 1 g) was added to a solution of 159 in glacial AcOH (75 ml) and the 
mixture was stirred under a hydrogen balloon overnight. The mixture was filtered through 
Celite®. Concentration in vacuo gave a dark brown oil which was taken into CH2C12 (20 ml). 
The CH2C12 solution was washed with 10% NaOH (15 ml), water (10 ml) and brine (10 ml) 
before drying over MgSO4. The solvent was evaporated in vacuo to yield a brown solid which 
was recrystallised from MeOH affording compound 160 as pale yellow crystals (0.81 g, 2.3 
mmol, 58 %), mp 72-73 OC (lit., 117 78-79 0C). 8H(400 MHz, CDC13)1.28 (4H, m, H-9), 1.53 
(4H, m, H-8), 2.48 (4H, m, H-7), 3.78 (6H, s, OCHS), 3.79 (6H, s, OCHS), 6.39 (4H, m, H-2 
and 5), 6.72 (2H, m, H-6). 
1,6-Bis-(4,5-dimethoxy-2-nitrophenyl)hexane 161 
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Compound 161 (0.45 g, 77 %) was prepared from 160 (0.47 g, 1.31 mmol) and 
concentrated nitric acid (70 %, 0.47 ml, 7.3 mmol) in glacial acetic acid (7 ml) by the method 
used to prepare 154, mp 148-149 0C. (Found: C, 58.71; H, 6.35; N, 6.06; C22H28N208 
requires C, 58.93; H, 6.25; N, 6.25 %); vniax (KBr disc)/cm-1 2932m and 2853s (OCHS)1 
1614s (Ar), 1584s and 1525s (N02); 8H(400 MHz, CDC13) 1.40 (4H, m, H-9), 1.58 (4H, m, 
H-8), 2.84 (4H, m, H-7), 3.85 and 3.90 (each 6H, each s, OCH3), 6.64 (2H, s, H-2), 7.50 (2H, s, 
H-5); 8C(100 MHz, CDC13) 28.2 (C-9), 29.5 (C-8), 32.8 (C-7), 55.2 and 55.3 (OCHS), 107.2 
(C-5), 112.2 (C-2), 132.3,140.0,146.0 and 152.0 (C-1,3,4 and 6); m/z (EI) 448.1842 (M+). 
C22H2808N2 requires 448.1839; m/z (%) 448 (80), 403 (44), 369 (8), 190 (35), 180 (100), 151 
(84), 107 (13), 77 (11). 
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1,6-Bis-(2-amino-4,5-dihydroxyphenyl)hexane dihydrobromide 162 
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A solution of 161 (0.4 g, 0.89 mmol) in EtOH-DCM (3: 2) (40 ml) containing 10% 
Pd/C (0.15 g) was stirred under 3 atm of hydrogen at 25 OC for 5 h. The mixture was filtered 
through Celite®. Concentration in vacuo provided a dark green solid (0.34 g, 97%). 8H(400 
MHz, d6-DMSO) 1.34 (4H, m, H-9), 1.47 (4H, m, H-8), 2.35 (4H, m, H-7), 3.61 and 3.65 
(each 6H, each s, OCH3), 4.66 (4H, br, NH2), 6.33 (2H, s, H-5), 6.53 (2H, s, H-2). The dark 
green solid (0.21 g, 0.54 mmol) was dissolved in 48% HBr (7 ml) and the mixture was heated 
at reflux for 3h and the resultant brown precipitate was collected to give 162 as a brown solid 
(0.18 g, 71%). mp 320 0C. vmax (KBr disc)/cm-1 3597s (OH), 1641s (Ar); 8H(400 MHz, 
D20) 1.23 (4H, m, H-9), 1.43 (4H, m, H-8), 2.41 (4H, t, J 7.6 Hz, H-7), 6.73 and 6.74 (4H, two 
s, H-2 and 5); 8C(100 MHz, D2O) 28.6 (C-9), 29.4 (C-8), 29.7 (C-7), 111.5 (C-5), 117.7 (C- 
2), 120.1 (C-1), 128.9,143.0 and 144.9 (C-3,4 and 6). Found: [M+H]+ (FAB) 333.1811. 
C18H2504N2 requires 333.1808. 
N (3,4-Dimethoxybenzyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]ammonium bromide 1638 
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2-(3,4-Dimethoxyphenyl)ethylamine (0.57 g, 0.53 ml, 3.16 mmol) was added to a 
solution of 3,4-dimethoxybenzaldehyde (0.50 g, 3.01 mmol) in dry EtOH (15 ml) and the 
mixture was heated at reflux under N2 for 18 h. After cooling to rt the mixture was concentrated 
in vacuo to give the intermediate imine as a brown oil. The crude imine was taken up in fresh 
EtOH (20 ml) and treated portionwise with NaBH4 (0.57 g, 15.04 mmol). The mixture was 
heated at reflux for I h, allowed to cool and stirred overnight at rt. The resultant mixture was 
poured into water (60 ml), extracted with CHC13 (2 x 20 ml) and the combined organic extracts 
were washed with water (20 ml) and brine (20 ml) before drying over MgSO4. Concentration in 
vacuo gave a white solid which was recrystallised from 48% HBr to give compound 163 as a 
yellow solid (1.2 g, 97%), mp 185-186 aC (lit., 
8 187 OC). SH (400 MHz, d6-DMSO) 2.91 (2H, 
147 
t, J 9.1 Hz, H-9), 3.11 (2H, m, H-8), 3.72,3.74,3.76 and 3.78 (each 3H, each s, OCH3), 4.11 
(2H, t, J 5.6 Hz, H-7), 6.74-7.26 (6H, m, ArH), 8.34 (2H, bs, NH2). 
N-(3,4-Dihydroxybenzyl)-N-[2-(3,4-dihydroxyphenyl)ethyl jammonium bromide 164 8 
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Compound 164 (0.16 g, 72 %) was prepared from 163 (0.25 g, 0.61 mmol) and 48% 
HBr (10 ml) by the method used to prepare 115.8H (400 MHz, d4-MeOH) 2.75 (2H, m, H-9), 
3.06 (2H, m, H-8), 3.95 (2H, s, H-7), 6.47-6.96 (6H, m, ArH). 
New data. mp 199-201 OC; 6C (100 MHz, d4-MeOH) 33.0 (C-9), 50.0 (C-8), 52.6(C-7), 
117.1,118.5,121.4 and 123.3 (C-2,5,6,11,12 and 15), 123.9 and 129.5 (C-1 and 10), 145.9, 
147.3 and 148.2 (C-3,4,13 and 14). 
N-{4-[N'-(3,4-Dimethoxybenzyl)]-N'-[2-(3,4-dimethoxyphenyl)ethyljbutyl) 
phthalimide 165 
The method of Ozaki and his coworkers 120 was modified as follows. A mixture of 163 
(2.0 g, 6.04 mmol), N-(4-bromobutyl)phthalimide (2.05 g, 7.25 mmol) and K2CO3 (2.09 g, 
15.1 mmol) in DMF (35 ml) was stirred at 110 OC for 48 h. The resulting mixture was diluted 
with water (200 ml) and extracted with CHC13 (2 x 150 ml). The combined CHC13 extracts 
were washed with saturated NaHCO3 (2 x 200 ml), water (2 x 200m1) and brine (100 ml) 
before drying over Na2SO4. The solvent was evaporated and the residue was purified by silica 
gel column chromatography (EtOAc-petroleum ether 1: 2 with 10% Et3N) to give compound 
165 as a light yellow oil (1.71 g, 3.2 mmol, 53%). vm (neat)/cm 1 2935s (OCHS), 1719s and 
1770s (imide), 1607s (Ar); SH (400 MHz, CDC13) 1.48 (2H, in, H-17), 1.62 (2H, in, H-18), 
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2.45 (2H, t, J 7.0 Hz, H-16), 2.59 (4H, m, H-8 and 9), 3.48 (2H, s, H-7), 3.58 (2H, t, J 7.2 Hz, 
H-19), 3.74,3.75,3.76 and 3.77 (12H, each s, OCH3), 6.69 (6H, m, H-2,5,6,11,12 and 15), 
7.63 (2H, m, H-24 and 25), 7.75 (2H, m, H-23 and 26); 8C (100 MHz, CDC13) 23.5 (C-17), 
25.5 (C-18), 32.0 (C-9), 36.9 (C-19), 52.1 and 54.5 (C-8 and 16), 57.3 (C-7), 54.8 and 54.9 
(OCH3), 109.7,110.1,110.8 and 111.1 (C-2,5,12 and 15), 119.5 and 119.7 (C-6 and 11), 
122.1 (C-23 and 26), 131.4 and 132.3 (C-1 and 10), 131.1 (C-22 and 27), 146.2,146.8,146.8, 
147.7 and 147.8 (C-3,4,13 and 14), 167.4 (CO). Found: [M+Na]+ (FAB), 555.2475. 
C31H36O6N2Na requires 555.2479. 
N-(3,4-Dimethoxybenzyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-1,4-butanediamine 166 
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A solution of 165 (1.36 g, 2.56 mmol) and hydrazine hydrate (0.14 g, 0.14 ml, 2.82 
mmol) in MeOH (7 ml) was heated at reflux for 3.5 h and concentrated in vacuo. The residue 
was taken into 6M HCl (11 ml) and the reaction mixture was heated at reflux for 2 h. The 
precipitate was filtered off and the filtrate was treated with 5% NaOH (75 ml). The resulting 
milky mixture was extracted with CHC13 (2 x 120 ml) and the combined extracts were washed 
with water (2 x 120 ml), brine (120 ml) and dried over Na2S 04. Concentration in vacuo yielded 
166 as a brown oil (0.96 g, 2.39 mmol, 93 %) pure enough without further purification. 
vmax(neat)/cm' 3367s (NH2), 2935s (OCH3); SH (400 MHz, CDC13) 1.34 and 1.44 (each 2H, 
each m, H-17 and 18), 1.69 (2H, bs, NH2), 2.42 (2H, t, J 7.0 Hz, H-19), 2.78 (2H, t, J 7.0 Hz, 
H-16), 2.63 (4H, m, H-8 and 9), 3.50 (2H, s, H-7), 3.77,3.78,3.79 and 3.80 (12H, each s, 
OCHS), 6.69 (6H, m, ArH); SC (100 MHz, CDC13) 23.5 (C-17), 30.6 (C-18), 32.1 (C-9), 41.2 
(C-19), 52.6 and 54.5 (C-8 and 16), 54.8 and 54.9 (OCH3), 57.3 (C-7), 109.7,110.1,110.8 and 
111.1 (C-2,5,12 and 15), 119.6 and 119.7 (C-6 and 11), 131.5 and 132.4 (C-1 and 10), 146.2, 
146.8,147.7 and 147.8 (C-3,4,13 and 14). Found: [M+H]+ (FAB), 403.2596. C23H3504N2 
requires 403.2595. 
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N-(3,4-Dihydroxybenzyl)-N-[2-(3,4-dihydroxyphenyl)ethyl J-1,4-diaminobutane 
dihydrobromide 167 
A mixture of 166 (0.31 g, 0.77 mmol) and 48% HBr (3 nil) was heated at reflux under 
N2 for 3 h. The resulting dark brown solution was concentrated in vacuo to give 167 as a 
brown solid (0.35 g, 0.69 mmol, 90%), mp 156-157 0C. v,,, (KBr disc)/cm' 3609s (OH), 
2402s (NH+), 1609s (Ar and NH3); 6H (400 MHz, D20) 1.62 (4H, m, H-17 and 18), 2.73 
(2H, m, H-9), 2.86 (2H, t, J 7.6 Hz, H-19), 3.02 (2H, m, H-16), 3.13 (2H, m, H-8), 4.06 (2H, dd, 
J 16 and 2.4 Hz, H-7), 6.68 (6H, m, ArH); 8C (100 MHz, D20) 20.9 (C-18), 24.3 (C-17), 29.3 
(C-9), 39.1 (C-19), 52.5 (C-16), 53.4 (C-8), 57.6 (C-7), 116.7,116.8,118.7,121.4 and 124.2 
(C-2,5,6,11,12 and 15), 128.9 (C-1 and 10), 143.4,144.6,144.8 and146.1 (C-3,4,13 and 
14). Found: [M+H]+ (FAB) 347.1975. C19H2704N2 requires 347.1979. 
N-(2-Cyanoethyl)-N-(3,4-dimethoxybenzyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]amine 168 
11 
12 
OMe 
13 
MeO 3217$ 10 
14 OMe N9 
15 
M 46 
6 17 
S 16 
NI 
N 
A mixture of 163 (0.50 g, 1.51 mmol) and acrylonitrile (0.08 g, 0.10 ml, 1.51 mmol) 
was heated at 60-70 OC in a sealed tube for 48 h. The remaining acrylonitrile was distilled off 
and the residue was purified by silica gel chromatography (EtOAc-petroleum ether 1: 1.5 with 
10% Et3N) to yield 168 as a colourless oil (0.44 g, 1.16 mmol, 77%). vm, x(neat)/cm 
1 2936s 
(OCH3), 2245s (CN), 1606s (Ar); 6H (400 MHz, CDC13) 2.30 (2H, t, J 6.8 Hz, H-17), 2.72 
(6H, m, H-8,9 and 16), 3.56 (2H, s, H-7), 3.78,3.79,3.80 and 3.81 (12H, each s, OCH3), 6.70 
(6H, m, ArH); 8C (100 MHz, CDC13) 17.0 (C-17), 33.8 (C-9), 49.6 (C-16), 56.1 (C-8), 56.2 
and 56.3 (OCH3), 58.7 (C-7), 111.2,111.6,112.0 and 112.5 (C-2,5,12 and 15), 119.4 (CN), 
120.9 and 121.0 (C-6 and 11), 131.8 and 133.0 (C-1 and 10), 147.8,148.6,149.2 and 149.5 
(C-3,4,13 and 14). mlz (EI) 384.2050 (M+). C22H2804N2 requires 384.2050; m/z (%) 384 
(3), 233 (13), 151 (100), 107 (4), 106 (3). 
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N-(3,4-Dimethoxybenzyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-1,3 propanediamine 169 
12 
1 OMe 
Z781 
ICI 
v 
Me0 34 
9l4 OMe 
01 
4 
MeO 56 
16 17 
NH2 
To a stirred suspension of LiAlH4 (0.05 g, 1.33 mmol) in dry THE (6 ml) was added 
A1C13 (0.18 g, 1.37 mmol) portionwise and the resulting mixture was stirred for 10 min. A 
solution of 168 (0.24 g, 0.62 mmol) in THE (2 ml) was added dropwise and the mixture was 
stirred at rt for 18 h. The mixture was cooled with an ice bath and excess LiAlH4 was 
decomposed via careful addition of water (0.06 ml), 15% NaOH (0.16 ml) and water (0.06 ml). 
The resulting solid was filtered off and the filtrate was concentrated in vacuo to give a light 
yellow oil which was taken into CHC13 (5 ml). The CHC13 solution was washed with 15% 
NaOH (1.5 ml) and the aqueous layer was re-extracted with CHC13 (2 ml). The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo to give 
169 as a light yellow oil (0.167 g, 0.43 mmol, 69%) pure enough without further purification. 
v.. (neat)/cm 1 2935s (OCH3), 3370s (NH2), 1590s (Ar); SH (400 MHz, CDC13) 1.29 (2H, 
bs, NH2), 1.54 (2H, tt, J 6.8 H, H-17), 2.46 (2H, t, J 6.8 Hz, H-18), 2.65 (6H, m, H-8,9 and 16), 
3.49 (2H, s, H-7), 3.77,3.78 and 3.79(12H, each s, OCH3), 6.70 (6H, m,, ArH); SC (100 MHz, 
CDC13) 29.9 (C-17), 32.0 (C-9), 39.5 (C-18), 50.3 (C-16), 54.5 (C-8), 54.8 and 54.9 (OCHS)1 
57.4 (C-7), 109.7,110.2,110.8 and 111.1 (C-2,5,12 and 15), 119.6 and 119.7 (C-6 and 11), 
131.5 and 132.3 (C-1 and 10), 147.2,147.9,147.7 and 147.8 (C-3,4,13 and 14). Found: 
[M+H]+ (FAB) 389.2443. C22H3304N2 requires 389.2445. 
N-(3,4-Dihydroxybenzyl)-N-[2-(3,5-dihydroxyphenyl)ethyl]-1,3-diaminopropane 
dihydrobromide 170 
12 
OH Il 3 
HO 
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HO 
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A mixture of 169 (0.10 g, 0.27 mmol) and 48% HBr (2 ml) was heated at reflux under 
N2 for 3 h. Concentration in vacuo yielded 170 as a grey solid (0.1271 g, 0.257 g, 97%). mp 
179-180 0C. v,. (KBr disc)/cm' 3570s (OH), 1606s (Ar); 8H (400 MHz, D20) 1.99 (2H, m, 
H-17), 2.75 (2H, m, H-9), 2.88 (2H, t, J 7.8 Hz, H-18), 3.14 (4H, m, H-8 and 16), 4.13 (2H, s, 
H-7), 6.72 (6H, m, ArH); 6C (100 MHz, D20) 22.0 (C-17), 29.2 (C-9), 36.9 (C-18), 50.1 (C- 
151 
16), 53.5 (C-8), 57.7 (C-7), 116.8,116.9,118.8,121.5 and 124.3 (C-2,5,6,11,12 and 15), 
128.8 (C-1 and 10), 143.5,144.6,144.8 and 146.2 (C-3,4,13 and 14). Found: [Free base+H+] 
(FAB) 333.1813. C18H2504N2 requires 333.1812. 
N, N'-Bis(p-anisyl)ethylenediimine 171122 
IR 
OMe 
Z3ý 
4I 
r161 
MeO 
5 
Glyoxal (0.7 ml, 0.88 g, 40% aqueous solution, 6.1 mmol) was added dropwise to a hot 
solution of p-anisidine (1.5 g, 12.18 mmol) in MeOH (10 ml). The resulting yellow suspension 
was heated at reflux for a further 40 min. The precipitate was collected, washed well with cold 
MeOH, ether and dried to yield 171 as yellow needles (1.26 g, 4.68 mmol, 77%) pure enough 
without further purification, mp 153 OC (lit., 122 mp 153-154 0C). 8H (400 MHz, CDC13) 3.77 
(6H, s, OCHS), 6.87 (4H, q, J 8.9 Hz and 3.3 Hz, AA'BB' system, H-3 and 5), 7.25 (4H, q, J 8.9 
Hz and 3.3 Hz, AA'BB' system, H-2 and 6), 8.34 (2H, s, H-7); SC (100 MHz, CDC13) 54.5 
(OCH3), 113.6 (C-3 and 5), 122.0 (C-2 and 6), 141.9(C-1), 156.6 (C-7), 158.7 (C-4). 
N, N'-Bis(p-anisyl)-1,2-diaminoethane 172 
ýOMe 
2 Hý 
_ _ 
MeO 
67H 
5 
To a solution of 171 (0.3 g, 1.12 mmol) in dry EtOH (25 ml) was added NaBH4 (0.42 
g, 11.2 mmol) portionwise. The mixture was heated at reflux for 4 h, allowed to cool and stirred 
overnight at rt. The resulting mixture was poured into water (15 ml) and the EtOH was 
evaporated. The remaining aqueous solution was extracted with CHC13 (2 x 15 ml). The 
combined CHC13 extracts were washed with brine (10 ml), dried over Na2SO4 and 
concentrated in vacuo to give 172 as a yellow solid (0.28 g, 1.02 mmol, 91 %) pure enough for 
synthetic work without further purification, mp 132-133 0C. vm. (KBr disc)/cm' 2849s 
(OCHS), 3274s (NH), 1593 (Ar); 6H (400 MHz, D20 + CDC13) 3.25 (4H, s, H-7), 3.68 (6H, 
s, OCH3), 6.55 (4H, q, J 8.9 Hz and 3.6 Hz, AB system, H-3 and 5), 6.72 (4H, q, J 8.9 Hz and 
3.6 Hz, AB system, H-2 and 6); 8C (100 MHz, CDC13) 43.4 (C-7), 54.8 (OCH3), 113.6 and 
113.9 (C-2,3,5 and 6), 141.0 (C-1), 151.5(C-4). m/z (EI) 272.1528 (M+). C16H2002N2 
requires 272.1531; m/z (%) 272 (30), 136 (100), 122 (14), 121 (8), 108 (6), 93 (4), 77 (4). 
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N, N'-Bis(p-hydroxyphenyl)-1,2-diaminoethane dihydrobromide 173 
OH 
2 
gI 
ý+ 
/ 
4I7 H2 6 2Br- HO 5 
A solution of 172 (0.21 g, 0.77 mol) in 48% HBr (20 ad) was heated at reflux for 4 h. 
Concentration in vacuo afforded 173 as a brown solid (0.22 g, 0.54 mmol, 70%), mp 175-176 
0C. (Found: C, 41.51; H, 4.37; N, 6.88; C14H18N2O2Br2 requires C, 41.38; H, 4.43; N, 
6.90%); vm. (KBr disc)/cm ' 2849s (OCH3), 3274s (NH), 1593 (Ar); 8H (400 MHz, D20) 
3.65 (4H, s, H-7), 6.89 (4H, m, H-3 and 5), 7.15(4H, m, H-2 and 6); SC (100 MHz, D20) 45.7 
(C-7), 117.3 (C-3 and 5), 123.6 (C-2 and 6), 156.6 (C-4), 128.0 (C-1). Found: [M+H]+ (FAB) 
245.1287. C14H17N202 requires 245.1284. 
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